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Chapter 1 
Introduction 
  
1 Introduction 
 
1. Introduction 
1.1. G-Protein Coupled Receptors 
G-protein coupled receptors (GPCRs) represent the largest and most diverse 
superfamily of membrane receptors. There are approximately 800 genes in the human 
genome encoding GPCRs, accounting for roughly 3 % of the transcribed genes.P1-3P Thereof, 
a large portion comprises chemoreceptors, involved in taste and smell perception, whereas 
∼360 receptors are targeted by endogenous ligands.4 The latter GPCRs are one of the most 
important targets for drug discovery, and currently, approximately 30 % of the marketed 
drugs are associated with GPCRs.5 Despite their importance, the majority of these approved 
drugs addresses only a small fraction of the “drugable” GPCRs, leaving a large untapped 
potential for future discoveries.5 
 
1.1.1. Classification 
Today, the common system for the classification of GPCRs follows the so-called 
GRAFS system introduced by Fredriksson et al. in 2003.4 It divides the GPCR superfamily 
into five phylogenetic classes, named glutamate, rhodopsin, adhesion, frizzled/taste2 and 
secretin receptor family.4 The receptor classification of the International Union of 
Pharmacology (IUPHAR) is largely consistent with the GRAFS system, containing five 
classes, class A (rhodopsin), class B (secretin), class C (glutamate) and the Adhesion and 
Frizzled class (http://www.guidetopharmacology.org/). 
Class A (rhodopsin family) is the largest family of GPCRs, containing roughly 670 
receptors subdivided into four groups, designated α to δ.4 The receptors of this class are 
highly diverse with regard to structure and the nature of their natural ligand, including 
peptides, small molecules like amines, nucleosides and lipids or odorants in case of the 
olfactory receptors. Class B (secretin family) is a small family of peptide hormone receptors, 
including the calcitonin and glucagon receptors. Class C (glutamate family) contains the 
metabotropic glutamate and GABA receptors, the Frizzled class consists of the ten frizzled 
receptors, binding the family of Wnt glycoproteins, as well as the smoothened receptor.6,7 
The Adhesion class is the second largest GPCR family. Although it shares similarities with 
the class B receptors, it is poorly understood. 
As the histamine and neuropeptide Y receptors covered in this thesis all belong to the 
Class A of rhodopsin like GPCRs, the following paragraphs on receptor structure, signaling 
and regulation will focus solely on this family. 
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1.1.2. Protein structure 
The general architecture of GPCRs can be divided into three parts, the extracellular 
region, comprised of the N-terminus and the three extracellular loops (ECL1-3), a 
membrane domain consisting of the seven transmembrane helices and the intracellular 
region, consisting of the three intracellular loops (ICL1-3) and the C-terminus (cf. Fig. 1-1).8 
In principle, the extracellular domain conveys ligand access and specificity, the 
transmembrane domain relays the extracellular signal to the intracellular domain that then 
transduces the signal on to the cellular signaling machinery.8 
Our understanding of GPCR architecture and function was greatly facilitated by the 
availability of high-resolution crystal structures. In 2000, Palczewski et al. had published the 
structure of bovine rhodopsin (Fig. 1-1),9 long before the first structure of a nonvisual GPCR, 
the βR2R adrenergic receptor was resolved in 2007.10-13 Since then, improvements in protein 
engineering and crystallography techniques resulted in an increasing number of solved 
structures.8 In 2011, the first structure of an active receptor in complex with the GRαR protein 
gave insight into the mechanisms of receptor-G-protein interaction.13 
The general 7TM architecture was confirmed by the available crystal structures, with 
the transmembrane domains arranged in a counter clockwise manner, and an intracellular 
helix H8 running parallel to the plasma membrane.14 The available class A receptor 
structures reveal two distinct types of the extracellular domains, that either occlude the 
Fig. 1-1: 3D model of the histamine H1 receptor in complex with doxepin and a T4L 
insertion into the third ICL. The seven transmembrane helices are depicted in blue (TM1) 
through red (TM7) (adapted from Shimura et. al. 2011).15 
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ligand binding pocket or leave it water accessible.8,15 In rhodopsin, the N-terminus and the 
ECL2 fold into β-hairpin loops, forming a lid for the binding pocket.9 Such a lid is also present 
in other receptors addressed by lipophilic ligands.16 In receptors of hydrophilic ligands, the 
ECL2 structure is diverse, but in most cases, ECL2 is believed to play a role in initial ligand 
binding and in guiding the ligand to the binding pocket.8,17 ECL1 and ECL3 are much shorter 
than ECL2 and generally lack distinct structural features. 
By contrast to the extra- and intracellular domains, the transmembrane domains of 
class A GPCRs show a higher similarity amongst the different receptor structures.18 Two of 
the most prominent conserved features are the so-called E(D)R3.50Y and NP7.50xxY(x)R5,6RF 
motifs (superscripts according to the Ballesteros–Weinstein numbering19). The E(D)R3.50Y 
motif is part of a hydrogen bonding network between TM3 and TM6, the so-called ionic 
lock, that stabilizes the receptor in its inactive conformation.14,20 Of the NP7.50xxY(x)R5,6RF 
motif, Asn7.49 is part of a hydrogen bonding network between TM1, TM2 and TM7, while 
the Y(x)R5,6RF submotif constrains the TM7-H8 microdomain.14 Another feature, with 
implications on receptor stability, is the conserved disulfide bridge between Cys3.25 (inTM3) 
and a cysteine residue in the ECL2, anchoring the helix near the ligand binding site, thereby 
limiting conformational flexibility during receptor activation.9,14 
The intracellular domain of the receptor is responsible for coupling to cellular 
effectors, like G-proteins, G-protein receptor kinases (GRKs) and arrestins. ICL1 is 
approximately six amino acids long and contains a helical turn, while ICL2 usually comprises 
one or two α-helical turns.8 Most receptors contain an additional short aliphatic helix H8 
close to the C-terminus.8 In the active receptor, ICL2 interacts with the N-terminus of the 
G-protein13, and H8 is involved in initial G-protein recruitment. On the other hand, in many 
GPCRs, ICL3 and the C-terminus are long and intrinsically disordered, containing linear 
peptide motifs responsible for the formation and specificity of various protein-protein 
interactions.8,21 
 
1.2. G-Protein signaling 
The most prominent unifying feature of the GPCR superfamily is the ability to couple 
to and to activate heterotrimeric G-proteins, although this paradigm was attenuated by the 
inclusion of receptors like members of the frizzled class, that signal exclusively through 
other pathways.22 In their inactive form, the G-proteins are heterotrimers, composed of 
the GRαR subunit that contains the GTPase active site, and the tightly bound GRβγR heterodimer. 
Agonist-induced conformational changes of the receptor trigger an interaction with the 
inactive, GDP bound form of the heterotrimeric G-protein, leading to the formation of the 
so-called ternary complex. Then, the active receptor acts as a guanine-nucleotide exchange 
factor (GEF) on the G-protein, stimulating the exchange of GDP for GTP by the GRαR subunit. 
The associated conformational changes lead to the release of the heterotrimeric G-protein 
from the receptor, and, subsequently, to the dissociation of the α subunit from the GRβγR 
dimer. Subsequently, the GRαR subunit and, to a lesser extent, the GRβγR dimer interact with a 
multitude of signal effector proteins, activating distinct signaling cascades. Upon hydrolysis 
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of the bound GTP, the GRαR subunit is inactivated, leading to its reassociation with the GRβγR 
dimer. 
In mammals, 16 known genes encode different GRαR subunits; furthermore there are 5 
genes for the GRβR subunit and 12 for the GRγR subunit.23 Receptor specificity of the 
heterotrimeric G-protein is mainly procured by the GRαR subunit, although it has been shown 
that association with different GRβγR dimers influences receptor coupling.24 Mutational 
studies and investigations using GRαR chimeras revealed that the extreme C-terminal domain 
of GRαR plays a crucial role in receptor recognition.24 In the inactive trimeric form of the G-
protein, GRβγR functions as a guanine nucleotide dissociation inhibitor (GDI), increasing the 
affinity of GRαR for GDP.25 
The heterotrimeric G-proteins are grouped into four families, based on sequence 
homologies and functional similarities of the different GRαR subunits. The GRαSR family includes 
GRαSR, expressed as long and short splice variants, as well as the olfactory α subunit, GRαolfR.22 
These GRαR subunits signal through activation of membrane-bound adenylate cyclases 
(ACs).26 The GRαiR family is composed of the AC inhibiting subunits GRαi1R GRαi2R GRαi3 Rand GRαoR, 
furthermore the retinal α subunit, transducing or GRαTR, as well as GRαgustR and GRαzR.22,26 The GRαqR 
family comprises GRαqR and GRα11R as well as GRα14R and GRα15R, all activating the phospholipases 
Cβ1-3 (PLCβs).27 The residual GRαR family includes GRα12R and GRα13R, that primarily signal through 
the small GTPase Rho.28 In addition to the GRαR mediated signaling, it has been demonstrated 
that the GRβγR dimer, formerly considered a mere negative regulator of GRαR, modulates a vast 
array of signaling effectors.25 These include canonical GRαR pathways involving ACs and PLCs, 
but also novel GRβγR interaction partners such as kinases or GEFs.25,26,29-31 
Adenylate cyclases, catalyzing the formation of the second messenger cyclic-
adenosine-3’,5’-monophosphate (cAMP), represent one of the most important classes of 
G-protein signaling effectors. There are 9 different mammalian isoforms of membrane-
bound ACs, differing in their susceptibility to individual GRαR and GRβγR subunits, as well as in 
G-protein independent regulation mechanisms.26,32 AC activation leads to a rise in the 
cytosolic cAMP concentration, that subsequently activates protein kinase A (PKA).33 The 
activated PKA modulates via phosphorylation a plethora of downstream effectors, 
including metabolic enzymes, small G-proteins and, most importantly, the transcription 
factor cAMP-response element-binding protein (CREB) i.e. inducing the transcription of 
gene under control of the cAMP response element promoter (CRE).33,34 In the cell, cAMP 
levels are carefully controlled by the regulation of its synthesis catalyzed by ACs and its 
degradation mediated by phosphodiesterases (PDE), both enzymes regulated by PKA in a 
feedback mechanism.34 
The phospholipases Cβ, the second main class of G-protein effectors, catalyze the 
hydrolysis of phosphatidylinositol-4,5-bisphosphate yielding the two second messengers 
diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (IPR3R).27 The four mammalian isoforms 
of PLCβ are all activated by the GRαqR family, but differ in their regulation mechanisms and 
their susceptibility to different GRβγR dimers.35 IPR3R mainly acts through activation of the 
inositolphosphate receptor, a Ca2+ channel located primarily in membrane of the 
endoplasmatic reticulum (ER), resulting in an increase in the intracellular (cytosolic) calcium 
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concentration.36 Calcium is a ubiquitous cellular effector that signals through sensors like 
troponin C (TnC) and calmodulin (CAM), subsequently modulating the activity of various 
signaling proteins, including Ca2+/calmodulin dependent protein kinases (CAMK), protein 
kinase C (PKC) and several transcription factors.37 DAG is the second effector produced by 
PLCβ that, besides activating PKC, interacts with a separate set of six distinct protein 
families, sharing a C1 domain for DAG recognition, including protein kinase D (PKD), the 
DAG kinases and the MRCK family.38,39 
The broad variety of G-protein signaling is further complicated by the omnipresent 
crosstalk between convoluted signaling pathways and the influence of the large family of 
regulators of G-protein signaling (RGS) that modulate GRαR activity.33,35,40 Furthermore, the 
cellular response to a GPCR mediated signal depends on the tissue specific expression of 
different isoforms of certain effectors and regulators and even on the formation of site 
specific signaling scaffolds, so called signalsomes. The latter influence the availability and 
stoichiometry and, thus, the interaction of the different signaling proteins and second 
messengers.25,41 
 
1.3. Arrestins 
Classically, arrestins are considered universal regulators of GPCRs, playing a crucial 
role in receptor desensitization and trafficking. In addition, there is a growing body of 
evidence that by interacting with a variety of cell signaling proteins, arrestins act as 
multifunctional adaptors on their own and mediate distinct, G-protein independent 
signaling pathways. 
 
1.3.1. Arrestin isoforms  
In comparison to the huge, diverse superfamily of GPCRs, arrestins represent a 
relatively small clan of cytosolic regulatory proteins. The arrestin family comprises 4 
isoforms revealing high sequence homology. Arrestin 1 and 4 are exclusively expressed in 
the retina, where they regulate the activity of the photosensor rhodopsin.42,43 Contrary to 
the two visual arrestins, in mammals arrestin 2 and 3, more commonly referred to as β-
arrestin 1 and 2, are ubiquitously expressed in almost any tissue and cell type and have 
been demonstrated to interact with the vast majority of GPCRs.44 In addition to the classic 
arrestin proteins, a new family of protein that, despite low overall sequence similarity with 
β-arrestins, share the overall “arrestin fold” structure, was identified. In mammals, six 
members of this family, called α-arrestins or arrestin domain containing proteins (ARRDC), 
named ARRDC 1 – 5 and thioredoxin-interacting protein (Txnip) have been described so 
far.43 Their function in mammals is only starting to be elucidated, but they seem to act as 
versatile adaptors that link GPCRs to E3 ubiquitin ligases and endocytic factors.45 
The crystal structures of all four members of the arrestin family have been solved and 
reveal a remarkably similar structure, generally referred to as the arrestin fold.43 They are 
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composed of two seven stranded β sandwiches, the N-terminal and C-terminal domains, 
connected by a hinge region.46-49 In the inactive conformation, the unstructured C-terminus 
folds back towards the N-terminal domain, where it forms hydrophobic interactions as well 
as an ion pair with the so-called polar core, the main phosphate sensor of the 
molecule.47,48,50 These interactions, in concert with additional salt bridges within the polar 
core, constrain the protein in its inactive conformation.48 The conformational changes 
associated with the binding of an active, phosphorylated receptor involve a rotation of the 
N- and C-terminal domain relative to each other.51 The polar core of the arrestin most likely 
interacts with the phosphorylated residues of the receptor, thereby exposing the C-
terminus of arrestin and giving access to several binding motifs responsible for an 
interaction with components of the endocytic machinery.51,52 
 
1.3.2. Mechanisms of receptor desensitization and trafficking 
The most prominent and name giving function of arrestins is their ability to inhibit G-
protein signaling by the activated GPCR. A decisive step hereby is the phosphorylation of 
the ligand-activated receptor by G-protein receptor kinases (GRK) at specific sites in the 
ECL3 and the C-terminus.50 There are seven mammalian GRKs, the two “visual” GRKs (GRK 
1 and 7) are exclusively expressed in the retina, while four of the other GRKs are 
ubiquitously expressed and interact with the majority of GPCRs.53 In its active conformation 
the receptor is immediately targeted by GRKs, either in a G-protein independent manner 
or through recruitment by the GRβγR dimer.43,54 The phosphorylated receptor subsequently 
recruits arrestins that bind to the cytosolic face of the receptor, thus sterically hindering 
further interaction of the receptor with the G-protein.55,56 Furthermore, β-arrestins have 
been shown to scaffold enzymes such as phosphodiesterases and diacylglycerol kinases 
involved in the degradation of second messengers.57,58 In combination, the two effects lead 
to an effective deactivation of the G-protein mediated signal transduction.55 
Beyond desensitization, the bound arrestin, serving as essential adaptor, that links 
the receptor to components of the endocytic pathway and leads to its internalization via 
clathrin coated pits (CCP), plays a crucial role in receptor trafficking.43 Hereby, arrestin 
interacts with clathrin and the adaptor AP2, a protein complex involved in cargo selection 
for CCPs, via highly conserved binding motifs at its C-terminus, promoting the recruitment 
of the GPCR-arrestin complex to CCPs.55,59-61 
After vesicle formation, the fate of the receptor-arrestin complex is determined by 
the stability of its protein-protein interaction.55 Accordingly, receptors can be grouped into 
two classes; class A receptors such as the βR2R adrenergic or dopamine DR1RA receptor, 
preferentially form a transient complex with arrestin and are recycled to the plasma 
membrane soon after internalization.62,63 Class B receptors, including neurotensin receptor 
1 and vasopressin receptor VR2R, on the other hand form a stable complex with arrestin that 
persists after internalization and serves as a scaffold for several other interaction partners 
at the endosomes.43,62 Furthermore, class B receptors are subject to proteasomal 
degradation instead of recycling to the cell membrane.64 Class A and B receptors also differ 
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in their affinities to the arrestin isoforms, while class A receptors exhibit a higher affinity to 
β-arrestin 2 than to β-arrestin 1 and do not interact with visual arrestin, class B receptors 
have comparable affinities to both β-arrestin isoforms and also recruit visual arrestin.43,62 
It has been demonstrated that different phosphorylation patterns, especially in the C-
terminus of the receptor, are responsible for the stability of the complex and additionally 
influence arrestin conformations that drive interactions with various components of the 
ubiquitin-proteasome system.63,65-67 Ubiquitination of the receptor as well as the 
accompanying arrestin defines the trafficking itinerary of the internalized receptor and 
furthermore the formation of distinct endosomal signaling complexes.55,64,68 Hereby, β-
arrestins are pivotal in the sophisticated regulation between assembly and degradation of 
defined ubiquitination patterns, acting as adaptors of different E3 ubiquitin ligases, like 
Nedd4 or Mdm2, as well as deubiquitinases like USP20 and 33.55,69-72 
 
1.3.3. Arrestin mediated cell signaling 
Beyond their function as modulators of G-protein dependent signaling, arrestins 
interact with a plethora of signaling proteins. Proteomic analyses identified a total of 71 
interaction partners of β-arrestin 1 and 167 of β-arrestin 2, thereof 102 proteins interacted 
with both isoforms, including various proteins involved in cellular signaling and nucleic acid 
binding.73 Furthermore, quantitative phosphoproteomics analysis after stimulation of 
angiotensin II type 1A receptor with an arrestin biased agonist demonstrated arrestin 
mediated phosphorylation and dephosphorylation of 224 different proteins, including 38 
kinases and 3 phophatases.74 The combination of these findings using sophisticated 
bioinformatics tools allowed the construction of a kinase network for arrestin mediated 
signaling, demonstrating that arrestin signaling is far more complex than previously 
anticipated.74,75 The function and the physiological consequences of the majority of these 
interactions is only poorly understood, but there is more detailed information available on 
the impact of arrestin on certain pathways, especially the MAP kinase network. 
There are three major classes of MAPKs in mammals, the extracellular signal 
regulated kinases, ERK1/2; the c-Jun N-terminal kinase/stress-activated protein kinases 
(JNK/SAPK); and the p38/HOG1 MAPKs.76 The cellular function of the different MAPKs is 
pleiotropic, including regulation of cell cycle progression, growth arrest and apoptosis.76 
The different MAPKs are organized in a series of parallel phosphorylation cascades that are 
regulated by the spatial coordination of the individual components through scaffolding 
proteins.41,77 Arrestins act as GPCR regulated scaffolds for the regulation of all three classes 
of MAPKs.76 Especially the arrestin mediated activation of the ERK1/2 cascade was studied 
in detail. All three components of the ERK cascade, c-Raf1, MEK1/2 and ERK1/2 interact 
with β-arrestin 2, and receptor induced arrestin conformations strongly increase ERK1/2 
binding.76,78,79 When mediated by class B GPCRs, receptor, arrestin and the components of 
the ERK cascade form a stable signalsome complex that is crucial for the regulation of ERK.80 
Likewise, the stability of this signalsome complex is tightly regulated by the 
phosphorylation and ubiquitination pattern of the receptor and the associated arrestin in 
particular.64,66,81 Most interestingly, arrestin mediated ERK activation is temporally and 
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spatially distinct from the canonical G-protein or receptor tyrosine kinase induced 
activation pattern.82 G-protein activated ERK is not spatially restricted and readily diffuses 
into the nucleus, where it influences a multitude of transcription factors.83 Furthermore, it 
is rapidly inactivated by MAPK phosphatases, i. e. the ERK signal closely follows the rapid 
time course of G-protein activation.76 On the other hand, arrestin activated ERKs, at least 
when mediated by class B GPCRs, are spatially restricted to the cytosol through the stable 
signalsome complex that additionally protects ERK from phosphatase inactivation resulting 
in a long lasting signal.76,80,84 Thus, these two distinct ERK populations influence different 
effectors resulting in different G-protein and arrestin mediated ERK signaling.82,85 Beyond 
MAPK signaling, arrestins have been demonstrated to regulate signaling through the Src 
family of nonreceptor tyrosine kinases in a similar manner.76,86 
The MAPKs and Src pathways are only two out of several physiologically important 
signaling pathways regulated by arrestins that influence a plethora of cellular functions. 
Thereby, the spatiotemporal organization through the arrestin signalsome is pivotal for the 
control of directed physiological responses like chemotaxis and cell migration.87 
 
1.4. The concept of biased agonism 
In the classic “two state” model, the receptor is regarded as a bimodal switch that 
can adopt two distinct conformations, whereof the active one interacts with the G-proteins 
and induces cellular signaling.88 Ligand binding to the receptor can influence the 
equilibrium between the two receptor states; agonists shift the equilibrium towards the 
active conformation, while inverse agonists favor the inactive state and neutral antagonists 
preserve the unimpaired condition. This model was sufficient to describe ligand activation 
of the receptor measured through a single readout and allowed the characterization of 
different compounds by assigning them a single efficacy determining their power to induce 
the investigated response. This approach elegantly allowed for the generation of structure-
activity relationships, useful to guide drug development. 
Advances in molecular biology provided recombinant test systems, allowing the 
independent observation of multiple ligand induced receptor behavior, including activation 
of different G-proteins, arrestins or other effects like receptor phosphorylation and 
internalization.89 This refined methodology revealed discrepancies in the function of 
certain ligands, when different cellular effectors were analyzed. Findings, like receptor 
internalization by ligands described as antagonists, differential activation of ACs or PLC 
through ligands acting on the same receptor or especially the G-protein independent 
activation of arrestins,90-93 are incompatible with the existence of a single active state of a 
receptor.94,95 This implies that efficacy cannot be regarded as an intrinsic property of the 
ligand-receptor couple, but has to be considered as a pluridimensional phenomenon 
depending on the nature of the receptor-effector coupling as well as on the ligand-receptor 
interaction.89,96 Therefore, ligands can be functionally biased with multiple different 
efficacies for the different readouts, i.e. activating only certain receptor states. Since the 
first recognition of functional selectivity in the mid-1990s,97 this so called biased agonism 
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has been demonstrated for an ever growing number of ligands at a multitude of 
therapeutically relevant GPCR targets,88 including serotonin receptors,98,99 opioid 
receptors,100 β-adrenoceptors,92,96,101 dopamine receptors93,102-104 and the angiotensin type 
1A receptor.105-107 
The observed versatility in signal transduction through GPCRs is incompatible with 
the existence of a single active conformation of the receptor. According to current 
understanding, receptors rather exist in ensembles of multiple conformations that interact 
with various downstream effectors.89 In this “multistate model”, functional selectivity can 
be explained by the stabilization of distinct ligand specific receptor conformations that 
selectively interact with only a subset of the cellular effectors.89,108 GPCRs possess a much 
higher plasticity than previously anticipated and for several receptors, the existence of 
multiple conformations was demonstrated by advanced NMR techniques.108,109 For the βR2R 
adrenergic receptor, such distinct ligand specific conformation were demonstrated even 
for functionally closely related ligands.110,111 Furthermore, it was shown that the interaction 
of the receptor with G-proteins and arrestins is mediated by different receptor 
conformations.112 
 
1.4.1. Functional selectivity in drug discovery, challenges and 
opportunities 
The general acceptance of functional selectivity at GPCRs poses a new challenge for 
drug discovery efforts. To address receptor activation, the majority of high throughput 
screening and drug development programs in industry and academia rely on readout 
systems based on measurement of easily accessible second messengers, such as Ca2+ or 
cAMP, or directly measuring G-protein activation, for example via binding of radiolabeled 
GTPγS. While adequate and robust for the characterization of unbiased compounds, this 
approach falls short to address the putative pluridimensional efficacy of new ligands 
towards multiple signaling pathways. Therefore, this procedure is prone to errors: ligands 
producing desired or undesired effects may not be identified. The identification of ligand-
specific undesired cellular responses is of particular relevance to prevent the failure of drug 
candidates at later stages of the development process. Holistic readouts such as label free 
cell-based assays offer the advantage to address the full plethora of signaling pathways but 
fail to provide insights into the mode of action of the investigated ligands.89 A 
comprehensive characterization of new compound libraries needs to include alternate 
systems, such as arrestin recruitment or ERK phosphorylation assays, to account for the 
versatility of GPCR signaling. 
So far, there are only a few examples of ligand bias producing a desired effect in 
patients. Out of 16 investigated βR1R-blockers, carvedilol was the only β-arrestin biased 
agonist at the βR2R adrenoreceptor.92 Interestingly, carvedilol exhibits a unique beneficial 
profile in the treatment of chronic heart failure, and although the underlying physiological 
mechanisms are unclear, these findings point towards the involvement of arrestin 
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mediated pathways.89,92,113 The arrestin biased angiotensin II type 1 receptor ligand 
TRV120027, that is currently in clinical development for the treatment of heart failure, is 
another example .107,108 TRV120027 is able to reduce blood pressure, but unlike unbiased 
agonists, that decrease cardiac performance, it increases cardiac output.107,114 Opioid µ 
receptors represent another target for biased ligands.108 In β-arrestin 2 knockout mice, 
morphine induced prolonged analgesia with reduced constipation and respiratory 
depression compared to the wild type animals, suggesting a favorable pharmacological 
profile of G-protein biased compared to unbiased agonists.108,115,116 These findings led to 
the development of TRV130, a G-protein biased agonists causing less gastrointestinal 
dysfunction and respiratory suppression than morphine at equivalent doses.100 
Collectively, these findings emphasize the necessity for a full pharmacological 
characterization of newly developed receptor ligands with regard to alternate signaling 
pathways to enable a comprehensive analysis of their physiological implications. 
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2. Scope and Objectives 
The conformational flexibility and functional selectivity of GPCRs has been a hot topic 
in pharmacology over the past decade. Although the concept of biased agonism was 
substantiated by an increasing amount of evidence at many GPCR targets, we are only 
beginning to understand its physiological consequences and its implications on the drug 
discovery process.1-3 Nonetheless, these findings emphasize the necessity to integrate 
alternate readout systems, addressing non-canonical, G-protein independent signaling 
pathways, into the ligand characterization process in order to account for the full functional 
versatility and flexibility of GPCRs. 
This thesis aimed at establishing a reliable method to measure arrestin recruitment 
to selected GPCR targets allowing for the comprehensive characterization of GPCR ligands 
regarding their functional properties with respect to arrestin activation. Several procedures 
making use of proximal or distal readouts to access arrestin activation are described in 
literature.4 Distal readouts, such as the measurement of arrestin induced ERK 
phosphorylation, have the advantage of addressing changes in downstream signaling. 
Unfortunately, differential amplification of the signal and putative crosstalk between 
convoluted signaling pathways may complicate the interpretation of the results. 
Alternatively, several cellular assay systems relying on proximal readouts are available, 
mostly employing fluorescence/bioluminescence resonance energy transfer (FRET/BRET) 
or enzyme fragment complementation (EFC) techniques using genetically engineered 
arrestin and receptor fusion constructs. Especially EFC based approaches have proven 
valuable tools to investigate arrestin activation. Such assays can be easily adapted to 
multiwell formats enabling high throughput for the screening of large compound libraries. 
Fusion constructs of receptor and effector at a stoichiometry of 1:1 guarantee a direct 
proportionality between receptor occupancy and the measured signal. An enzyme 
fragment complementation assay, using split luciferase fragments from P. termitilluminans, 
developed by Misawa et al., was considered an ideal method to achieve this goal.5 
Consequently, the generation of HEK293T cells, stably expressing different arrestin 
and receptor constructs fused to N- and C-terminal fragments of the luciferase, was the 
initial subject of this dissertation project. These transfectants allowed the measurement of 
ligand induced arrestin recruitment to representative aminergic and peptidergic receptors 
in a timely and reliable manner, using bioluminescence in the 96 well format as readout. 
Due to the chosen modular approach, the assay is easily adaptable to a multitude of GPCRs 
as drug targets, e.g. for the screening of larger compound libraries. 
In our medicinal chemistry department, extensive work has been performed to 
design, synthesize and investigate new ligands for two prototypic GPCR targets, the 
histamine receptor family as representative of aminergic GPCRs as well as the 
neuropeptide Y receptor family as peptidergic receptors.6,7 The majority of these 
compounds was characterized by pharmacological techniques such as fluorescence-based 
or radioligand binding studies and G-protein based functional assays. So far, the functional 
properties of these ligands in noncanonical signaling pathways, especially concerning 
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arrestin activation, are elusive. Combining the aforementioned arrestin recruitment assay, 
established and optimized during this work, with classical G-protein readouts, primarily the 
thesis aimed at an identification of ligands exhibiting functional bias between arrestin and 
G-protein activation. For this purpose, a broad variety of structurally diverse ligands of 
representative GPCRs at hand was considered. For the histamine HR1R and HR2R receptor, the 
selected compound libraries included several standard ligands, some of them drugs 
approved for decades, as well as a variety of structurally different compound classes 
designed and synthesized in our lab. Currently, the HR4R  is in the focus of extensive drug 
development efforts and explored as a potential new target for the therapy of 
inflammatory diseases. In this context, biased signaling at the HR4R , reported for some 
ligands, is becoming an issue, also addressed in the thesis. By analogy, argininamide-type 
antagonists developed as pharmacological tools for the NPY YR1R and YR2R receptor were 
included in view of putative arrestin selectivity, as these compounds exhibit 
insurmountable antagonism, a phenomenon, explainable by a stabilization of ligand 
specific receptor conformations. 
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3. Establishing a luciferase complementation assay 
to quantify arrestin recruitment by GPCRs 
3.1. Introduction 
For the investigation of functional selectivity of 7TM receptors regarding G-protein 
and arrestin mediated pathways, there was a need to complement the canonical G-protein 
based readouts routinely used in our lab. For this purpose a reliable method to measure 
arrestin activation by the GPCR, allowing the characterization of a multitude of receptor 
ligands in a robust, convenient and cost effective manner, was aimed at. 
Therefore, a luciferase complementation assay developed by Misawa et al.1 using 
fragments of the emerald luciferase (ELuc) from the Brazilian click beetle Pyrearinus 
termitilluminans, was taken into consideration. In comparison to the more widely used 
firefly luciferase, the emerald luciferase offers an advantage with respect to brightness, i.e. 
photon counts are roughly 10 times higher, and the emission spectrum is pH independent.1 
In a semirational combinatorial screening, Misawa et al. identified a pair of N-terminal (aa 
1 – 415) and C-terminal (aa 394 – 542) fragments of the ELuc that yielded excellent signal 
to noise ratios. Using these fragments, the authors were able to establish an arrestin 
recruitment assay and adapt it to several GPCRs. Fig. 3-1 illustrates the principle of the 
luciferase complementation assay. HEK293T cells were genetically engineered to express 
two fusion constructs, the GPCR of interest, C-terminally fused to the C-terminal fragment 
of ELuc, and either β-arrestin 1 or 2, fused to the N-terminal ELuc fragment. Upon agonist 
binding, conformational changes of the receptor lead to the activation of the signaling 
Fig. 3-1: Schematic illustration of the EFC-based β-arrestin recruitment assay 
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machinery and subsequently induce binding of the arrestin fusion construct. Thereby, the 
two inactive fragments of ELuc come into close proximity, restoring enzyme activity. The 
luciferase activity, reflecting the degree of arrestin recruitment to the receptor, can be 
determined by measuring the bioluminescence emitted upon oxidation of D-luciferin. 
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3.2. Results and discussion 
3.2.1. Generation of stable HEK293T transfectants 
In order to achieve maximal versatility of the assay for adaption to different GPCRs, 
a modular approach was chosen, starting with the generation of the parental cell lines 
expressing either one of the ELucN-βarrestin isoforms. The plasmid vectors, encoding the 
arrestin and receptor constructs, were kindly provided by Prof. Dr. Takeaki Ozawa from the 
University of Tokyo. HEK293T cells were transfected with pcDNA 3.1 HIS-myc B vectors, 
encoding either the ELucN-βArrestin1 or ELucN-βArrestin2 fusion constructs, using the 
FugeneHD transfection reagent. The vectors were linearized to facilitate the stable 
integration into the genome. G418 antibiotic selection afforded stable transfectants after 
2 – 3 weeks. These parental cells were subject to a second transfection using the pcDNA 4 
V5-HIS B vector encoding the different receptor-ElucC constructs and subsequent antibiotic 
selection using zeocin. 
In case of the βArr1 construct, the first transfection using a FugeneHD/DNA ratio of 
9/2 (µl/µg) was successful, giving an appropriate signal after transfection with the HR2R  
constructs. On the contrary, the βArr2 cells (termed HEK293T βArr2 T1), gave only poor 
results after HR2R  transfection. Therefore, the transfection was repeated using a 
FugeneHD/DNA ratio of 8/2 (µl/µg), varying the incubation period between the 
transfection and the start of the antibiotic selection from 24 to 48 h. The transfectants 
obtained after 24 h of incubation gave the most promising results after transfection with 
the HR2R  (termed HEK293T βArr2 T2). 
Using the three different parental cell lines, the arrestin recruitment assay was 
established for 5 different receptors, namely the HR1R, HR2R and HR4R receptor from the histamine 
receptor family as well as the YR1R and YR2R receptor from the NPY receptor family. For the HR1R  
and HR4R , the cells derived from the βArr2 T1 parental cell lines gave the highest signal 
intensity, whereas for the HR2R , YR1R  and YR2R  the cells originating from the βArr2 T2 parental 
cell line were superior. 
In total, 24 stable cell lines were generated. The detailed characterization of the 
transfectants, described below, was only performed in case of the parental cells and the 
receptor expressing cells used for further investigations. 
 
3.2.2. Expression analysis of the fusion constructs 
The expression levels of the ELucN-βArr and receptor-ElucC fusion proteins in the 
stably transfected HEK293T cells were analyzed using three different methods. Both, the 
arrestin and the receptor constructs, were investigated by western blot analysis. 
Furthermore, arrestin expression was analyzed by flow cytometry, whereas receptor 
expression was confirmed by radioligand saturation binding. 
- 26 - 
3.2 Results and discussion 
 
3.2.2.1. Western blot analysis 
The stably transfected HEK293T cells were analyzed using an antibody against the c-
myc tag of the arrestin fusion constructs and an antibody against the V5 epitope of the 
receptor fusion constructs. Whole cell extracts of the respective engineered cells and the 
untransfected HEK293T cells as negative control were prepared in RIPA buffer. For the 
detection of the arrestin fusion constructs, prior to SDS-PAGE, the samples were prepared 
according to a standard protocol: addition of Laemmli sample buffer followed by boiling for 
5 min. However, in case of the receptor constructs, preliminary experiments revealed that 
this procedure was inadequate, as a large portion of the receptor constructs formed 
aggregates and did not migrate into the gel properly. Therefore, the incubation was 
performed at different temperatures, and urea was added as a chaotropic agent, 
facilitating the solubilization of the hydrophobic transmembrane domains. The best results 
were achieved by incubation at RT for 30 min in the presence of 4 M urea. 
The theoretical molecular weights of the fusion constructs, calculated from their 
amino acid sequence, are 97 kDa for ELucN-βArr1 and ElucN-βArr2, 77 kDa for HR1R -ElucC, 
62 kDa for HR2R -ElucC, 66 kDa for HR4R -ElucC and YR1R -ElucC and 64 kDa for the YR2R -ElucC 
fusion construct. The samples were analyzed on two separate gels, the first loaded with the 
extracts of βArr1 and βArr2 T1 parental cells as well as with those of the corresponding HR1R  
and HR4R  expressing cells (Fig. 3-2 A, B: upper row, samples 2-7). Extracts of the βArr1 and 
βArr2 T2 parental cells and the corresponding HR2R , YR1R  and YR2R  cells were analyzed in a 
second gel. (Fig. 3-2 A, B: lower row, samples 2, 8-14). Untransfected HEK293T cells were 
included as negative control (sample 1). After protein transfer, the membranes were cut in 
two parts closely above the 50 kDa band of the prestained protein ladder. The upper part 
was treated with the antibodies recognizing the c-myc or the V5 epitope, while the lower 
part was developed with a β-actin AB and served as a loading control for the protein 
samples. 
The ELucN-arrestin fusion proteins migrated as sharp, single bands shortly below the 
100 kDa band of the biotinylated protein ladder for both, the βArr1 and βArr2 isoform (cf. 
Fig 3-2), in accordance with the theoretical molecular weight of the constructs. No 
unspecific binding of the anti c-myc AB was detected in the relevant range of the HEK293T 
control (1). The βArr1 (2) and βArr2 T1 (3) parental cells revealed comparable expression 
levels of the fusion proteins, whereas a considerably lower expression was found for the 
βArr2 T2 cells. The analysis of the receptor expressing cells revealed a drastic impact of the 
second transfection and the subsequent selection procedure on the expression levels of 
the arrestin constructs. The βArr1 + HR1R  (4) and βArr1 + HR2R  (9) cell lines showed a higher 
arrestin expression than the corresponding parental cells. By contrast, several other 
receptor expressing cells exhibited a distinct reduction of the expression level, most 
pronounced in case of the βArr2 + HR2R  (10), βArr2 + YR1R  (12), and βArr1 + YR2R  cells (13). 
The receptor-ElucC fusion proteins, except for the YR2R  construct, migrated untypically, 
producing a smear without clearly resolved bands, which complicated the quantification of 
the signal intensities. In the negative control samples, no unspecific binding of the AB was 
detected in the relevant size range. However, in preliminary experiments conducted 
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without β-actin staining as loading control, the AB produced strong unspecific bands at 
approximately 25 and 45 kDa The HR1R  construct (4 and 5) showed a strong diffuse band at 
approximately 90 kDa and two additional feint, faster migrating bands. The expression level 
was slightly higher in the βArr1 than the βArr2 cell line. The HR4R -ELucC proteins (6 and 7) 
produced a fuzzy band at approximately 70-80 kDa and a faint smear above and below. The 
expression level was higher in the βArr2 than in the βArr1 cells, but for both considerably 
Fig. 3-2: Western blot analysis of the stably transfected HEK293T cell lines. A: 
Immunodetection using a c-myc AB against the ELucN-βArr fusion proteins. B: 
Immunodetection using a V5 AB against the receptor-ELucC fusion proteins. A and B: The lower 
part of the blots was developed using a β-actin AB and served as loading control. Whole cell 
extracts of the following cell lines were analyzed: 1) HEK293T (untransfected); 2) HEK293T 
βArr1; 3) HEK293T βArr2 T1; 4) HEK293T βArr1 + H1R; 5) HEK293T βArr2 + H1R; 6) HEK293T βArr1 
+ H4R; 7) HEK293T βArr2 + H4R; 8) HEK293T βArr2 T2; 9) HEK293T βArr1 + H2R; 10) HEK293T 
βArr2 + H2R; 11) HEK293T βArr1 + Y1R; 12) HEK293T βArr2 + Y1R; 13) HEK293T βArr1 + Y2R; 14) 
HEK293T βArr2 + Y2R. 
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lower than in the HR1R  expressing cells. The HR2R  construct (9 and 10) gave a faint smear 
from ∼120-80 kDa and a slightly more distinct band shortly above 60 kDa with slightly 
higher overall expression in the βArr1 than in the βArr2 cells. The YR1R -ElucC protein (11 and 
12) gave a similar picture as the HR2R  construct with a clearer band at approx. 90 kDa. The 
expression levels were comparable for both cell lines. The YR2R  construct (13 and 14) was 
the only one that migrated as a single defined band at ∼70 kDa. The signal intensity was 
several times higher for the βArr2 compared to the βArr1 cells, but for both cell lines, the 
YR2R  expression was on a high level. 
Overall, the detected migration pattern correlated poorly with the theoretical 
molecular masses of the receptor fusion proteins. The higher molecular masses could be 
explained by variations in the degree and pattern of glycosylation of the different 
receptors.2,3 Moreover, the putative formation of receptor dimers was proposed as an 
explanation for similar observations.4 
 
3.2.2.2. Flow cytometric analysis 
Contrary to western blots, flow cytometry allows to analyze the expression of a target 
protein on a cellular level, enabling the identification of different subpopulations. For the 
analysis of the arrestin and the receptor fusion proteins the cells were fixed with 
paraformaldehyde and subsequently permeabilized by means of saponin. 
The flow cytometric analysis of the ELucN-arrestin expression was performed using 
an anti c-myc AB and a secondary R-PE coupled AB. Forward and side scatter gating was 
applied to exclude cell debris and aggregates (cf. Fig. 3-3 A). The background fluorescence 
of the stained, untransfected HEK293T cells served as negative control, allowing for setting 
a cut-off gate in the relevant fluorescence channel to discriminate between positive and 
negative cell populations (cf. Fig. 3-3 A). The fraction of positive cells and their mean 
fluorescence as well as the mean fluorescence of the total cell population are given in Table 
3-1. The transfected cells revealed a very inhomogeneous picture, as a high portion of 
negative cells was identified in case of several transfectants, e. g.  54 % of βArr1 parental 
cells were negative (cf. Fig. 3-3 B). The second transfection and subsequent antibiotic 
selection had a substantial influence on the ELucN-arrestin expression (cf. Fig. 3-3 B). For 
the HR1R  and YR1R  receptor expressing cells, the fraction of positive cells increased 
considerably to 89 and 83 %, respectively, whereas for the HR4R  and YR2R  expressing cells, 
the fraction of negative cells remained around 50 %. The mean fluorescence of the positive 
cell population increased for the HR2R  cells, while all other cell lines exhibited a reduction 
compared to the parental cell line. 62 % of the HEK293T βArr2 T1 parental cells were 
immunopositive, and the fraction increased upon repeated transfection, giving up to 92 % 
positive cells with slightly elevated mean fluorescence for the corresponding HR4R  cells (cf. 
Fig 3-3 C). For the βArr2 T2 parental cells, transfection led to an increase in the receptor 
positive cell population as well as the mean fluorescence thereof for the HR2R  and YR1R  cell 
lines, while the YR2R  cell line showed a lower fraction of positive cells, although with an 
considerably increased mean fluorescence intensity(cf. Fig 3-3 D). 
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Fig. 3-3: Flow cytometric analysis of ELucN-arrestin expression using the c-myc AB. A: Physical gate 
and background fluorescence of the stained HEK293T negative control. B: ELucN-arrestin 
expression by the HEK293T βArr1 parental cell line and the receptor cell lines derived therefrom. 
C: ELucN-arrestin expression of the HEK293T βArr2 T1 parental cells and the receptor expressing 
cells derived therefrom. D: ELucN-arrestin expression of the HEK293T βArr2 T2 parental cells and 
the receptor expressing cells derived therefrom. 
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 Table 3-1: Flow cytometric analysis of the ELucN-arrestin expression. The percentage 
of cells giving a positive R-PE signal as well as the mean fluorescence of the R-PE 
positive and total cell population is given. 
Cell line % R-PE + cells mean fluorescence (R-PE + cells) 
mean fluorescence 
(total cells) 
HEK293T 0.1  6.9 
HEK293T βArr1 45.6 93.0 47.2 
HEK293T βArr1 + HR1R  88.6 69.5 62.7 
HEK293T βArr1 + HR2R  74.8 142 108 
HEK293T βArr1 + HR4R  49.9 71.6 39.5 
HEK293T βArr1 + YR1R  82.7 79.8 68.0 
HEK293T βArr1 + YR2R  51.9 78.3 44.0 
HEK293T βArr2 T1 62.0 66.2 44.1 
HEK293T βArr2 + HR1R  75.9 51.7 41.5 
HEK293T βArr2 + HR4R  92.4 79.4 74.2 
HEK293T βArr2 T2 56.8 54.8 34.8 
HEK293T βArr2 + HR2R  80.3 84.9 70.0 
HEK293T βArr2 + YR1R  81.8 64.6 54.6 
HEK293T βArr2 + YR2R  53.3 104 59.9 
    
Unfortunately, due to the lack of a suitable antibody, analysis of the receptor-ElucC 
constructs by analogy with the procedure used for the ElucN-arrestin expression was 
impossible. Three different anti V5 antibodies were tested in the flow cytometric analysis, 
all of them revealed very high unspecific binding at the HEK293T cells used as negative 
control. Reduction of the photomultiplier voltage failed to discriminate between 
transfected and untransfected cells. In western blot analysis, all three antibodies produced 
a similar pattern of unspecific bands. 
 
3.2.2.3. [3H]Mepyramine saturation binding at the HR1R  expressing cells 
[3H]Mepyramine bound in a specific, saturable manner to 
both the HEK293T βArr1 + HR1R  and the HEK293T βArr2 + HR1R  cells. 
Unspecific binding was determined in the presence of 10 µM 
diphenhydramine and accounted for less than 12 % of total 
binding at radioligand concentrations up to 80 nM. The 
determined KRDR values for [3H]mepyramine, 4.5 nM at the 
HEK293T βArr1 + HR1R  and 4.4 nM at the HEK293T βArr2 + HR1R  
cells, are in accordance with data reported in literature.2,5 The 
determined BRmaxR values allowed the calculation of the number of 
Fig. 3-4: Structure of 
[3H]mepyramine 
N
N
NO
3H
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specific binding sites per cell, revealing a comparably high receptor expression level for 
both cell lines, 5.5·105 receptors/cell for the HEK293T βArr1 + HR1R  and 4.7·105 
receptors/cell for the HEK293T βArr2 + HR1R  cells, respectively. 
 
 
3.2.2.4. [3H]UR-DE257 saturation binding at the HR2R  expressing cells 
[3H]UR-DE257 bound in a specific, 
saturable manner to both the HEK293T 
βArr1 + HR2R  and HEK293T βArr2 + HR2R  
cells. Unspecific binding, determined in 
the presence of 10 µM famotidine, 
accounted for up to 48 % of the total 
binding at a radioligand concentration 
of 150 nM at the HEK293T βArr2 + HR2R  and 31 % at the HEK293T βArr1 + HR2R  cells, 
respectively. The determined KRDR value of 17 nM at the βArr2 cells was considerably lower 
than that at the βArr1 cells (KRDR = 44 nM). This discrepancies are probably caused by the 
high unspecific binding at the βArr2 cells, as the determined KRDR value at the HEK293T βArr1 
+ HR2R  cells correlated well with previous findings either using Sf9 membranes expressing 
HR2R -GRsαSR fusion proteins (KRDR = 31 nM) or HEK293T CRE-Luc hHR2R  cells (KRD R= 55 nM).6 The 
calculation of the binding sites yielded an expression level of 4.0·105 receptors/cell for the 
HEK293T βArr1 + HR2R  cells and 2.9·105 receptors/cell for the HEK293T βArr2 + HR2R  cells. 
Fig. 3-5: [3H]Mepyramine saturation binding experiments using HEK293T βArr1 + H1R and HEK293T 
βArr2 + H1R cells. Total (circles), specific (triangles) and unspecific (squares) binding was fitted by 
nonlinear regression to a one site saturation binding model. Unspecific binding was determined in 
the presence of diphenhydramine (10 µM). Data are mean values ± SEM of a single experiment 
performed in triplicates. 
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Fig. 3-6: Structure of [3H]UR-DE257 
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3.2.2.5. [3H]Histamine saturation binding at the HR4R  expressing cells 
[3H]Histamine bound in a specific, saturable manner to both the 
HEK293T βArr1 + HR4R  and HEK293T βArr2 + HR4R  cells. Unspecific 
binding, determined in the presence of 10 µM thioperamide, was 
accounted for up to 48 % of the total binding at the HEK293T βArr1 + 
HR4R  and 39 % at the HEK293T βArr2 + HR4R  cells. The determined KRDR 
values, 23 nM at the HEK293T βArr1 + HR4R  and 39 nM at the HEK293T 
βArr2 + HR4R  cells, were considerably higher than previously 
reported.4,7,8 The BRmaxR values for the [3H]histamine binding at the HR4R  were substantially 
lower than for the saturation binding experiments at the HR1R  and HR2R  expressing cells; the 
Fig. 3-9: [3H]Histamine saturation binding experiment using the HEK293T βArr1 + H4R and HEK293T 
βArr2 + H4R cells. Total (circles), specific (triangles) and unspecific (squares) binding was fitted by 
nonlinear regression to a one site saturation binding model. Unspecific binding was determined in 
the presence of thioperamide (10 µM). Data are mean values ± SEM of a single experiment 
performed in triplicates. 
N
HN
NH2
3H
Fig. 3-8: Structure 
of [3H]histamine 
Fig. 3-7: [3H]UR-DE257 saturation binding experiment using the HEK293T βArr1 + H2R and HEK293T 
βArr2 + H2R cell lines. Total (circles), specific (triangles) and unspecific (squares) binding was fitted 
by nonlinear regression to a one site saturation binding model. Unspecific binding was determined 
in the presence of famotidine (10 µM). Data are mean values ± SEM of a single experiment 
performed in triplicates. 
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expression levels amounted to 3.7·104 receptors/cell for the HEK293T β-Arr1 + HR4R  and 
8.1·104 receptors/cell for the HEK293T β-Arr2 + HR4R  cells. 
 
3.2.2.6. [3H]UR-MK136 saturation binding at the YR1R  expressing cells 
[3H]UR-MK136 bound specifically to both the 
HEK293T βArr1 + YR1R  and HEK293T βArr2 + YR1R  
cells. Unspecific binding was determined in the 
presence of 1 µM BIBO3304 and was well 
controlled, accounting for less than 25 % in the 
used concentration range. [3H]UR-MK136 binding 
was not saturable at the investigated cells at 
concentrations up to 8 nM. Unfortunately, higher 
concentration of the radioligand failed to 
determine specific binding, a phenomenon often 
associated with the existence of a second, low affinity binding site for the radioligand. The 
determined KRDR values, 24 nM at the HEK293T βArr1 + YR1R  and 11 nM at the HEK293T βArr2 
+ YR1R  cells, are considerably higher than previously reported for different cellular 
backgrounds (2.0 nM at SK-NM-C cells and 6.2 nM at MCF-7-YR1R cells). The receptor 
expression calculated from the BRmaxR values, 1.4·105 receptor/cell at the HEK293T βArr1 + 
YR1R  and 1.0·105 receptor/cell at the HEK293T βArr2 + YR1R  cells, was on an average level. 
Unfortunately, the reliability of both, the determined KRDR and BRmaxR values, is challenged by 
the insufficient concentration range for a saturation binding experiment. Especially the 
BRmaxR values estimated with the GraphPad Prism software were considerably higher as the 
highest experimentally determined specific binding value. 
 
Fig. 3-11: [3H]UR-MK136 saturation binding experiment using the HEK293T βArr1 + Y1R and 
HEK293T βArr2 + Y1R cells. Total (circles), specific (triangles) and unspecific (squares) binding was 
fitted by nonlinear regression to a one site saturation binding model. Unspecific binding was 
determined in the presence of BIBO3304 (1 µM). Data are mean values ± SEM of a single 
experiment performed in triplicates. 
Fig. 3-10: Structure of [3H]UR-MK136 
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3.2.2.7. [3H]UR-PLN187 saturation binding at the YR2R  expressing cells 
[3H]UR-PLN187 bound in a specific, saturable manner to both the HEK293T βArr1 + 
YR2R  and the HEK293T βArr2 + YR2R  cells. Unspecific binding, determined in the presence of 
10 µM JNJ31020028, accounted for up to 56 % of the total binding at a radioligand 
concentration of 90 nM at the HEK293T βArr1 + YR2R  and 32 % at the HEK293T βArr2 + YR2R  
cells, respectively. The differences in the determined KRDR values, 37 nM at the HEK293T 
βArr1 + YR2R  and 71 nM at the HEK293T βArr2 + YR2R  cells, are probably caused by the 
substantially lower specific binding at the HEK293T βArr1 + YR2R  cells and, thus, high portion 
of unspecific binding. Additionally, the saturation binding experiment could not be carried 
out at higher radioligand concentrations, as the unspecific binding increased excessively at 
concentrations above 90 nM, preventing the generation of meaningful binding data. 
Receptor expression was calculated to 8.3·105 receptors/cell for the HEK293T βArr1 + YR2R  
and 2.1·106 receptors/cell for the HEK293T βArr2 + YR2R  cells, thus showing the highest 
receptor expression level of all cells investigated in this project, although the reliability is 
likewise questioned by the insufficient concentration range. 
Fig. 3-13: [3H]UR-PLN187 saturation binding experiment using the HEK293T βArr1 + Y2R and 
HEK293T βArr2 + Y2R cells. Total (circles), specific (triangles) and unspecific (squares) binding was 
fitted by nonlinear regression to a one site saturation binding model. Unspecific binding was 
determined in the presence of JNJ31020028 (10 µM). Data are mean values ± SEM of a single 
experiment performed in triplicates. 
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Fig. 3-12: Structure of [3H]UR-PLN187 
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3.2.2.8. Overview of the receptor expression levels determined by 
radioligand binding 
The receptor expression levels for the 
different cell lines, given in Table 3-2 were 
calculated from the BRmaxR values derived from 
the corresponding saturation binding 
experiments. The expression levels differed 
considerably. The lowest expression was 
found for the HR4R  with only 40000, 
respectively, 80000 receptors/cell, while for 
the YR2R , up to 2.1 million receptors/cell were 
found. Unfortunately, some of the saturation 
binding experiments could not be performed 
at sufficiently high radioligand concentration, 
especially for the YR1R  and YR2R , thus impairing 
the reliability of the determined expression 
levels. 
 
3.2.2.9. Comparison of the expression levels 
The expression of the receptor constructs was verified by western blot and 
radioligand saturation binding. For the 5 different receptors, the results from both 
analytical methods correlated well. For the HR1R , radioligand binding revealed a higher 
number of binding sites/cell for the βArr1 compared to the βArr2 cells, coinciding with the 
corresponding intensities detected in the western blot analysis. A similar correlation was 
found for the HR2R  and YR1R  cells in both readouts. For the HR4R , the lowest receptor 
expression of all cell lines was determined in radioligand binding and confirmed by the low 
intensity in the western blot, especially, when the strong bands of the loading control were 
taken into account. For the YR2R , by far the highest number of receptors/cell was found in 
radioligand binding, although the reliability of the determined BRmaxR values was 
questionable due to the insufficient concentration range in the respective saturation 
binding experiments. However, a high expression level was confirmed in the western blot 
analysis, where a very strong signal relative to the loading control was found, especially for 
the βArr2 cells. 
The comparison of the expression data for the ELucN-arrestin constructs derived 
from western blot and flow cytometric analysis was more complicated. Flow cytometric 
analysis allows to investigate expression levels at a cellular level, enabling the identification 
of different subpopulations. However, the obtained fluorescence values are difficult to 
quantify in terms of expression levels. The most suitable measure for flow cytometric 
quantification of the average expression level is the mean fluorescence of the total cell 
population, although a rather contrived value for cell lines with different subpopulations. 
Table 3-2: receptor expression levels 
calculated from the Bmax values 
 
Cell line receptors/cell (/105)  
βArr1 + H1R 5.5  
βArr2 + H1R 4.7  
βArr1 + H2R 4.0  
βArr2 + H2R 2.9  
βArr1 + H4R 0.4  
βArr2 + H4R 0.8  
βArr1 + Y1R 1.4  
βArr2 + Y1R 1.0  
βArr1 + Y2R 8.3  
βArr2 + Y2R 21  
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The mean fluorescence correlated well with the signal intensities in the western blot when 
comparing the different cell lines for each individual receptor, but globally, much more 
pronounced differences became obvious from western blot analysis compared to flow 
cytometry. 
 
3.2.3. Optimization of the assay conditions 
3.2.3.1. Influence of DMSO on the assay performance 
Many ligands for the histamine and neuropeptide Y receptors are rather lipophilic 
compounds exhibiting poor solubility in aqueous solutions and therefore require the use of 
DMSO as solvent for the preparation of higher concentrated stock solutions. As DMSO can 
strongly influence the performance of cellular assays, the tolerance of the arrestin 
recruitment assay against DMSO was explored. For this purpose, the HEK293T βArr1 + HR2R  
cells were stimulated with 100 µM of histamine in the presence of up to 8 % (v/v) DMSO. 
Concentrations of DMSO up to 3 % led to an increase in the luciferase signal intensity and 
up to 6 % were well tolerated. By contrast, DMSO concentrations exceeding 6 %, resulted 
in a considerable drop in signal intensity. Therefore, while DMSO at the relevant 
concentrations did not impair the arrestin recruitment assay, care had to be taken with 
regard to the normalization of the data. Thus, the raw data for the respective ligands were 
normalized to the maximal effect induced by the endogenous ligand and the solvent, both 
containing the corresponding amount of DMSO. Furthermore, the DMSO concentration 
was kept constant within the dilution series. 
 
  
Fig. 3-14: Influence of increasing concentrations of DMSO on the luciferase signal intensity of 
the β-arrestin recruitment assay. HEK293T βArr1 + H2R were stimulated by 100 µM histamine 
and the indicated concentrations of DMSO. Data are mean values ± SEM of quadruplicates. 
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3.2.3.2. Time dependence of β-arrestin recruitment 
In order to determine the optimal incubation period for the arrestin recruitment 
assay, the time course of the signal intensity after ligand stimulation was investigated. 
Hereby, the different receptors in combination with the two arrestin isoforms exhibited 
rather divergent characteristics. At the HR1R , the recruitment of both βArr1 and βArr2 
followed a similar time course with the maximal signal intensity after approximately 60 
min. In combination with the HR2R , the two arrestin isoforms differed considerably. The 
Fig. 3-15: Time dependence of the β-arrestin recruitment assay after stimulation with 100 µM 
histamine (A, B, C) or 1 µM NPY (D, E). A: Stimulation of the HEK293T βArr1 + H1R (squares) or 
HEK293T βArr2 + H1R (triangles) cells; B: Stimulation of the HEK293T βArr1 + H2R (squares) or 
HEK293T βArr2 + H2R (triangles) cells; C: Stimulation of the HEK293T βArr1 + H4R (squares) or 
HEK293T βArr2 + H4R (triangles) cells; D: Stimulation of the HEK293T βArr1 + Y1R (squares) or 
HEK293T βArr2 + Y1R (triangles) cells; E: Stimulation of the HEK293T βArr1 + Y2R (squares) or 
HEK293T βArr2 + Y2R (triangles) cells. Data are mean values ± SEM of a single experiment. 
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onset of βArr1 recruitment was rather slow, the signal reached maximum intensity only 
after 90 min and remained constant for up to 120 min. βArr2 recruitment already reached 
high levels after 30 min with the maximum after 60 min and showed a slow decrease in 
signal intensity with longer incubation periods. At the HR4R , both isoforms, while differing 
in absolute signal intensity, showed a similar characteristic. The signal reached maximum 
intensity already after 30 min and quickly decreased after 45 min. At the YR1R , βArr2 
recruitment gave a maximum signal intensity after 45 min, only slowly degrading with 
longer incubation time and retaining at more than 80 % of the maximal signal even after 
120 min. The βArr1 cell line produced a much lower signal of constant intensity for up to 
45 min incubation time, slowly degrading afterwards. At the YR2R , both isoforms exhibited 
a similar time course, with the signal intensity reaching a maximum after 45-60 min, 
followed by a pronounced decline with longer incubation times. The incubation times for 
the investigation of ligands were adapted accordingly to achieve maximal signal intensity 
with each of the cell lines. 
 
3.2.3.3. General considerations 
The luciferase complementation assay was performed using the BrightGlo luciferase 
assay reagents from Promega. As the reagent was added to the cells at a 1:1 ratio with 
respect to the assay mixture, 50 µl were removed from each well prior to BrightGlo 
addition, giving a final volume of 100 µl. This step had only a marginal effect on the signal 
intensity, but cut the reagent consumption and thus costs of the assay by 50 %. The 
adaption of the workup procedure according to a luciferase reporter gene assay 
established in our lab9 was not successful, as the self-complemented luciferase was 
unstable under the harsher assay conditions, so that little to no bioluminescence was 
detectable. Furthermore, the reconstituted luciferase revealed thermal instability, as 
incubation at 37 °C after ligand addition completely abolished the bioluminescence signal. 
Therefore, incubation was carried out using a plate shaker tempered to 25 °C in an air-
conditioned laboratory to avoid temperature related variation in assay performance. 
 
3.2.4. Signal intensities and signal-to-noise ratios 
Fig. 3-16 gives a summary of the signal intensities achieved in the luciferase 
complementation assay using the stably transfected HEK293T cells expressing the different 
receptor constructs in combination with either one of the arrestin fusion proteins. The 
absolute signal intensities differed tremendously between the individual cell lines, from 
more than 220 000 cps for the HR2R  expressing cells with either arrestin isoform to only 
about 4000 cps for the βArr1 + HR4R  cells. Fortunately, the background noise was well 
controlled in this assay. In the worst case i. e. with HEK293T βArr2 + HR1R  cells, the maximal 
signal was about 7 fold above the noise level, whereas with HEK293T βArr1 + YR1R  cells a 
signal-to-noise ratio higher than 200 was achieved. 
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The differences between the signal 
intensities in the luciferase 
complementation assay found for the 
different receptors cannot be explained by 
varying expression of the necessary protein 
constructs. For example, both HR1R  
expressing cell lines showed comparable or 
higher expression levels of both, the 
receptor and arrestin constructs, with those 
of the corresponding HR2R  cell lines, but 
produced only a fraction of the signal in the 
arrestin recruitment assay. In case of the 
YR1R  receptor, the bioluminescence signal 
was distinctly dependent on the co-
expressed arrestin isoform, with an 8-fold 
higher signal intensity for βArr2 than βArr1 
recruitment, despite comparable expression 
levels of the constructs in both cell lines. 
These findings might point towards 
basal differences in receptor-arrestin 
interaction inherent for the individual 
receptors, although the exact nature of 
these effects remains elusive. 
  
βArr1 βArr2 βArr1 βArr2 βArr1 βArr2 βArr1 βArr2 βArr1 βArr2
H1R H2R Y1R Y2RH4R
Fig. 3-16: Maximum signal intensities of the different transfectants in the luciferase 
complementation assay after stimulation with the endogenous ligands, i. e. histamine for the HxR 
cells and NPY for the YXR cells. 
Table 3-3: Signal-to-noise ratios of the 
luciferase complementation assay  
 
Cell line signal/noise ratio  
HEK293T βArr1 + H1R 34  
HEK293T βArr2 + H1R 7  
HEK293T βArr1 + H2R 17  
HEK293T βArr2 + H2R 14  
HEK293T βArr1 + H4R 14  
HEK293T βArr2 + H4R 11  
HEK293T βArr1 + Y1R 277  
HEK293T βArr2 + Y1R 215  
HEK293T βArr1 + Y2R 119  
HEK293T βArr2 + Y2R 57  
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3.3. Summary and conclusions 
The luciferase complementation assay proved to be a versatile and reliable method 
to measure arrestin recruitment to the receptor. Adapted for the investigation of three 
histamine and two NPY receptor subtypes, the assay worked reliably and with very low 
noise. The expression of the ELucN-arrestin fusion constructs was verified by western blot 
and flow cytometry in all transfectants. In addition, the expression of the receptor-ELucC 
fusion constructs was demonstrated by western blot analysis and saturation binding 
experiments using radioligands suitable for the individual receptors. The implementation 
of the 96 well microtiter format provides the throughput necessary to enable the 
investigation of a multitude of compounds within a short period of time. Furthermore, the 
employed modular approach will allow for a convenient adaption of the assay to different 
GPCRs in subsequent projects. 
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3.4. Materials and methods 
3.4.1. Materials 
Unless stated otherwise, all chemicals and reagents were from Sigma-Aldrich Chemie 
(Munich, Germany) or Merck (Darmstadt, Germany). FCS and G418 sulfate were from 
Biochrom (Berlin, Germany). Zeocin was from Thermo Fisher Scientific (Rockford, IL, USA). 
PvuI restriction enzyme was from New England Biolabs (Frankfurt a.M., Germany). 
QIAquick PCR Purification Kit was from Qiagen (Hilden, Germany). Fugene HD transfection 
reagent was from Roche Diagnostics (Mannheim, Germany). The DC protein assay kit was 
purchased from Bio-Rad Laboratories (Munich, Germany), BSA (Albumin bovine Fraction V 
receptor grade) was from Serva Electrophoresis (Heidelberg, Germany). Biotinylated 
Protein Ladder (9-200 kDa) was from Cell Signaling Technology (Danvers, MA, USA). The 
precision plus protein dual color standard was from Bio-Rad Laboratories (Munich, 
Germany). Pierce 9E10 mouse anti c-myc antibody, life technologies mouse anti c-myc 
mAb, Pierce V5 tag AB (E10/V4RR) from mouse and life technologies mouse anti V5 mAb 
were from Thermo Fisher Scientific (Rockford, IL, USA). AbD-Serotec mouse anti V5-TAG: 
DyLight549 was from Bio-Rad Laboratories (Munich, Germany). β-actin (13E5) rabbit mAb 
was from Cell Signaling Technology (Danvers, MA, USA). Anti mouse IgG HRP conjugated 
was from Sigma-Aldrich Chemie (Munich, Germany). Donkey anti-rabbit IgG-HRP (sc-2305) 
was from Santa Cruz Biotechnology (Dallas, TX, USA) Pierce ECL Western Blotting substrate 
was from Thermo Fisher Scientific (Rockford, IL, USA). [3H]Mepyramine and [3H]histamine 
were from Hartmann Analytic (Braunschweig, Germany). The radioligands [3H]UR-DE257, 
[3H]UR-MK136 and [3H]UR-PLN187 were synthesized in our lab.6,10,11 Diphenhydramine was 
from Sigma-Aldrich Chemie (Munich, Germany). Famotidine was from Sigma (St Lois, MO, 
USA). Thioperamide was from Tocris Bioscience (Ellisville, MO, USA). BIBO3304 
JNJ31020028 were synthesized in our lab. BrightGlo luciferase assay reagent was from 
Promega (Mannheim, Germany). 
 
3.4.1.1. Plasmids 
The plasmids encoding the arrestin and receptor fusion constructs were kindly 
provided by Prof. Dr. Takeaki Ozawa from the Department of Chemistry, School of Science, 
University of Tokyo. Fig. 3-17 gives an overview of the plasmids used in this thesis as well 
as the utilized expression vectors and the employed cloning strategy. For the expression of 
the ELucN-arrestin constructs, the pcDNA 3.1 myc-HIS B vector, allowing the expression of 
the fusion protein under control of the highly active CMV promoter, was used. 
Furthermore, the vector comprises the neomycin resistance gene, allowing the generation 
of stable transfectants via G418 antibiotic selection. The receptor-ELucC fusion constructs 
were cloned into the pcDNA 4 V5 HIS B vector, providing the zeocin resistance gene for 
antibiotic selection. The arrestin fusion proteins include a c-myc epitope tag for antibody 
recognition as well as a C-terminal hexahistidine tag for increased proteolytic stability. The 
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receptor fusion proteins instead were expressed with a V5 epitope tag for antibody 
recognition and the C-terminal hexahistidine tag. 
3.4.2. Cell culture 
HEK293T cells were cultivated in Dulbecco’s Modified Eagle Medium containing L-
glutamine, 4.5 g/L glucose, 3.7 g/L NaHCOR3R, 110 mg/L sodium pyruvate (DMEM) and 10 % 
(v/v) FCS at 37 °C in a water saturated atmosphere containing 5 % COR2R. Whenever 
necessary, cells were detached by treatment with 0.05 % trypsin, 0.02 % EDTA in PBS (137 
mM NaCl, 2.7 mM KCl, 10 mM NaR2RHPOR4,R 2 mM KHR2RPOR4R, pH 7,4) and diluted as needed in 
fresh DMEM + 10 % FCS. For the HEK293T cells transfected with the β-arrestin constructs 
in the pcDNA 3.1 myc-HIS (B) vector, 600 µg/ml G418 were added to the media. In case of 
the cells co-transfected with the receptor constructs in the pcDNA 4 V5-HIS (B) vector, 400 
µg/ml zeocin were additionally added. For storage, logarithmically growing cells were 
harvested and resuspended in DMEM + 10 % FCS +10 % (v/v) DMSO. Aliquots were slowly 
cooled down to -80 °C prior to storage in the vapor phase of liquid nitrogen. 
MCSMCS
ELucN ARRB1 myc-HIS
ELucN ARRB2 myc-HIS
H1R/H4R/Y2R ELucC V5-HIS
LinkerHindIII XhoI SacII Stop
H2R ELucC V5-HIS
LinkerBamHI XhoI SacII StopLinkerHindIII + Kz BamHI EcoRI Stop
LinkerHindIII + Kz EcoRI XhoI Stop
Y1R ELucC V5-HIS
LinkerHindIII XbaI SacII Stop
Fig. 3-17: Maps of the used eukaryotic expression vectors pcDNA 3.1 myc-HIS B and pcDNA 4 V5-
HIS B including the β-arrestin and receptor fusion constructs. The restriction sites used for cloning 
are given in the common nomenclature. 
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3.4.3. Stable transfection of HEK293T cells  
The plasmids for the transfection of the HEK293T cells were linearized prior to use in 
order to promote integration of the gene constructs into the genome. The plasmids were 
digested with the restriction enzyme PvuI for 3 h at 37 °C. The mixture contained 40 µg 
plasmid DNA, 5 µl NEB4 buffer, 0.5 µl 100x BSA, 2 µl PvuI brought to 50 µl with sterile 
filtered HR2RO. Afterwards, the linearized plasmids were purified using the QIAquick PCR 
Purification Kit according to manufacturer´s instructions. 24 h prior to the transfection, the 
HEK293T cells were seeded in 2 ml DMEM + 10 % FCS into 6 well plates at a density of 1 
mio cells/well. For the transfection, Fugene HD transfection reagent was used. DMEM was 
added to 2 µg of plasmid DNA to a total volume of 100 µl, and thoroughly mixed before the 
addition of 6 – 9 µl of Fugene HD transfection reagent. After incubation for 15 min at RT, 
the transfection mixture was added in a drop wise manner to the cells. The cells were then 
incubated for 24 or 48 h at 37 °C in a water saturated atmosphere containing 5 % COR2R 
before starting with the antibiotic selection. Cells transfected with the pcDNA 3.1 myc-HIS 
(B) vector were cultivated in the presence of 600 µg/ml G418 for up to 3 weeks until stable 
growth was observed. For the cells transfected with the pcDNA 4 V5-HIS (B) vector, 400 
µg/ml zeocin was used. 
 
3.4.4. Western blot analysis 
3.4.4.1. Sample preparation 
The HEK293T cells were seeded in 75-cm2 tissue culture flasks and cultivated for 2 to 
3 days in DMEM + 10% FCS to a confluence of about 60-90 %. The cells were then washed 
3 times with ice cold PBS and subsequently lysed with 1 ml of RIPA buffer(20 mM Tris/HCl 
pH 7.8, 200 mM NaCl, 1 mM EGTA, 1 mM, 1 % w/v Triton X-100, 5 mM KR2RHPOR4R, 1 x protease 
inhibitor mix (Sigma)). The crude mixture was transferred to 1.5-ml reaction vessels and 
incubated on ice for 20 min. During this period, the vessels were vigorously vortexed 
several times. The cell debris was removed by centrifugation (13000 g, 5 min). The 
supernatant was mixed with 10 % (v/v) glycerol, and aliquots were frozen and stored at -
80 °C. 
The protein content of the samples was determined using the DC protein assay kit 
(Bio-Rad) according to manufacturer’s instructions. The samples were 10-fold diluted with 
PBS, and a dilutions series of BSA up to 1.5 mg/ml was used to construct a calibration curve. 
The assay was performed in clear, flat bottom 96-well micro titer plates and the absorbance 
was measured at a wavelength of 700 nm using the Sunrise remote plate reader (Tecan 
Austria, Grödig, Austria). 
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3.4.4.2. SDS-PAGE 
The protein samples were analyzed by SDS-PAGE on a 12 % acrylamide gel according 
to the general procedure established by Laemmli et al.12 The solution for the preparation 
of two small 12 % gels was prepared by mixing 5.3 ml of water, 4 ml of buffer A (1.5 M 
Tris/HCl pH 8.8, 0.4 % (w/v) SDS), 6.2 ml of 30 % acrylamide/ bisacrylamide solution (Sigma) 
and 7 µl of N,N,N',N'-tetramethylethylenediamine (TEMED). The polymerization was 
started by adding 70 µl of 10 % (w/v) ammonium peroxodisulfate (APS) solution. After filling 
the gel apparatus, the solution was overlaid with water-saturated isobutyl alcohol to 
support the formation of a smooth gel front. The gel was then allowed to polymerize for at 
least 30 min, followed by adding the stacking gel, containing 6.5 ml of water, 2.5 ml of 
buffer B (0.5 M Tris/HCl pH 6.8, 0.4 % (w/v) SDS), 1 ml of 30 % acrylamide/bisacrylamide 
solution, 7 µl of TEMED and 70 µl of 10 % (w/v) APS. The gel was then stored at 4 °C 
overnight to allow complete polymerization. 
For gel electrophoresis, 20 µg of protein per sample were loaded onto each lane. The 
samples for the detection of the V5-tagged receptor fusion constructs were mixed with 1 
volume of 2x sample buffer containing 8 M urea and incubated for 30 min at room 
temperature. The samples for the detection of the c-myc-tagged arrestin fusion constructs 
were mixed with 1 volume of 2x sample buffer (Sigma) and incubated for 10 min at 98 °C. 
The precision plus dual color and biotinylated protein ladder were used as molecular weight 
markers. Electrophoresis was performed at 150 V for approximately 2 h until the 
bromphenol blue front had migrated completely through the gel. 
 
3.4.4.3. Western blotting 
For western blotting, the gels were placed on top of a nitrocellulose membrane 
between filter papers soaked in blotting buffer (25 mM Tris/HCl pH 8.3, 0.2 M glycine, 20% 
(v/v) methanol). Blotting was performed for 45 min at 250 mA. Afterwards, the membranes 
were incubated for at least 1 h in blocking solution (20 mM Tris/HCl pH 7.6, 0.14 M NaCl, 
0.1 % (v/v) Tween 20, 5 % (w/v) fat free milk powder). After blocking, the membranes were 
cut closely above the 50 kDa band of the prestained protein marker. The lower part of the 
blots were developed using the anti β-actin antibody, the upper part using the Pierce anti 
c-myc antibody for detecting the arrestin constructs or the life technologies anti V5 
antibody for the receptor constructs, respectively. Incubations with the primary antibodies 
were performed using a 1:1000 dilution of the respective AB in blocking solution at 4 °C 
overnight. After 3 washing steps in TBST (20 mM Tris/HCl pH 7.6, 0.14 M NaCl, 0.1 % (v/v) 
Tween 20) for 10 min each, the membranes were incubated with the secondary HRP-
coupled antibodies, at a 1:1000 dilution in blocking solution for 1 h at RT. After 3 additional 
washing steps, the immunoreactive bands were detected using Pierce ECL Western Blotting 
substrate and the ChemiDoc MP imaging system (Bio-Rad Laboratories, Munich, Germany). 
The scans of the blots were analyzed using the Image Lab 5.0 software (Bio-Rad 
Laboratories, Munich, Germany). 
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3.4.5. Flow cytometry 
For the flow cytometric analysis, the corresponding cells were cultivated in a 75- cm2 
cell culture flask in DMEM + 10 % FCS to a confluence of 70 – 90 %. The cells were detached 
by treatment with 5 ml of 0.05 % trypsin, 0.02 % EDTA in PBS. After addition of 5 ml of PBS 
+ 5 % FCS, the cells were thoroughly singularized and harvested by centrifugation (400 g, 5 
min). The cell pellet was resuspended in 2 ml of PBS + 4 % (w/v) paraformaldehyde, 
transferred to 2-ml reaction vessels and incubated on ice for 15 min. After centrifugation 
(all following centrifugation steps were carried out at 400 g, 5 min and 4 °C), the cells were 
resuspended in 2 ml of PBS + 0.2 % (w/v) saponin and incubated on ice for another 15 min. 
Then, cells were harvested by centrifugation and resuspended in 2 ml of PBS + 5 % FCS 
following incubation on ice for 15 min. After centrifugation, cells were resuspended in 1 – 
2 ml of PBS + 5 % FCS, depending on the size of the pellet, and 300 µl were transferred to 
fresh 1.5-ml reaction vessels. After centrifugation, the cells were resuspended in 200 µl of 
PBS + 5 % FCS containing the respective primary AB at an appropriate concentration (for 
details see below). Subsequently, the cells were incubated at 4 °C in the dark for 30 min, 
before addition of 1 ml of PBS + 5 % FCS and centrifugation. The cells were washed once 
with 1 ml of PBS + 5 % FCS and resuspended in 200 µl of PBS + 5 % FCS containing the 
secondary goat anti mouse R-PE coupled antibody in a 1:100 dilution. After incubation for 
30 min at 4 °C in the dark, 1 ml PBS + 5 % FCS was added, and the cells were harvested by 
centrifugation. Following a washing step with 1 ml of PBS + 5 % FCS, the cells were 
resuspended in 300 µl of PBS + 5 % FCS and transferred to FACS tubes. 
Flow cytometry was performed using a FACSCalibur cytometer (BD Biosciences, 
Heidelberg, Germany). The R-PE and DyLight 549 fluorochromes were excited with the 
488 nm laser, and emission was measured using the 585/42 BP filter. The photomultiplier 
voltage was adjusted to the fluorescence of the stained, untransfected HEK293T cells, 
which served as negative control. Cell debris and viable cells were discriminated using 
forward (FSC) and side scatter (SSC) gating. The flow rate of the cytometer was adjusted to 
give less than 1000 events/s. In total, 5·104 events were measured per sample. 
For the detection of the c-myc epitope tag of the arrestin fusion proteins, the life 
technologies mouse anti c-myc mAb was used in a 1:500 dilution. For the detection of the 
V5 epitope tag of the receptor fusion construct, three different antibodies were tested in 
dilutions from 1:100 to 1:1000, life technologies mouse anti V5, Pierce V5 tag AB 
(E10/V4RR) from mouse and mouse anti V5 TAG: DyLight549 ( AbD-Serotec). 
 
3.4.6. Radioligand saturation binding assays 
The radioligand saturation binding assays to determine the receptor expression was 
performed using whole cells. The HEK293T cells, expressing the respective receptor 
constructs, were cultivated in DMEM +10 % FCS in a 75-cm2 cell culture flask to a confluence 
of about 70 – 90 %. Then, the cells were detached by treatment with 0.05 % trypsin, 0.02 % 
EDTA in PBS. After addition of 1/10 volume FCS, cells were harvested by centrifugation (400 
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g, 5 min), subsequently resuspended in Leibovitz L-15 medium + 1 % FCS and adjusted to a 
cell density of 2 million cells/ml. The binding assay was performed in flat bottom, 
polypropylene 96-well microtiter plates. The reaction mixture contained 10 µl of the 
respective radioligand dilution, 55 µl of Leibovitz + 1 % FCS and 25 µl of cell suspension, 
giving a concentration of 50000 cells/well. The wells for the determination of the total 
binding contained additional 10 µl of Leibovitz, while, for the unspecific binding, 10 µl of 
the respective competitor dissolved in Leibovitz were added. The mixture was incubated 
for 60 to 90 min at RT under shaking at 300 rpm. Afterwards, the cells were harvested by 
filtration through GF/C filters using a Brandel 96 sample harvester (Brandel, Gaithersburg, 
MD). After 3 washing steps with ice cold PBS, the filter bound radioactivity was measured 
by liquid scintillation counting using the Micro Beta2 1450 scintillation counter (Perkin 
Elmer, Rodgau, Germany). 
Data analysis was performed using GraphPad Prism 5 software (GraphPad Software, 
La Jolla, CA). Specific binding values were calculated by subtraction of the unspecific 
binding from the respective total binding values. Data was plotted against the 
corresponding radioligand concentration and fitted by nonlinear regression using the one 
site saturation binding model. From the extrapolated BRmaxR values, the binding sites per cell 
were calculated using the specific activity of the corresponding radioligands. 
 
3.4.6.1. [3H]Mepyramine saturation binding at HR1R  expressing cells 
Saturation binding was performed using [3H]mepyramine at concentrations up to 
80 nM. In order to save radioligand, 1 part of [3H]mepyramine was diluted with 1 part of 
unlabeled mepyramine. Unspecific binding was determined in the presence of 10 µM 
diphenhydramine. 
 
3.4.6.2. [3H]UR-DE257 saturation binding at HR2R  expressing cells 
Saturation binding was performed using [3H]UR-DE257 at concentrations up to 
150 nM. In order to save radioligand, 1 part of [3H]UR-DE257 was diluted with 3 parts of 
the corresponding unlabeled compound, UR-DE92 (equivalent to UR-DE257). Unspecific 
binding was determined in the presence of 10 µM famotidine. 
 
3.4.6.3. [3H]Histamine saturation binding at HR4R  expressing cells 
Saturation binding was performed using [3H]histamine at concentrations up to 
80 nM. Unspecific binding was determined in the presence of 10 µM thioperamide. 
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3.4.6.4. [3H]UR-MK136 saturation binding at YR1R  expressing cells 
Saturation binding was performed using [3H]UR-MK136 at concentrations up to 
16 nM. Unspecific binding was determined in the presence of 1 µM BIBO3304. 
 
3.4.6.5. [3H]UR-PLN187 saturation binding at YR2R  expressing cells 
Saturation binding was performed using [3H]UR-PLN187 at concentrations up to 
160 nM. In order to save radioligand, 1 part of [3H]UR-PLN187 was diluted with 3 parts of 
unlabeled UR-PLN187. Unspecific binding was determined in the presence of 10 µM 
JNJ31020028. 
 
3.4.7. Luciferase complementation assay 
One day before the experiment, the HEK293T cells expressing the arrestin and 
receptor fusion constructs were harvested by trypsin treatment (0.05 % trypsin, 0.02 % 
EDTA in PBS), and subsequent centrifugation (400 g, 5 min). The cells were thoroughly 
resuspended in DMEM (without phenol red) + 5 % FCS, and 90 µl of the cell suspension 
were seeded in white, TC treated, flat bottom 96 well micro titer plates at a density of 
approximately 100000 cells/well. The cells were cultivated at 37 °C overnight in a water 
saturated atmosphere containing 5 % COR2R. Shortly before the experiment, the cells were 
removed from the incubator and allowed to equilibrate to RT. The dilutions of the test 
compounds at the respective concentrations were transferred to a 96 well plate in the 
desired order to allow for the addition of the compounds to the test plates using a multi-
channel pipette in order to reduce the time delay between individual wells. Per well, 10 µl 
of compound solution were added. After compound addition, the plates were incubated in 
an air-conditioned room at a plate shaker tempered to 25 °C for the indicated time. Shortly 
before the end of the incubation period, 50 µl of medium were removed from each well 
using a multichannel pipette in order to reduce the amount of assay reagent necessary in 
the next step. To measure luciferase activity, 50 µl of BrightGlo luciferase assay reagent 
were added to each well, the reagent was prepared according to manufacturer`s 
instructions and allowed to equilibrate to RT prior to use. Following reagent addition, the 
plates were incubated under vigorous shaking (800 rpm) for 5 min. Bioluminescence was 
measured for 1 s per well using the GENios Pro microplate reader (Tecan, Salzburg, Austria). 
 
3.4.7.1. Optimization of the assay conditions 
To determine the influence of DMSO, the HEK293T βArr1 + HR2R  cell line was used. 
1 mM stock solutions of histamine were prepared containing 0 – 80 % DMSO, giving a final 
concentration of 0 – 8 % DMSO in the assay mixture. The same DMSO solutions without 
histamine served as background control. Incubation time was set to 60 min. The 
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background values of the corresponding DMSO concentrations were subtracted from the 
raw data. 
The time dependence of the arrestin recruitment assay was determined for all 5 
receptors included in this thesis in combination with either one of the two β-arrestin 
isoforms. Arrestin recruitment was stimulated for the indicated period of time using the 
endogenous ligand of the receptor, either histamine at a concentration of 100 µM for the 
HR1R , HR2R  and HR4R  or 1 µM of NPY for the YR1R  and YR2R . 
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4. Investigation of arrestin recruitment at the NPY 
Y1 and Y2 receptors 
4.1. Introduction 
Neuropeptide Y (NPY), peptide YY (PYY) and pancreatic polypeptide (PP) are 
structurally closely related peptides sharing the same tertiary structure, termed “PP-
fold”,1,2 and targeting the same family of GPCRs, the NPY receptors. For humans, the 
functional expression of four receptor subtypes, the YR1R , YR2R , YR4R  and YR5R , is confirmed 
and could be verified by molecular cloning of the receptor cDNAs.3-6 A fifth receptor, the 
y6 receptor, was cloned but is only functional in mice while inactive in most other 
mammalian species.2 
The NPY receptor family shares similar signal transduction pathways, coupling to the 
pertussis toxin sensitive GRi/o Rfamily of heterotrimeric G-proteins.2,7 Thus, receptor 
activation subsequently leads, for example, to inhibition of adenylyl cyclases (ACs) and 
induction of a Ca2+ signal.7 Furthermore, NPY has been shown to activate alternate, non-
canonical signaling pathways.7 Depending on the tissue or cell type investigated, in a G-
protein dependent manner, NPY receptors can activate or block calcium and potassium 
channel in the cell mebrane8,9 as well as signal through MAP kinase pathways.10 
Regarding the interaction of the NPY receptors with β-arrestin, the different subtypes 
show distinct characteristics. While the YR1R  was shown to exhibit pronounced recruitment 
of β-arrestin 2 with a fast kinetics of association, the YR2R  and YR4R  gave a much lower signal 
in the BRET recruitment assay and revealed a slower association rate.11 These results 
correlate well with previous findings about the internalization and desensitization behavior 
of the Y receptors.  Whereas the YR1R  was shown to internalize rapidly upon agonist 
stimulation, the YR2R  exhibited a much slower or no internalization at all.12,13 The 
characteristics of arrestin recruitment of the YR1R  and YR2R  were confirmed by confocal 
microscopy based on bimolecular fluorescence complementation (BiFC).14 Furthermore, 
the argininamide-type YR1R  antagonists BIBP3226 and BIBO3304 as well as the peptide 
antagonist GR231118 were demonstrated to be competitive antagonists regarding arrestin 
recruitment.14 
NPY receptor ligands represent potential new therapeutics for the treatment of 
various disorders, such as obesity and anxiety.15 Unfortunately, subtype selective, 
nonpeptidic tracers for the detailed characterization of the receptors in vivo and in vitro 
were unavailable. Therefore, compound libraries based on either the YR1R  selective 
antagonists BIBP3226 and BIBO3304 or the YR2R  selective antagonist BIIE0246 were 
synthesized in our lab, aiming at the development of new, subtype selective 
pharmacological tools. This chapter is dealing with the characterization of selected NPY 
receptor ligands from these substance libraries, using the established arrestin recruitment 
assay. 
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4.1.1. Selected YR1R  antagonists 
BIBP3226 (1) was the first selective, nonpeptidic antagonist described for the YR1R .16 
The attachment of acyl, alkoxycarbonyl and carbamoyl substituents to the guanidine of 
BIBP32226 (Cpd. 2-7) resulted in a series of potent antagonist as potential new radioligands 
for the YR1R .17-19 Furthermore, two triazole derivatives (Cpd. 8, 9) and two fluorinated 
compounds (Cpd. 10, 11), representing potential new PET ligands, as well as two bivalent 
compounds with a free amine function19 (Cpd. 12 and 13) were included in the investigation 
ofYR1R  dependent arrestin recruitment. The structures of the selected compounds are given 
in Fig.4-1. 
  
Fig. 4-1: Structures of the selected Y1R antagonists derived from BIBP3226 
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BIBO3304 (14) is a urea derivative of BIBP3226 with subnanomolar affinity for the 
YR1R , originally designed to overcome the CNS toxicity of the latter.20 Starting from this 
pharmacophore, several potential new radioligands (Cpd. 15-18) have been designed by 
introduction of acyl, carbamoyl or alkylamide substituents at either the NG position of the 
guanidine or the NU position of the urea (see Fig. 4-2).19 Furthermore, the bivalent NG 
coupled UR-MK177 (19) and the propanoic amide UR-MK280 (20) were included in this 
study. In addition to the BIBP3226 and BIBO3304 derivatives synthesized in our lab, several 
known, structurally diverse YR1R  antagonists were investigated for functional selectivity 
including the dihydropyridine BMS 193885 (21)21 and the nitroquinoline PD 160170 (22).22 
Besides these nonpeptidic compounds, two known peptide YR1R  antagonists BW1911U90 
(23) and GR231118 (24),23 were investigated. 
  
Fig. 4-2: Structures of the selected Y1R antagonists 
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4.1.2. Selected YR2R  antagonists 
The argininamide BIIE0246 (25) was published as high affinity (KRiR values of 8 to 15 
nM), nonpeptidic antagonist for the YR2R  with selectivity over the other NPY receptor 
subtypes.24 Using the BIIE0246 pharmacophore, Pluym et al. synthesized a series of 
potential new radioligands and precursors by introduction of different functionalized acyl 
or carbamoyl substituents at the NG position of the guanidine.25,26 Hereof, several amine 
precursors as well as the corresponding amides were selected for the screening (Cpd. 26 – 
36). Furthermore, several fluorinated compounds of this series (Cpd. 37 – 41), potential 
new PET ligands, as well as the bivalent ligand UR-PLN176 (42) were added (structures see 
Fig. 4-3). 
Fig. 4-3: Structures of the selected Y2R antagonists derived from BIIE0246 
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In addition to the BIIE0246 derivatives from our lab, several structurally diverse 
compounds with known affinity for the YR2R  were selected. JNJ5207787 (43) was described 
as neutral antagonist for the YR2R  with over 100 fold selectivity over the other NPY receptor 
subtypes.27 SF11 (44) was identified as YR2R  ligand in a high throughput screening and 
published with a KRiR value of 1.55 nM in [125I]-PYY competition binding.28 Unfortunately, 44 
was several orders of magnitude less potent when studied in our laboratory in a flow 
cytometric binding assay using Cy5-pNPY (cf. Tab 4-2). CYM9484 is a derivative of SF11 with 
strongly improved affinity for the YR2R  (cf. Tab. 4-2).29 JNJ31020028 (46) and the structurally 
related urea UR-KK51 (47) are another class of brain penetrating, high affinity YR2R  
antagonists.30,31 The structures of the selected compounds is given in Fig. 4-4. 
  
Fig. 4-4: Structures of the selected Y2R antagonists 
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4.2. Results and discussion 
To determine the functional characteristics of the selected YR1R  and YR2R  ligands 
regarding receptor-arrestin interaction, all compounds were tested in the established 
arrestin recruitment assay (cf. Chapter 3). An initial screening using the respective β-
arrestin 1 or 2 cell lines, revealed no significant differences between the two arrestin 
isoforms. Therefore, the following screening was conducted solely with the HEK293T βArr2 
+ YR1R  and HEK293T βArr2 + YR2R  cells, respectively. 
 
4.2.1. Activity of pNPY in the βArr2 recruitment assay 
Instead of the human NPY, which contains a methionine residue in position 17 that is 
susceptible to oxidation, the porcine analog is used routinely in pharmacological assays. 
 
Fig. 4-5: A: Absolute signal intensity and 
background of the HEK293T βArr2 + Y1R and 
HEK293T βArr2 + Y2R cell lines in the arrestin 
recruitment assay. Approx. 100000 cell were 
seeded per well. Data are mean values ± SEM of 
5 – 6 independent experiments. B, C: 
Concentration response curves of pNPY in the 
β-arrestin 2 recruitment assay using the 
HEK293T βArr2 + Y1R (B) and HEK293T βArr2 + 
Y2R (C) cell lines. Data represent mean values ± 
SEM of 5 – 6 independent experiments 
performed in triplicates. Data were analyzed by 
nonlinear regression and best fitted to 
sigmoidal concentration response curves. 
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The effect measured in the luciferase complementation assay was normalized to the 
maximal effect induced by pNPY, as the endogenous ligand is by definition regarded as full, 
unbiased agonist. As expected, pNPY showed agonistic activity in the arrestin recruitment 
assay at both, the YR1R  and the YR2R . Previous findings, where the YR1R  showed a considerably 
faster and more pronounced recruitment of β-arrestin 2 than the YR2R ,11 could not be 
confirmed in our assay system. In the luciferase complementation assay, the YR2R  cells 
produced a higher absolute signal than the YR1R  cell line (cf. Fig. 4-5), though the far higher 
expression level of the YR2R  in the corresponding cells has to be taken into account (cf. 
3.2.2). At the YR1R , the potency of pNPY for arrestin recruitment determined in our 
luciferase complementation was significantly lower than previously reported data gained 
from BiFC techniques14 (pECR50R (ELuc-Comp.) = 7.36 ± 0.05; pECR50R (BIFC) = 8.57 ± 0.05). By 
contrast, for the YR2R , the potencies of pNPY determined in the two assay systems were in 
good agreement (pECR50R (ELuc-Comp.) = 6.89 ± 0.12; pECR50R (BIFC) = 7.15 ± 0.0814). At the 
YR1R , the potencies for NPY in G-protein based readouts reported in literature (pECR50R = 8.1 
– 9.432,33) are considerably higher than in our arrestin recruitment assay. In comparison, 
the decrease in potency for the YR2R  is much less pronounced (pECR50R (G-Protein) = 7.5 – 
8.332-35). For the interpretation of the data for pNPY in the arrestin recruitment assay, it has 
to be taken into consideration that the assay was not optimized for the use of peptidic 
ligands. It is known that surface adhesion and/or protein binding to the serum albumin 
present in the assay mixture might influence the effective concentration of the peptide 
ligand and therefore can significantly affect the detected potencies. Besides physiological 
differences like variations in signal amplification, such effects might also account at least in 
part for the huge discrepancies found in the potencies reported for NPY in the different G-
protein based readouts. However, a decrease in potency in arrestin recruitment compared 
to G-protein based readout became also obvious in case of the histamine receptor 
subtypes, although histamine is uncritical regarding adhesion and protein binding. Thus, 
the observed differences seem to be inherent to the system. A pNPY concentration of 1 µM 
was sufficient for full stimulation of arrestin recruitment by both receptors (cf. Fig. 4-5) and 
was, therefore, used for normalization of the ligand-induced effects in the investigation of 
antagonists. 
 
4.2.2. Investigation of selected YR1R  antagonists for agonism in the 
arrestin recruitment assay 
The selected YR1R  antagonists were tested at concentrations from 0.1 – 10 µM for 
their ability to stimulate arrestin recruitment to the YR1R  using the HEK293T βArr2 + YR1R  cell 
line. The efficacies of the ligands normalized to the maximal effect induced by 1 µM pNPY 
(100 % value) and solvent (0 % value) as well as the affinities of the selected compounds 
for the YR1R  are given in Tab. 4-1. Previous findings indicating neutral antagonism of the 
parent compounds BIBP3226 (1) and BIBO3304 (14) in arrestin recruitment were confirmed 
(cf. Tab. 4-1).14 None of the modifications introduced in Cpd. 2 – 13 and 15 – 20 had 
significant  
- 58 - 
4.2 Results and discussion 
 
Table 4-1: Efficacies in arrestin recruitment assay and YR1R  affinity of the tested 
YR1R  antagonists 
Cpd. 
βArr2 recruitment[a]  YR1R  affinity  
ERmaxR ± SEM [%]  KRiR ± SEM [nM] 
BIBP3226 (1) -0.03 ± 0.01  1.3 ± 0.2[b] 
UR-MK114 (2) -0.02 ± 0.02  1.2 ± 0.1[c] 
UR-MK50 (3) -0.08 ± 0.03  1.6 ± 0.3[d] 
UR-MK121 (4) -0.02 ± 0.03  0.94 ± 0.06[e] 
UR-HU496 (5) -0.07 ± 0.03  0.17 ± 0.01[d] 
UR-HU404 (6) 0.04 ± 0.06  0.21 ± 0.05[d] 
UR-MK139 (7) -0.05 ± 0.03  7.3 ± 1[f] 
UR-SW1404 (8) 0.02 ± 0.02  0.56 ± 0.06[d] 
UR-SW1403 (9) -0.01 ± 0.02  3.1 ± 0.6[d] 
UR-MK130 (10) -0.02 ± 0.00  1.3 ± 0.4[d] 
UR-MK137 (11) -0.04 ± 0.00  7.2 ± 2.3[d] 
UR-MK163 (12) -0.06 ± 0.01  25 ± 1.7[f] 
UR-MK188 (13) -0.05 ± 0.00  24 ± 1.1[f] 
BIBO3304 (14) -0.05 ± 0.03  0.25 ± 0.01[b] 
UR-MK70 (15) -0.06 ± 0.05  7.8 ± 2.6[d] 
UR-MK165 (16) -0.02 ± 0.01  31 ± 1[f] 
UR-MK190 (17) -0.07 ± 0.02  73 ± 5.3[f] 
UR-MK184 (18) -0.02 ± 0.01  14 ± 1.1[f] 
UR-MK177 (19) -0.06 ± 0.00  230 ± 24[f] 
UR-MK280 (20) -0.09 ± 0.01  4.2 ± 0.7[g] 
BMS 193885 (21) 0.18 ± 0.08  3.3 ± 0.17[h] 
PD 160170 (22) 0.06 ± 0.10  0.05[i] 
BW1911U90 (23) -0.02 ± 0.03  8.3 ± 0.0[j] 
GR231118 (24) -0.06 ± 0.02  10.2 ± 0.1[j] 
[a] Efficacies in arrestin recruitment determined at the HEK293T βArr2 + YR1R  cells as described in 4.3.2 
[b], [d], [e], [f]: Determined by competition binding with [3H]UR-MK114 (KRdR = 1.2 nM, c = 1.5 nM) on SK-N-
MC cells taken from [b] Keller et al. 201136 [d] Dr. Max Keller, personal communication [e] Keller et al. 200918 
[f] Keller et al. 201319 
[c] KRDR value of [3H]UR-MK114 at SK-N-MC cells17 
[g] Determined by competition binding with [3H]UR-MK136 on SK-N-MC cells 
[h] Determined by competition binding with [125I]PYY on SK-N-MC cell membranes, Poindexter et al. 200437 
[i] Determined by competition binding with [125I]PYY on SK-N-MC cell membranes, Wielgosz et al. 200222 
[j] Determined by competition binding with [125I]PYY on CHO-K1 YR1R cell membranes, Parker et al. 199823 
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influence on their functional characteristics regarding arrestin recruitment, with all 
determined efficacies comparable to the solvent value. Furthermore, neither the peptidic 
antagonists (Cpd. 23 and 24) nor the dihydropyridine BMS 193885 (21) and the 
nitroquinoline PD 160170 (22) revealed functional selectivity towards arrestin recruitment. 
 
4.2.3. Investigation of selected YR2R  antagonists for agonism in the 
arrestin recruitment assay 
The selected YR2R  antagonists were tested at concentrations from 0.1 – 10 µM in the 
arrestin recruitment assay using the HEK293T βArr2 + YR2R  cells. Normalization of the data 
was performed as described above (cf. 4.2.2). Table 4-1 gives the normalized efficacies of 
the tested compounds for arrestin recruitment as well as their affinities for the YR2R . None 
of the selected BIIE0246 derivatives (Cpd. 25 – 42) exhibited significant efficacy towards 
arrestin recruitment (cf. Tab. 4-2). Several ligands of this class, including the parent 
compound BIIE0246 or the radioligand UR-PLN196 (structurally equivalent to UR-PLN33), 
were previously described as insurmountable antagonists at the YR2R  exhibiting pseudo-
irreversible binding.26,38 Hereby, the ligands, when preincubated with the receptor, could 
not be completely displaced by NPY, leading to a depression of the maximal response of 
the system. Besides possible allosteric modulation, slow ligand dissociation or slow 
receptor interconversion rates, the stabilization of ligand specific, alternate receptor 
conformations, as generally associated with functionally biased compounds, explain such a 
behavior. However, the findings in the arrestin recruitment assay do not support this 
hypothesis. At least regarding arrestin and the canonical G-protein mediated pathways, the 
compounds of this class of YR2R  ligands exhibit no functional bias. A similar profile was found 
for the other tested antagonists, which have scaffolds different from that of BIIE0246 (Cpd. 
43 – 47) and produced signals comparable to the assay background. 
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Table 4-2: Efficacies in the arrestin recruitment assay and YR2R  affinity of the 
tested YR2R  antagonists 
Cpd. 
βArr2 recruitment[a]  YR2R  affinity[b]  
ERmaxR ± SEM [%]  KRiR ± SEM [nM] 
BIIE0246 (25) 0.05 ± 0.19  10.2 ± 1.1 
UR-PLN208 (26) -0.14 ± 0.02  5.2 ± 1.8 
UR-PLN73 (27) -0.04 ± 0.27  2.1 ± 0.3 
UR-PLN74 (28) 0.23 ± 0.15  3.2 ± 0.3 
UR-PLN187 (29) 0.33 ± 0.19  64 ± 4 
UR-PLN82 (30) 0.00 ± 0.12  55 ± 15 
UR-PLN83 (31) 0.28 ± 0.04  84 ± 64 
UR-PLN26 (32) 0.18 ± 0.39  3.4 ± 0.1 
UR-PLN27 (33) 0.14 ± 0.56  2.3 ± 1.4 
UR-PLN33 (34) 0.29 ± 0.37  9.9 ± 1.0[c] 
UR-PLN78 (35) -0.10 ± 0.17  18 ± 1 
UR-PLN84 (36) 0.39 ± 0.13  15 ± 0.2 
UR-PLN60 (37) 0.54 ± 0.08  27 ± 4 
UR-PLN86 (38) 0.09 ± 0.10  68 ± 8 
UR-PLN87 (39) -0.05 ± 0.04  82 ± 7 
UR-PLN35 (40) -0.09 ± 0.03  8.3 ± 6.4[c] 
UR-PLN88 (41) -0.34 ± 0.01  22 ± 9 
UR-PLN176 (42) 0.18 ± 0.19  21 ± 6 
JNJ5207787 (43) 0.10 ± 0.34  100 ± 25[d] 
SF11 (44) 0.00 ± 0.27  1251 ± 348[e] 
CYM9484 (45) -0.10 ± 0.33  24 ± 3[e] 
JNJ31020028 (46) -0.20 ± 0.32  9.9 ± 0.1[e] 
UR-KK51 (47) -0.16 ± 0.41  22 ± 5[e] 
[a] Efficacies in arrestin recruitment determined at the HEK293T βArr2 + YR1R  cells as described in 4.3.2 
[b] Determined by flow cytometric binding assay using Cy5-pNPY (KRDR = 5.2 nM, c = 5 nM) on CHO YR2R cells39 
[c] Determined by flow cytometric binding assay using Dy-635-pNPY (KRDR = 5.2 nM, c = 5 nM) on CHO YR2R 
cells39 
[d] Determined by competition binding with [125I]PYY on hYR2R KAN-Ts cells, Bonaventure et al.27 
[e] personal communications, Kilian Kuhn 
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4.3. Materials and methods 
4.3.1. Materials 
Unless stated otherwise, all chemicals and reagents were purchased from Sigma-
Aldrich Chemie (Munich, Germany) or Merck (Darmstadt, Germany). For media and 
reagents used for the luciferase complementation assay, see Chapter 3.4. 
 
4.3.1.1. Ligands 
The porcine NPY (aa sequence: YPSKPDNPGE DAPAEDLARY YSALRHYINL ITRQRY) was 
used instead of the human peptide in order to avoid problems associated with the 
oxidation of methionine, as it contains a leucine at position 17 instead of methionine. pNPY 
and the BIBP3226 and BIBO3304 derivatives (1 – 20) were synthesized in our lab.17-19,36 
BMS 193885 (21) and PD 160170 (22) were purchased from Tocris Bioscience (Ellisville, MO, 
USA). The peptide ligands BW1911U90 (23) and GR231118 (24) were kindly provided by 
Prof. Dr. Chiara Cabrele, University of Salzburg. The BIIE0246 derivatives (25 – 42),25,26,39 
JNJ5207787 (43), SF11 (44), CYM9484 (45), JNJ31020028 (46) and UR-KK51 (47) were 
synthesized in our lab. For the compounds 1 – 7, 10 – 15, 17 – 19, 21, 22 and 25 – 47, 5 mM 
or 10 mM stock solutions were prepared in DMSO. For the compounds 8, 9, 16 and 20, 10 
mM stock solutions were prepared in 50 % MeCN/ 0,05 % TFA. The peptide ligands pNPY, 
BW1911U90 (23) and GR231118 (24) were dissolved in 10 mM HCl at suitable 
concentrations. 
 
4.3.2. Methods 
4.3.2.1. Luciferase complementation assay 
The luciferase complementation assay was performed as described above (cf. 3.4.7) 
using the HEK293T-β-Arr2-YR1R  and HEK293T-β-Arr2-YR2R  cells stably expressing either the 
YR1R -ElucC or YR2R -ElucC and the β-Arr2-ElucN fusion constructs (cf. 3.2). For cell culture 
conditions and media requirements, see 3.4.2. Working solutions for the compounds 1 – 7, 
10 – 15, 17 – 19, 21, 22 and 25 – 47 were prepared in 5 % DMSO / 10 mM TFA. Working 
solutions for the compounds 8, 9, 16 and 20 were prepared in 5 % MeCN / 10 mM TFA. For 
pNPY, 23 and 24, the working solutions were prepared in 10 mM HCl. 
The cells were stimulated for 45 min with the ligands at concentrations from 0.1 – 10 
µM, at least 10- to 100-fold the corresponding KRiR value of the ligand. The results were 
normalized to the maximum effect induced by 1 µM pNPY (100 % value) and solvent (0 % 
value). 
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4.3.2.2. Data analysis 
The functional data was analyzed using the GraphPad Prism 5 software (GraphPad 
Software, La Jolla, CA). Concentration response data was best fitted by nonlinear regression 
to a three parameter sigmoidal function. 
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histamine H1 receptor 
5.1.1. Introduction 
The histamine HR1R receptor is a 487 aa protein and belongs to the class A of rhodopsin-
like GPCRs. The term HR1R receptor has been first introduced in 1966, when the findings that 
several actions of histamine, like the stimulation of gastric acid secretion and the positive 
chronotropic effect on isolated atria, could not be blocked by low concentrations of 
antihistamines, suggested the involvement of a second distinct histamine receptor.1  
Various studies have been performed investigating the distribution pattern of the 
HR1R  in mammalian tissues. Through the use of selective radioligands, like [3H]mepyramine,2 
receptor expression was detected in the brain, the smooth muscles from airways and the 
gastrointestinal tract, the genitourinary system and the cardiovascular system.3,4 
The HR1R  mediated response has been studied extensively in a variety of these tissues. 
In the mammalian brain, the histaminergic neurons are gaining attention for their profound 
involvement in basic brain functions. The HR1R  has been shown to regulate the circadian 
rhythm and has been linked to several neuronal disorders, such as Alzheimer`s disease and 
schizophrenia,5 its pathological function yet to be elucidated.6 The best understood 
pathophysiological role of the HR1R  is its function in allergic reactions (type I) and 
inflammation.7 Histamine induced activation of the HR1R  leads to vasodilation and 
bronchoconstriction in the airways and plays a major role in allergic rhinitis.8 The HR1R  is 
also a key player in the treatment of allergic conjunctivitis,9 urticaria10 and atopic 
dermatitis.11 
In several different cell types and tissues, the HR1R  has been shown to mediate 
histamine induced activation of phospholipase C (PLC), leading to the hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIPR2R) into diacyl glycerol (DAG) and inositol 1,4,5-
trisphosphate (IPR3R).3,12 The advent of molecular biology, which in course led to the 
successful cloning of the cDNAs of several HR1R  species orthologs13-17 in the early 1990s, 
allowed for the detailed molecular analysis of the receptor signaling profile. The HR1R  has 
been shown to couple primarily to the GRq/11 Rfamily of trimeric G-proteins leading to PLC 
activation and formation of DAG and IPR3R.18-20 IPR3R subsequently triggers Ca2+ release from 
intracellular stores and the increase in the cytosolic Ca2+ concentration leads to various 
cellular responses, like the activation of calcium-calmodulin dependent protein kinases or 
nitric oxide (NO) formation.21 DAG activates protein kinase C (PKC), which in turn 
phosphorylates a multitude of effector proteins.22 Furthermore, HR1R  exhibited agonist 
dependent activation of nuclear factor κB (NFκB), a transcription factor involved in 
inflammation.23 Interestingly, hereby the HR1R  also showed constitutive, GRβγR dependent 
activation of NFκB. Constitutive activity of the HR1R  has been confirmed for inositol 
phosphate accumulation.24 HR1R  activation induced phosphorylation of mitogen activated 
protein kinases (MAPKs) in a pertussis toxin sensitive manner.25 In other recombinant 
- 68 - 
4.4 References 
 
systems showing high receptor expression levels, histamine activation of the HR1R  was also 
able to induce a cAMP response, albeit with much lower potency than for Ca2+ 
mobilization.26 Thus, the HR1R  seems to be capable of also coupling to G-proteins other than 
GRq/11R. It remains to be established, weather those findings in recombinant, artificial system 
are of physiological relevance, especially with regard to constitutive activity, which shows 
strong dependence on expression levels of the investigated GPCRs. 
The HR1R  represents a well-established drug target and extensive work has been 
performed investigating its function on the molecular and physiological level. Despite this 
fact, knowledge about β-arrestin recruitment and the involvement of arrestin-dependent 
signaling in the cellular response of the HR1R  is still scarce. In human myometrial cells, down 
regulation of β-arrestin 2 expression, but not β-arrestin 1 down regulation, enhanced and 
prolonged HR1R -stimulated Ca2+ responses and decreased receptor desensitization. 
Additionally, β-arrestin 2 depletion abolished histamine induced ERK1/2 phosphorylation 
and increased p38 MAPK phosphorylation.27 
So far, no pharmacological data is available for HR1R  ligands regarding β-arrestin 
recruitment. In the following, the pharmacological profile of various HR1R  ligands, 
investigated in the established β-arrestin recruitment assay, is described. 
 
5.1.2. Selected HR1R receptor ligands 
Except for betahistine, which is used as a drug for the treatment of Menière’s 
disease,28 HR1R  agonists have no clinical relevance but are important tools to decipher 
receptor function. By now, several different classes of HR1R  agonists are known. While the 
first HR1R  selective agonists, like 2-pyridylethylamine, showed reduced potency compared 
to histamine,12 the investigation of 2-phenyl-histamine derivatives led the discovery of 
potent and selective HR1R  ligands.29,30 Replacement of the 2-phenyl substituent by a 
diphenylpropyl moiety resulted in another class of HR1R  agonists, the histaprodifens.31-33 
For the investigation of β-arrestin recruitment, in addition to the endogenous ligand 
histamine (1), a set of 2-phenylhistamine (2-5) and histaprodifen derivatives (6-12) was 
selected (for chemical structure, see Fig. 5-2). 
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Since the discovery of the first antihistamines in the 1930s, the search for selective 
and potent HR1R  antagonists was highly successful. HR1R  antagonists have been used for the 
treatment of allergic conditions for decades, the first generation antihistamines showing 
side effects like drowsiness and fatigue caused by blocking the HR1R  in the brain. Due to 
their lipophilic character, these compounds easily cross the blood brain barrier. To prevent 
these undesired drug effects, a second generation of HR1R  antagonists was developed, 
showing strongly reduced CNS availability.4,34 
For the investigations in the arrestin assays, a set of structurally diverse first and 
second generation HR1R  antagonists was selected. Diphenhydramine (13) and mepyramine 
(14) are standard antagonists that have been used extensively to characterize the HR1R  in 
vivo. Clemastine (16) and cyproheptadine (15) are high affinity HR1R  antagonists, the latter 
still used for the treatment of mental disorders.35,36 Levocetirizine (17), azelastine (18), 
ketotifen (19) and terfenadine (20) belong to the second generation HR1R  antagonists and 
are widely used for the treatment of allergies. 
Fig. 5-1: Structures of selected H1 receptor agonists 
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Besides the dedicated HR1R  antagonists, a variety of clinically used antipsychotics and 
antidepressants have antagonistic or inverse agonistic effects at the HR1R .37-39 Mirtazapine 
(21) is a noradrenergic and specific serotonergic antidepressant (NaSSA), maprotiline (22) 
belongs to the class of norepinephrine reuptake inhibitor (NRI) and clozapine (23) as well 
as isoloxapine (24) represent atypical antipsychotics (AAP). The former three compounds 
show affinity for the HR1R  in the low nanomolar range37 (for chemical structures of the 
selected compounds, see Fig. 5-1). 
  
Fig. 5-2: Structures of selected H1 receptor antagonists and antipsychotics 
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5.2. Results and discussion 
To determine functional differences regarding G-protein versus β-arrestin activation, 
the selected HR1R  ligands were investigated in two different assay systems. G-protein 
activation was determined using the well-established [32P]GTPase assay, measuring ligand 
induced hydrolysis of [32P] labeled GTP on membranes of Sf9 insect cells expressing the HR1R  
and RGS4 proteins.40,41 β-Arrestin recruitment to the HR1R  was determined in the luciferase 
complementation assay (for details on the assay system, see chapter 3). 
Histamine induced activation of the HR1R  stimulated β-arrestin 1 and 2 recruitment 
with equivalent maximal effects. In both cases the signal-to-noise ratios were sufficiently 
high, although the β-arrestin 2 expressing cells showed only a 6 fold increase in signal 
intensity compared to a 30 fold increase for the β-arrestin 1 cell line, due to a 5 fold higher 
background level (cf. Fig. 5-3). These differences in background intensity cannot be 
explained by variations in receptor density, as the receptor expression levels were 
comparable in both transfectants (cf. 3.2.2.3). 
The finding that the HR1R  is capable of recruiting both β-arrestin isoforms is 
contradictory to results from literature, suggesting the involvement of β-arrestin 2, but not 
β-arrestin 1, in the signal transduction of the HR1R  in native cells.27 
 
5.2.1. Efficacies of HR1R  antagonists in β-arrestin recruitment 
All investigated compounds are high affinity ligands for the HR1R  and known as 
antagonists or inverse agonists with regard to G-protein activation.4,37,38 Information on β-
arrestin recruitment was not available so far. Therefore, the compounds were tested at 
concentrations of 10 and 100 µM for their ability to induce β-arrestin recruitment in the 
luciferase complementation assay. 
Fig. 5-3: Stimulation of 
HEK293T cells expressing 
the H1R-ELucC and either 
βArr1-ELucN or βArr2-ELucN 
fusion constructs by 1 mM 
histamine ( black bars) or 
solvent ( grey bars). 
Approximately 100000 cells 
were seeded per well. 
Values are given as mean ± 
95 % CI (N = 4). 
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Fig. 5-4 summarizes the efficacies of all tested HR1R  antagonists regarding β-arrestin 1 
or 2 recruitment. Evidently, these compounds did not exhibit agonism in this assay, but 
rather acted as inverse agonists with varying intrinsic activities. In case of β-arrestin 1 
recruitment, the inverse agonistic effects were negligible, between -0.6 and -2.4 % relative 
to the histamine induced maximal response. By contrast, in the β-arrestin 2 recruitment 
assay, the compounds exhibited stronger inverse agonistic effects, ranging from -0.8 to -
13.3 %. Among the investigated HR1R  antagonists, clemastine (16) showed the strongest 
inverse agonistic effect (-13.3 %) in β-arrestin 2 recruitment, while levocetirizine (17) had 
the weakest effect (-2.3 %). Of the tested antipsychotics, maprotiline (22) was the strongest 
inverse agonist (-12.8 % in β-arrestin 2 recruitment). Inverse agonism at the HR1R  has been 
shown in different assay systems for several of those HR1R  ligands,24,38 though strongly 
depending on the expression levels of the receptor and signal transducer proteins. Except 
for isoloxapine (24), which exhibited neutral behavior both assays, all ligands showed a 
strong increase in inverse intrinsic activity regarding β-arrestin 2 compared to β-arrestin 1 
recruitment. At first glance, these findings may point towards a functional bias of these 
ligands discriminating between the two arrestin isoforms. However, the extent of inverse 
agonism is depending on the degree of constitutive activity, that is, the magnitude of the 
signal background. Therefore, most probably, the difference in HR1R  inverse agonism 
between β-arrestin 2 and β-arrestin 1 cells has to be attributed to the different degrees of 
constitutive activity rather than a discrimination between arrestin isoforms. Normalization 
of the effects to the intensity of the background signal extenuates most of these 
differences, but was relinquished to prevent over-interpretation of minor effects, 
especially, with regard to the β -arrestin 1 data. 
Fig. 5-4: Efficacies of the tested antagonists in the β-arrestin recruitment assay using the β-arrestin 
1 ( grey bars) or β-arrestin 2 ( black bars) expressing cells. All compounds were investigated at 
a concentration of 100 µM. The results were normalized to the effect induced by 1 mM histamine 
(100 % value) and solvent (0 % value). The results are given as mean values  ± SEM of 2 to 3 
independent experiments performed in triplicate. 
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5.2.2. Pharmacological profiling of selected HR1R  agonists for G-
protein or β-arrestin bias 
Comprehensive data on HR1R  agonists has been gained from organ pharmacology and 
recombinant systems relying on G-protein based readouts. By contrast, so far, no 
information is available regarding ligand biased signaling at the HR1R . In order to investigate 
selected phenylhistamine- and histaprodifen-type HR1R  agonists for functional selectivity, 
concentration-response curves were determined in the GTPase and the β-arrestin 1 or 2 
recruitment assay, respectively. 
The potencies and efficacies of the tested ligands in the three different assays are 
given in Table 5-1. Ligand induced responses were normalized to maximal effect of 
histamine (100 % value) and the solvent (0 %). Thus, the endogenous ligand histamine (1) 
is defined as unbiased, full agonist (cf. Fig 5-7). Interestingly, while exhibiting comparable 
potencies in the GTPase and β-arrestin 1 recruitment assay (pECR50R (GTPase) = 6.91; pECR50R 
(βArr1) = 7.11), histamine has a significantly increased potency in the β-arrestin 2 assay 
(pECR50R (βArr2) = 7.74; 𝑝𝑝 < 0.01). Of all tested compound, UR-KUM530 (5) showed the 
highest potency and acted as a full agonist in all three assays (cf. Fig. 5-5). Compound 5 
exhibited the same profile as histamine with the highest potency in β-arrestin 2 
recruitment, albeit without significant differences between the assays (cf. Fig. 5-6). The 
phenylhistamine derivatives 2-4 acted as partial agonists in both readout systems and were 
less potent than histamine. Interestingly, all three compounds revealed a significant 
Fig. 5-5: Efficacies of the tested agonists in the [32P]GTPase assay (□ white bars), β-arrestin 1 
recruitment assay ( grey bars) and β-arrestin 2 recruitment assay ( black bars). The results 
were normalized to the effect induced by histamine (100 % value) and solvent (0 % value). The 
results are mean values ± SEM of at 2-4 independent experiments. Statistical analysis was 
performed using one way ANOVA including Bonferoni`s multiple comparison test (∗ ≙ 𝑝𝑝 < 0.05; ∗
∗ ≙ 𝑝𝑝 < 0.01;        ∗∗∗ ≙ 𝑝𝑝 < 0.001) 
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reduction in potency and efficacy in β-arrestin 1 recruitment compared to either the G-
protein or β-arrestin 2 based readout. Comparing the functional data of 2-(3-
bromophenyl)histamine (3) to UR-KUM530 (5) shows that the introduction of an 
imidazolylethyl moiety in Nα position of the molecule restores full agonistic activity and 
significantly increases potency. Functional bias, as in case of 3, was not detectable for 5. 
Histaprodifen (6) was previously described as a selective HR1R  agonists, equipotent 
with histamine.31,32,41 This was confirmed for G-protein activation: the pECR50R value for 6 
was comparable to that of histamine despite reduced efficacy. However, the β-arrestin 
recruitment assay revealed a dramatic change. Compound 6 was almost 20-fold less potent 
than 1 in the β-arrestin 2 assay and 17-fold less potent in β-arrestin 1 recruitment, 
reflecting a significantly reduced potency and efficacy of 6 in both arrestin recruitment 
assays compared to the GTPase assay. The chiral suprahistaprodifen derivatives, (R)-UR-
BS355 (7) and (S)-UR-BS354 (8), exhibited an interesting profile. Whereas the (R)-
configured compound 7 acted as a partial agonist in all three assay, showing the lowest 
efficacy in β-arrestin 1 recruitment, the (S)-enantiomer 8 was a neutral antagonists in the 
GTPase and β-arrestin 1 recruitment assay while retaining partial agonism in β-arrestin 2 
recruitment. The phenoprodifen derivatives 9-11 revealed another interesting effect. 
Whereas 9 showed comparable efficacies regarding G-protein and arrestin activation, the 
introduction of a methyl group, resulting in the two stereoisomers (R)-UR-BS358 (10) and 
(S)-UR-BS364 (11), gave a strong bias towards β-arrestin 2 (cf. Fig.5-5). Whereas 10 still 
showed very weak partial agonism in the GTPase and β-arrestin 1 recruitment assay, the 
Fig. 5-6: pEC50 values of the tested agonists in the [32P]GTPase assay ( circles), β-arrestin 1 
recruitment assay ( squares) and β-arrestin 2 recruitment assay ( triangles). The results are 
mean values ± SEM of 2-4 independent experiments. Lacking efficacy hampered with determining 
potencies for compounds 8, 10 and 11 in one or more assays. Statistical analysis was performed 
using one way ANOVA including Bonferoni`s multiple comparison test (∗ ≙ 𝑝𝑝 < 0.05;                                
∗∗ ≙ 𝑝𝑝 < 0.01; ∗∗∗ ≙ 𝑝𝑝 < 0.001) 
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(S)-enantiomer 11 was completely devoid of agonistic activity in those two assays, while 
still retaining 37 % efficacy in β-arrestin 2 recruitment. 
For the chiral histaprodifens exhibiting β-arrestin 2 bias, interesting findings were 
previously published, regarding their functional behavior at different HR1R  species 
orthologs.41 Compound 7 acted as partial agonist at all four tested receptor orthologs, 
whereas 8 activated only the guinea pig HR1R  (gpHR1R ) and was as a neutral antagonists at 
the other species, including the human HR1R  (hHR1R ). Compounds 10 and 11 were 
antagonists at all investigated HR1R  except for the gpHR1R . Surprisingly, this unique switch 
between agonism and antagonism correlates well with the functional selectivity of these 
compounds regarding G-protein and β-arrestin activation. Molecular dynamics simulations 
Fig. 5-7: Concentration-response curves of 
histamine (1) and the 2-phenylhistamine 
derivatives (2-5) in the [32P]GTPase assay 
( circles), β-arrestin 1 recruitment assay 
( squares) and β-arrestin 2 recruitment 
assay ( triangles). Data represented are 
mean values ± SEM of 2-4 independent 
experiments performed in triplicate. Data 
were analyzed by nonlinear regression 
and best fitted to sigmoidal concentration 
response curves. 
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revealed two possible orientations for the binding of the suprahistaprodifen derivatives 
into the HR1R  binding pocket. Only 7 fits well into the binding pocket in both orientations. 
By contrast one of these orientation is impossible for the (S)-configured compound 8 due 
to a steric clash of the methyl group.41 Though these findings suggest that different binding 
modes might be responsible for the functional bias found for these chiral compounds, 
further molecular modelling studies will be necessary to elucidate the nature of these 
effects. 
Unfortunately the interpretation of these finding is further complicated through the 
limited structural diversity of the tested compounds. Another problem occurring with 
several of the histaprodifens were adverse effects when using the compounds at 
concentrations exceeding 30 µM. At higher concentrations these effects became obvious 
from a drastic decrease in the detected signal intensity, rendering the generated data 
useless (data not shown). Most probably, these effects are caused by the amphiphilic 
nature of the compounds, causing changes in membrane permeability of the cells. These 
unspecific effects complicated the construction of complete concentration-response 
curves, especially, for some of the ligands with lower affinity (cf. Fig 5-8). 
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Fig. 5-8: Concentration response curves of 
the histaprodifen derivatives 6-12 in the 
[32P]GTPase assay ( circles), β-arrestin 1 
recruitment assay ( squares) and β-
arrestin 2 recruitment assay ( triangles). 
Data are mean values ± SEM of at least 3 
independent experiments performed in 
triplicate. Data were analyzed by nonlinear 
regression and best fitted to sigmoidal 
concentration-response curves. 
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GTPase assay   β-arrestin 1 recruitment   β-arrestin 2 recruitment 
pECR50 R± SEM ERmaxR ± SEM N   pECR50 R± SEM ERmaxR ± SEM N   pECR50 R± SEM ERmaxR ± SEM N 
1 6.91 ± 0.10 1.00 4  7.11 ± 0.10 1.00 4  7.74 ± 0.08 1.00 3 
2 6.14 ± 0.00 0.80 ± 0.01 3  5.25 ± 0.10 0.51 ± 0.03 3  6.15 ± 0.09 0.67 ± 0.04 3 
3 6.76 ± 0.03 0.62 ± 0.01 2  5.99 ± 0.03 0.43 ± 0.01 3  6.49 ± 0.01 0.63 ± 0.02 3 
4 6.71 ± 0.04 0.63 ± 0.03 3  5.68 ± 0.06 0.38 ± 0.01 3  6.73 ± 0.10 0.55 ± 0.06 3 
5 7.46 ± 0.19 0.95 ± 0.03 3  7.46 ± 0.03 0.91 ± 0.08 3  7.97 ± 0.23 0.99 ± 0.06 3 
6 6.95 ± 0.03 0.69 ± 0.06 4  5.85 ± 0.02 0.46 ± 0.01 4  6.48 ± 0.12 0.47 ± 0.06 3 
7 6.77 ± 0.08 0.37 ± 0.02 3  5.85 ± 0.07 0.26 ± 0.02 3  6.16 ± 0.14 0.48 ± 0.05 4 
8 n.d. 0.02 ± 0.02 3  n.d. 0.03 ± 0.00 3  4.99 ± 0.19 0.22 ± 0.04 4 
9 6.61 ± 0.08 0.55 ± 0.05 2  5.77 ± 0.06 0.50 ± 0.02 4  6.01 ± 0.11 0.58 ± 0.10 3 
10 n.d. 0.11 ±0.01 3  5.30 ± 0.25 0.09 ± 0.02 3  5.48 ± 0.08 0.43 ± 0.03 4 
11 n.d. 0.04 ± 0.03 3  n.d. 0.04 ± 0.01 3  5.49 ± 0.13 0.37 ± 0.08 4 
12 6.84 ± 0.05 0.55 ± 0.01 3   6.19 ± 0.10 0.33 ± 0.01 4   6.56 ± 0.18 0.54 ± 0.05 4 
Tab. 5-1: Potencies and efficacies of the tested H1R agonists in the GTPase and β-arrestin 1 and 2 recruitment assay. 
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5.3. Summary and conclusions 
None of the investigated HR1R  antagonists exhibited a functional bias. However, 
varying levels of inverse agonistic effects were detected at the two β-arrestin isoforms. 
Amongst the phenylhistamine- and histaprodifen-type HR1R  agonists, several compounds 
revealed functional selectivity regarding G-protein versus arrestin activation and exhibited 
a preference for one of the two β-arrestin isoforms. The phenylhistamines 2-4 were biased 
for G-protein and β-arrestin 2 activation over β-arrestin 1 recruitment, whereas the 
histaprodifen derivatives 8, 10 and 11 showed a strong bias for β-arrestin 2. Most studies 
published on functional selectivity of GPCR ligands were based on just one isoform of β-
arrestin, mostly β-arrestin 2, neglecting a possible preference for one of the two variants. 
Ligands exhibiting a functional bias are very useful tools for the deconvolution of 
complex receptor signaling profiles in vivo and in vitro. Ligands biased for either arrestin 
isoform could be especially useful to elucidate the complex influence of the two different 
arrestins on receptor regulation and downstream signaling such as the MAP kinase 
pathway. Unfortunately, the adverse effects at higher concentrations than 30 µM in 
combination with the low potency of some of the biased agonists severely limit their 
suitability as pharmacological tools for investigating arrestin mediated cellular signaling. 
The characterized compounds might, however, provide a starting point for the 
development of new biased agonists for the HR1R  with higher affinity and improved drug-
like properties. 
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5.4. Materials and methods 
5.4.1. Materials 
Unless stated otherwise, all chemicals and reagents were purchased from Sigma-
Aldrich Chemie (Munich, Germany) or Merck (Darmstadt, Germany). For media and 
reagents used for the luciferase complementation assay, see Chapter 3.4. 
 
5.4.1.1. HR1R receptor ligands 
The chemical structures of the investigated HR1R  ligands are shown in Fig. 5-1 and 5-
2. Histamine dihydrochloride (1) was from Alfa Aesar (Karlsruhe, Germany). The phenyl-
histamine derivatives 2-5 and histaprodifen derivatives 6-12 were synthesized in our 
laboratory.30,33 Mepyramine maleate (14), clemastine fumarate (16), ketotifen fumarate 
(19) and terfenadine (20) were from Tocris Bioscience (Ellisville, MO, USA). 
Diphenhydramine (13), cyproheptadine hydrochloride (15) and azelastine hydrochloride 
(18) were from Sigma-Aldrich Chemie (Munich, Germany). Levocetirizine dihydrochloride 
(17), mirtazapine (21) and maprotiline hydrochloride (22) were from Biotrend Chemikalien 
(Cologne, Germany). Clozapine (23) was a gift from Novartis Pharma (Nuremberg, 
Germany). Isoloxapine (24) was provided by Prof. Dr. S. Elz, University of Regensburg. Of all 
compounds, 10 mM stock solutions were prepared in 50 % DMSO. 
 
5.4.2. Methods 
5.4.2.1. [32P]GTPase assay 
The [32P]GTPase assay was performed as previously described.40,41 Ligand stimulated 
GRqR-protein catalyzed GTP hydrolysis was measured using membranes of Sf9 insect cells 
expressing the human HR1R  and the RGS4 protein. The functional data of the HR1R  agonists, 
determined in the GTPase assay, were kindly provided by Dr. Andrea Strasser. 
 
5.4.2.2. Luciferase complementation assay 
The luciferase complementation assay measuring β-arrestin recruitment to the 
receptor was performed as described above (cf. 3.4.7.) using the HEK293T-βArr1-HR1R  and 
HEK293T-βArr2-HR1R  cells stably expressing the HR1R -ElucC and either the βArr1-ElucN or 
βArr2-ElucN fusion proteins (cf. 3.2.). For cell culture conditions and media requirements, 
see 3.4.2. The working solutions of all HR1R  ligands contained 5 % DMSO, giving a final 
concentration of 0.5 % DMSO in the assay mixture. The cells were stimulated with the 
corresponding ligand concentrations for 60 min at RT. The tested HR1R  antagonists 13-24 
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were used at concentrations of 10 µM and 100 µM to stimulate β-arrestin recruitment. For 
the investigation of the agonists 1-12, dilution series ranging from 100 pM to 100 µM were 
prepared. The results were normalized to the response induced by 1 mM histamine (100 % 
value) and the solvent containing 5% DMSO (0 % value). 
 
5.4.2.3. Data analysis 
Data analysis was performed as described above (cf. 4.3.2.2). Statistical analysis of 
variances was performed by one way ANOVA followed by Bonferoni`s multiple comparison 
test using GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA). 
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6. Functional selectivity at the H2 receptor 
6.1. Introduction 
The existence of the histamine HR2R receptor, the second addition to the histamine 
receptor family, was postulated by Ash and Schild in 1966 due to the observation that 
several actions of histamine could not be blocked by “antihistamines”, the HR1R  
antagonists.1 The detailed pharmacological characterization of the HR2R  by Black and 
colleagues in the late 1960s led to the discovery of the first selective antagonist 
burimamide2 and to the development of cimetidine as a blockbuster antiulcer drug.3 
Another breakthrough in HR2R  research was achieved by the successful cloning of the HR2R  
gene by Gantz and coworkers in 1991.4 
Detailed analysis of the tissue distribution of the HR2R  has been compromised by the 
lack of suitable radioligands.5 Even though [125I]iodoaminopotentidine6 was successfully 
used to map the HR2R  in the brain,7 most information about HR2R  expression patterns is 
derived from functional studies.8 These efforts have been greatly facilitated by the 
development of several selective HR2R  agonists (i.e. dimaprit, impromidine, amthamine) and 
antagonists (i.e. burimamide, cimetidine, famotidine, tiotidine).9 HR2R  mediated cAMP 
accumulation was demonstrated in gastric parietal cells, where the HR2R  plays a crucial role 
in the regulation of gastric acid secretion.2,10 Furthermore activation of the HR2R  exhibits 
positive chronotropic and inotropic effects on atrial and ventricular tissue in the heart and 
leads to relaxation of airway, uterine and vascular smooth muscles.2,5 HR2R  expression has 
been demonstrated for various cells of the immune system,5 where it exerts diverse 
functions like inhibition of histamine release from mast cells and the antibody production 
of B-cells or modulation of cytokine production from T helper cells.8,11 
The HR2R  is a 359 aa protein and belongs to the class of rhodopsin-like GPCRs.5 It is 
now widely accepted, that the HR2R  couples primarily to GRαSR proteins leading to the 
activation of adenylate cyclases (ACs).8 The resulting cAMP accumulation leads to the 
activation of protein kinase A (PKA) and subsequently, for instance, to gene expression via 
the cAMP response element binding protein (CREB). Although HR2R  mediated cAMP 
accumulation seems to be the main response to HR2R  activation,8 it has been demonstrated 
for several cell lines and tissues that the HR2R  is capable of evoking a Ca2+ signal independent 
of AC activation, though there is controversial evidence, whether this observed rise in 
intracellular Ca2+ is due to influx of extracellular calcium12 or mobilization from intracellular 
stores.13,14 Additionally, HR2R  activation was demonstrated to induce GRαqR mediated PLC 
activation and incorporation of [32P]GTP azidoanilide into GRqR like proteins in different cell 
lines,15 while in other systems, GRqR coupling of the HR2R  could not be confirmed.16 
Collectively, these data suggest that the HR2R  is capable of coupling to different G-proteins 
and that the signal transduction pathways of the HR2R  are highly dependent on the cellular 
background. 
So far, only limited information is available on the involvement of β-arrestins on HR2R  
signaling and regulation. It has been demonstrated, that overexpression of β-arrestin 2, but 
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not β-arrestin 1, leads to a decrease in the HR2R  binding sites at the cell surface and a 
significant reduction of the amthamine induced cAMP response.17 Furthermore, down-
regulation of β-arrestin 2 by RNA interference abolished agonist-induced internalization of 
the HR2R  as well as subsequent resensitization.17 This data strongly supports the 
involvement of β-arrestin 2 in HR2R  regulation and trafficking. In a recently published work, 
Alonso et al. investigated the effect of the standard HR2R  antagonists cimetidine (CIM), 
ranitidine (RAN) and tiotidine (TIO) on receptor desensitization and internalization as well 
as on GRαSR protein independent pathways.18 They demonstrated that treatment with RAN 
and TIO lead to receptor internalization, which could be suppressed by expression of a 
dominant negative arrestin mutant. Furthermore, CIM, RAN and TIO induced receptor 
desensitization and ERK1/2 phosphorylation. Surprisingly, neither effect seemed to be 
mediated by β-arrestin. ERK phosphorylation of the ligands was rather mediated by the GRβγR 
subunit of the trimeric G-protein. To date, there is no information available about the 
functional profiles of various other HR2R  ligands regarding the activation of alternate 
signaling pathways through different receptor conformations, especially, towards arrestin 
dependent pathways. This chapter will focus on the profiling of a set of HR2R  agonists and 
antagonists for their pharmacological characteristics in β-arrestin activation using the 
previously introduced arrestin recruitment assay. 
 
6.1.1. Selected HR2R  ligands 
Fig. 6-1: Structures of the selected H2R agonists 
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Since the discovery of the first selective HR2R  antagonists burimamide in 1972,2 a 
multitude of new HR2R  ligands have been reported. Over the past decades, several HR2R  
agonists such as amthamine (2),19,20 dimaprit (3)21, impromidine (4)22 and arpromidine,23 
have been described. Unfortunately, the lack of selectivity for the HR2R  over the HR3R  and 
HR4R 24,25 for some of these compounds, as well as limited oral bioavailability and CNS 
penetration of guanidine-type agonists such as impromidine and arpromidine considerably 
reduced their value as pharmacological tools to study HR2R  function in vivo. Therefore, in 
our laboratory much effort has been spent to overcome these limitations, resulting in 
acylguanidines as bioisosteric replacements of the guanidine-type ligands.26,27 From these 
series, a set of compounds, containing either an imidazole (Cpd. 5-10) or 
amino(methyl)thiazole (Cpd. 11-16) as pharmacophoric entity, was selected for 
investigation in the arrestin recruitment assay (chemical structures, cf. Fig. 6-1). In addition 
several bivalent NG-acylated guanidine type ligands with varying chain lengths were 
included in this study, due to very high potency at the HR2R 28 (Cpd. 17-23, see Fig. 6-2). 
Unfortunately, some of the acylguanidine type compounds showed poor stability during 
storage in aqueous solutions. This stimulated the recent development of bivalent NG-
carbamoylated guanidine type HR2R  ligands with improved stability and high potency at the 
HR2R  (Cpd. 24-29, see Fig. 6-2). 
Fig 6-2: Structures of the selected bivalent H2R agonists 
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HR2R  antagonists have been used clinically for decades in the treatment of peptic 
ulcers and gastrooesophageal reflux disease.29 Cimetidine (31), representing the first 
clinically used HR2R  antagonist, famotidine (30) and ranitidine (32) are standard HR2R  
antagonists, which have been used extensively to characterize receptor function in vivo.5 
Recently, a series of squaramide derivatives related to the known HR2R  antagonist BMY-
2536830 was developed in our lab, representing an interesting starting point for the 
development of new radiolabeled or fluorescent tool compounds.31 From this series of 
compounds, two amine precursors as well as a propionylated (35) and a bivalent (36) ligand 
were included in this study (see Fig. 6-3).  
 
 
  
Fig 6-3: Structures of the selected H2R antagonists 
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6.2. Results and discussion 
In order to address putative functional selectivity of the selected HR2R  ligands for G-
protein or β-arrestin activation, two assay systems were selected. G-protein activation was 
determined using the [35S]GTPγS functional binding assay, measuring ligand stimulated 
binding of nonhydrolysable [35S]GTPγS to Sf9 insect cell membranes expressing the HR2R -
GRsαSR fusion protein. β-arrestin recruitment by the HR2R  was determined in the luciferase 
complementation assay (for details on the assay system, see Chapter 3). 
Table 6-1 gives an overview of the potencies and efficacies of the selected HR2R  ligands 
in the GTPγS functional binding, β-arrestin 1 recruitment and β-arrestin 2 recruitment 
assay. 
 
6.2.1. Comparison of the two β-arrestin isoforms 
In order to explore, whether the HR2R  prefers one of the two arrestin isoforms in a 
ligand-dependent manner, the selected compounds were investigated at the HEK293T 
βArr1+HR2R  and HEK293T βArr2+HR2R  cells. Fig. 6-4 gives a comparison of the potencies and 
efficacies of the compounds in the recruitment assay for either arrestin isoform. 
All compounds exhibited comparable efficacies for the recruitment of both β-arrestin 
1 and 2 (∆ERmax R< 0.05). The comparison of the pECR50R values revealed only minor differences 
between the two isoforms. The largest differences were found for the compounds 9, 13 
Fig. 6-4: Comparison of β-arrestin 1 and 2 in the luciferase complementation assay. A) Dot 
plot of the efficacies of the selected ligands in βArr1 against βArr2 recruitment. Responses 
were normalized to the maximal effect induced by histamine (100 %) and solvent (0 %). B) 
pEC50 values of the selected agonists in βArr1 against βArr2 recruitment. A, B) Data are mean 
values of 2-4 independent experiments. 
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and 16 (∆pECR50R ≙ 0.34 – 0.43), however those compounds only exhibited very weak partial 
agonism in both assays, with efficacies ranging from 0.08 – 0.16, thus strongly impairing 
the reliability of the determined potencies (Cpd. 9: 𝑝𝑝 = 0.043; Cpd. 13, 16: 𝑝𝑝 > 0.05). 
 
6.2.2. Functional bias between G-protein and β-arrestin 2 
Due to negligible differences between β-arrestin 1 and β-arrestin 2 recruitment, 
solely the βArr2 data were used for the analysis of functional bias in comparison to G-
protein activation. Fig. 6-6 gives a comparison of the potencies and efficacies of all tested 
compounds in the GTPγS binding and β-arrestin 2 recruitment assay. The responses in both 
assays were normalized to the maximal effect induced by 1 mM histamine (100 % value) 
and solvent (0 % value). Thus, histamine (1) is defined as a full, unbiased agonist in either 
readout. Interestingly, 1 exhibits a significantly lower potency in β-arrestin 2 recruitment 
compared to the GTPγS assay (pECR50R (GTPγS) = 6.24; pECR50R (βArr2) = 5.42; p = 0.0014). 
Similarly, the potencies of most of the investigated agonists was lower in the βArr2 
recruitment assay (cf. Fig. 6-6: B). The most prominent differences in potency were found 
for the bivalent agonists UR-BIT108 (20) (∆pECR50R = 1.16; p = 0.0046) and UR-NK3 (25) 
(∆pECR50R = 1.21; p < 0.0001), while the monovalent aminothiazoles UR-AK472 (11) (∆pECR50R 
= 0.08) and UR-BIT24 (16) (∆pECR50R = 0.05) were equipotent in both assays. Impromidine (4) 
was the only ligand exhibiting a higher potency in βArr2 recruitment than in G-protein 
activation (∆pECR50R = 0.55; p = 0.006). The systematic shift of the potencies between the 
Fig. 6-6: Comparison of [35S]GTPγS and β-arrestin 2 recruitment assay. A) The efficacies of the 
selected ligands in the GTPγS against βArr2 recruitment assay. Responses were normalized to the 
maximal effect induced by histamine (100 %) and solvent (0 %). B) pEC50 values of the tested ligands 
in GTPγS and βArr2 recruitment assay. A, B) Data are mean values of 2-6 independent experiments. 
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two readout systems complicates the use of the determined pECR50R-values to address 
functional selectivity of the tested ligands between G-protein and β-arrestin activation. 
Similar differences have been reported for G-protein-dependent pathways when using 
different readouts systems varying in signal amplification or receptor reserve. 
Furthermore, the validity of the detected differences in potency is affected by the observed 
decrease in efficacy in βArr2 recruitment for the majority of compounds. 
Most of the tested HR2R  agonists 1-29 were full agonists in the GTPγS binding assay. 
Interestingly, the published data, obtained using the [32P] GTPase assay at the same HR2R -
GRsαSR fusion construct, revealed discrepancies in the detected efficacies compared to the 
GTPγS data for several of the ligands.26-28,32,33 While these differences were rather subtle 
for most ligands, others exhibited a significant decrease in efficacies in the GTPase assay, 
for example the bivalent compound UR-AK381 (∆ERmaxR = 0.40) or the monovalent agonist 
UR-AK477 (∆ERmaxR = 0.26). Collectively, the efficacies of the tested ligands showed a much 
wider range in the GTPase assay (ERmaxR = 0.53 – 1.02) than in the GTPγS binding assay (ERmaxR 
= 0.77 – 0.98) (excluding Cpd. 9), suggesting the GTPase assay to be more sensitive towards 
subtle differences in ligand receptor interaction. 
Fig. 6-7: Concentration response curves of the standard H2R agonists 1-4 in the [35S]GTPγS binding 
( circles) and β-arrestin 2 recruitment assay ( triangles). Data presented are mean ± SEM of 
3-4 independent experiments. Data were analyzed by nonlinear regression and best fitted 
sigmoidal concentration response curves. 
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Most of the tested compounds revealed a completely different profile in arrestin 
recruitment. Beside the endogenous ligand histamine (1), only amthamine (2) acted as full 
agonists in βArr2 recruitment and, thus, displayed unbiased activity for both pathways (cf. 
Fig. 6-7). While dimaprit (3) showed only a slightly reduced efficacy in βArr2 recruitment 
(∆ERmaxR = 0.14; p = 0.12), the guanidine-type standard HR2R  agonist impromidine (4) exhibited 
Fig. 6-8: Concentration response curves of selected monovalent NG-acylated guanidines in the 
[35S]GTPγS binding ( circles) and β-arrestin 2 recruitment assay ( triangles). Data presented are 
mean values ± SEM of 3-4 independent experiments. Data were analyzed by nonlinear regression 
and best fitted to sigmoidal concentration-response curves. 
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a more than 4-fold decrease in efficacy in βArr2 compared to G-protein activation (∆ERmaxR = 
0.75; p < 0.0001). All tested NG-acylated or -carbamoylated guanidine-type ligands (5-29) 
exhibited a certain degree of bias towards G-protein activation. Except for UR-ML17 (9) 
(ERmaxR (GTPγS) = 0.50), the compounds of this class acted as strong partial or full agonists in 
the GTPγS assay (ERmaxR = 0.77-1.04), but were only weak partial agonists in βArr2 
recruitment (ERmaxR = 0.10-0.59). Amongst the monovalent NG-acylated guanidines, bias was 
most striking for the aminothiazole UR-AK479 (Cpd. 13), which was a full agonist in the 
GTPγS binding assay (ERmaxR = 0.94), while only showing very weak partial agonistic activity in 
βArr2 recruitment (ERmaxR = 0.11). By contrast, the imidazole UR-AK156 (Cpd. 5) displayed the 
highest efficacy of all NG-acylated guanidines regarding arrestin activation (ERmaxR = 0.59) (cf. 
Fig. 6-8). A similar functional profile is evident for all of the tested monovalent NG-acylated 
guanidines, with the imidazole containing compounds exhibiting a less pronounced bias for 
G-protein activation (Cpd. 5-10; ∆ERmaxR = 0.29-0.66) than the aminothiazoles (Cpd. 11-16; 
∆ERmaxR = 0.65-0.84). The replacement of the imidazole by an aminothiazole was so far 
regarded as bioisosteric concerning the function of the ligands at the HR2R , while 
concurrently procuring selectivity for the HR2R  over the HR3R  and HR4R .27 Regarding HR2R  
arrestin interaction, this assumption has to be challenged, as becomes apparent from the 
functional profiles of compounds sharing the same substitution pattern of the acyl moiety. 
While both, 5 and 12, exhibited comparable efficacies in the GTPγS assay (∆ERmaxR = 0.05; p 
> 0.05), the aminothiazole 12 had a significantly lower intrinsic activity in the βArr2 
recruitment assay compared to 5 (∆ERmaxR = 0.44; p < 0.0001) (cf. Fig. 7-8). The same 
phenomenon, although less pronounced, became obvious for 7 and 13 (∆ERmaxR (βArr2) = 
0.26; p < 0.0001). The addition of a 4-methyl substituent had no major impact on the 
functional properties of the ligands, despite a slight reduction of efficacy in the GTPγS assay 
(compare compounds 13 and 15). 
The bivalent ligands (Cpd. 17-29), in general, exhibited a similar characteristic as the 
monovalent NG-acylated guanidines, with varying degrees of G-protein bias (∆ERmaxR = 0.40-
0.77) (cf. Fig. 6-9). The influence of the imidazole/amino(methyl)thiazole substitution is 
also observed for these compounds, although less pronounced than for the monovalent 
ligands. The NG-carbamoylated imidazolylpropyl guanidine UR-NK52 (24) exhibited the 
highest efficacy in βArr2 recruitment (ERmaxR = 0.55), while the aminothiazole UR-BIT308 had 
the lowest intrinsic activity (ERmaxR = 0.10). The carbamoylguanidines containing either an 
imidazole (24-26) or aminothiazole moiety (27-29) revealed a minor influence of the chain 
length of the linker on the functional properties of the compounds. With increasing chain 
length, efficacy regarding βArr2 recruitment decreased and, conversely, the bias for G-
protein activation increased (24-26: ∆ERmaxR = 0.16; p = 0.0003; 27-29: ∆ERmax R= 0.13; p = 
0.0006).  
Neither the tested standard HR2R  antagonists famotidine (30), cimetidine (31) and 
ranitidine (32) nor the squaramide derivatives 33-36 exhibited functional bias for either 
pathway. They only exhibited negligible efficacies in arrestin recruitment, while exhibiting 
minor inverse agonistic effects in the GTPγS binding assay. While an unbiased profile is not 
uncommon, previous results of investigations for ligand bias using the standard antagonists 
RAN and CIM suggested a functional selectivity of 32 for β-arrestin recruitment, as it was 
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shown that RAN induced HR2R  depletion depended on β-arrestin 2 function.18 However, 
agonistic activity of RAN in β-arrestin recruitment could not be confirmed in our assay 
system. 
 
 
Fig. 6-9: Concentration response curves of selected bivalent H2R ligands in the [35S]GTPγS binding 
( circles) and β-arrestin 2 recruitment assay ( triangles). Data presented are mean ± SEM of 3-
4 independent experiments. Data were analyzed by nonlinear regression and best fitted sigmoidal 
concentration response curves. 
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  Tab. 6-1:Potencies and efficacies of the tested HR2R  ligands in the [35S]GTPγS binding and β-arrestin 1 and 2 recruitment assay 
Cpd. 
GTPγS assay β-arrestin 1 recruitment β-arrestin 2 recruitment 
pECR50R ± SEM ERmaxR ± SEM N  pECR50R ± SEM ERmax R± SEM N pECR50 R± SEM ERmax R± SEM N 
(1) HIS 6.24 ± 0.15 1.00 4 5.26 ± 0.03 1.00 5 5.42 ± 0.02 1.00 4 
(2) AMT 6.35 ± 0.13 1.01 ± 0.02 3 5.90 ± 0.06 0.92 ± 0.01 4 5.71 ± 0.04 0.96 ± 0.02 3 
(3) DIM 6.54 ± 0.21 0.91 ± 0.03 3 5.69 ± 0.05 0.75 ± 0.03 3 5.64 ± 0.10 0.77 ± 0.06 3 
(4) IMP 6.53 ± 0.07 0.98 ± 0.02 4 7.00 ± 0.02 0.25 ± 0.01 3 7.08 ± 0.10 0.23 ± 0.01 3 
(5) UR-AK156 8.05 ± 0.15 0.87 ± 0.05 3 7.27 ± 0.07 0.56 ± 0.03 4 7.13 ± 0.06 0.59 ± 0.02 4 
(6) UR-AK224 8.05 ± 0.08 0.94 ± 0.04 3 7.30 ± 0.03 0.50 ± 0.06 3 7.15 ± 0.00 0.52 ± 0.01 3 
(7) UR-AK437 7.95 ± 0.07 0.86 ± 0.04 3 7.24 ± 0.08 0.33 ± 0.05 3 7.12 ± 0.06 0.36 ± 0.02 3 
(8) UR-AK284 7.66 ± 0.17 0.93 ± 0.05 3 6.82 ± 0.07 0.26 ± 0.02 3 7.02 ± 0.04 0.27 ± 0.01 3 
(9) UR-ML17 8.10 ± 0.06 0.50 ± 0.05 3 7.62 ± 0.00 0.16 ± 0.01 3 7.18 ± 0.15 0.15 ± 0.01 3 
(10) UR-ML22 7.42 ± 0.17 0.90 ± 0.06 3 6.76 ± 0.04 0.47 ± 0.03 3 6.76 ± 0.03 0.42 ± 0.03 4 
(11) UR-AK472 7.75 ± 0.13 0.81 ± 0.02 3 7.87 ± 0.09 0.07 ± 0.01 3 7.68 ± 0.05 0.11 ± 0.01 3 
(12) UR-AK477 8.11 ± 0.10 0.92 ± 0.08 3 7.39 ± 0.06 0.13 ± 0.01 5 7.35 ± 0.13 0.14 ± 0.01 5 
(13) UR-AK479 7.76 ± 0.09 0.94 ± 0.09 3 7.10 ± 0.14 0.08 ± 0.01 4 7.51 ± 0.13 0.11 ± 0.01 4 
(14) UR-BIT336 7.98 ± 0.08 0.91 ± 0.08 4 7.12 ± 0.08 0.14 ± 0.02 3 7.31 ± 0.04 0.15 ± 0.01 3 
(15) UR-AK423 7.71 ± 0.07 0.77 ± 0.04 3 7.31 ± 0.04 0.09 ± 0.01 3 7.13 ± 0.13 0.12 ± 0.01 3 
(16) UR-BIT24 7.77 ± 0.10 0.91 ± 0.04 3 7.37 ± 0.07 0.16 ± 0.01 3 7.72 ± 0.11 0.14 ± 0.01 3 
(17) UR-BIT237 7.45 ± 0.12 0.95 ± 0.03 3 6.55 ± 0.08 0.34 ± 0.02 3 6.66 ± 0.16 0.39 ± 0.02 3 
(18) UR-AK480 7.85 ± 0.09 0.99 ± 0.03 4 7.26 ± 0.07 0.24 ± 0.01 3 7.42 ± 0.04 0.22 ± 0.01 3 
(19) UR-AK381 7.76 ± 0.16 0.93 ± 0.04 4 6.86 ± 0.06 0.16 ± 0.01 3 6.88 ± 0.01 0.15 ± 0.00 3 
 
  
 Tab. 6-1 (continued) 
Cpd. 
GTPγS assay β-arrestin 1 recruitment β-arrestin 2 recruitment 
pECR50 R± SEM ERmax R± SEM N pECR50 R± SEM ERmax R± SEM N pECR50 R± SEM ERmax R± SEM N 
(20) UR-BIT108 7.60 ± 0.24 0.91 ± 0.03 5 6.23 ± 0.13 0.24 ± 0.01 4 6.44 ± 0.06 0.24 ± 0.01 4 
(21) UR-BIT106 7.62 ± 0.22 0.84 ± 0.02 3 6.83 ± 0.03 0.16 ± 0.02 3 7.12 ± 0.03 0.18 ± 0.00 3 
(22) UR-BIT82 7.86 ± 0.16 0.83 ± 0.08 3 7.16 ± 0.17 0.19 ± 0.01 3 7.36 ± 0.03 0.18 ± 0.01 3 
(23) UR-BIT308 7.67 ± 0.20 0.80 ± 0.02 3 7.34 ± 0.06 0.13 ± 0.01 2 7.49 ± 0.09 0.10 ± 0.01 3 
(24) UR-NK52 7.29 ± 0.08 0.95 ± 0.03 6 6.80 ± 0.07 0.51 ± 0.02 3 6.85 ± 0.09 0.55 ± 0.00 3 
(25) UR-NK3 7.76 ± 0.03 0.88 ± 0.03 2 6.59 ± 0.03 0.37 ± 0.01 3 6.55 ± 0.01 0.39 ± 0.01 3 
(26) UR-NK60 8.37 ± 0.10 1.04 ± 0.05 4 7.46 ± 0.01 0.42 ± 0.01 3 7.42 ± 0.06 0.39 ± 0.02 4 
(27) UR-NK41 7.29 ± 0.13 0.99 ± 0.04 5 6.52 ± 0.04 0.32 ± 0.02 3 6.55 ± 0.09 0.33 ± 0.01 3 
(28) UR-NK22 8.03 ± 0.02 0.92 ± 0.01 2 7.02 ± 0.03 0.28 ± 0.01 3 7.19 ± 0.09 0.30 ± 0.02 3 
(29) UR-NK53 7.68 ± 0.08 0.91 ± 0.05 6 7.18 ± 0.02 0.20 ± 0.01 3 7.28 ± 0.05 0.20 ± 0.01 4 
(30) FAM n.d. -0.05 ± 0.01 2 n.d. 0.01 ± 0.01 2 n.d. 0.02 ± 0.01 2 
(31) CIM n.d. -0.07 ± 0.01 2 n.d. 0.01 ± 0.01 2 n.d. 0.02 ± 0.01 2 
(32) RAN n.d. -0.05 ± 0.01 2 n.d. 0.01 ± 0.01 2 n.d. 0.02 ± 0.00 2 
(33) UR-DE85 n.d. -0.05 ± 0.01 2 n.d. 0.00 ± 0.00 2 n.d. 0.00 ± 0.00 2 
(34) UR-DE86 n.d. -0.06 ± 0.02 2 n.d. 0.01 ± 0.01 2 n.d. 0.00 ± 0.00 2 
(35) UR-DE92 n.d. -0.06 ± 0.02 2 n.d. 0.00 ± 0.00 2 n.d. 0.01 ± 0.01 2 
(36) UR-DE114 n.d. -0.07 ± 0.02 2 n.d. 0.00 ± 0.00 2 n.d. 0.00 ± 0.00 2 
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6.2.3. Quantifying stimulus bias using the operational model 
With the general acceptance that GPCR ligands can produce a response biased for 
one pathway over another, the necessity arose to quantify this functional selectivity in 
order to allow for the analysis of structure-activity relationships (SAR) to guide the 
development of biased agonists. Unfortunately, the use of ligand potencies and efficacies 
as classically derived from concentration-response curves proved inadequate in many 
cases, as the comparison of rank orders of potency fails to discriminate between full and 
partial agonists, while the use of ligand efficacies cannot account for changes in potency 
between different pathways. Furthermore, a systematic bias between two different 
readout systems, as described above for the potencies of H2R agonists, can complicate the 
data interpretation. 
Several recent publications recommend the use of the operational model of 
agonism34 to overcome these limitations.35,36 Fig. 6-10 gives a schematic overview of the 
model. Here receptor agonism is defined as an allosteric system comprised of a modulator 
(agonist), operating on a protein conduit (receptor) to a protein guest (signaling 
molecule).35 The use of the operational model gives access to the 2 parameters, intrinsic 
efficacy and potency, defining the agonistic potential of the test compound. The 
equilibrium dissociation constant (KA) of the ligand receptor complex provides a measure 
for the ligand affinity and the τ value, derived from [RT]/KE, describes the agonists efficacy. 
Hereby, RT is the receptor density and KE describes the coupling efficiency of the ligand 
receptor complex to the respective downstream effector.35 From these two parameters, 
the so called “transduction coefficient” log (τ/KA) is derived, a composite parameter 
sufficient to describe agonism for a given pathway.37 The transduction coefficients for the 
tested compounds can be normalized to the log (τ/KA) of the endogenous ligand, thereby 
cancelling out potential systematic bias generated by differences in the cellular background 
and/or signal amplification of the chosen readout systems. The comparison of the 
normalized transduction coefficients of a ligand for different signaling pathways then 
allows for the quantification of the ligand bias. 
The functional data of the H2R agonists from either the GTPγS binding or arrestin 
recruitment assay were fitted to the operational model as described in 6.2.4.2. Tab. 6-2 
Fig 6-10: Schematic diagram for the use of the operational model 
of agonism33 to characterize agonist function. (Adapted from 
Kenakin et al., 201234) 
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gives the absolute and normalized transduction coefficients for either readout as well as 
the bias factors ∆∆log (τ/KA) of the ligands between the G-protein and arrestin pathway. 
The determined bias factors allowed for the quantification of the functional selectivity 
evident in the functional data of the tested acyl- and carbamoylguanidine-type ligands. For 
most of the test compounds, the determined bias factors correlated well with the 
differences identified by simply comparing the potencies and efficacies. UR-AK156 (5), for 
example, showed only a moderate degree of G-protein bias with a ∆∆log (τ/KA) of 0.44, 
which can be explained by the moderate decrease in efficacy in βArr2 recruitment 
compared to G-protein activation (cf. Tab. 6-1). The acylguanidines exhibiting the strongest 
bias, with ∆∆log (τ/KA) values from 1.27 to 1.38 (cf. Fig. 6-11), revealed pronounced 
differences in potency and/or efficacy between the two readouts. UR-BIT108 (20) exhibited 
the highest bias factor (cf. Fig. 6-12), and while not showing the highest of all differences 
in efficacy, the major decrease in potency found for arrestin recruitment accounts for the 
increased bias. Other compounds showing a strong bias, such as UR-AK381 (19) or UR-
Fig. 6-11: Quantification of the functional bias of the tested H2R agonists between the GTPγS 
binding and the arrestin recruitment assay. The normalized ∆log (τ/KA) values for the G-protein (A) 
and arrestin (B) pathway were calculated as described in 6.4.2.4 Eq. 2. Subtraction of the ∆log 
(τ/KA) values of the arrestin recruitment assay from the GTPγS binding yielded the bias factors 
∆∆log (τ/KA) (C) for the tested compounds. 
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AK477 (12), were amongst the compounds with the most pronounced decrease in efficacy 
in arrestin recruitment. Applying the model to the data of the neutral agonist amthamine 
(2) revealed the effectiveness of the data normalization. Amthamine acted as a full agonist 
in both assays, revealing a shift in potency comparable to histamine between the two 
readouts. The difference in the transduction coefficients log (τ/KA) for the individual 
readouts is cancelled out through the normalization, giving a bias factor around zero. Some 
Fig. 6-12: Concentration-response curves of selected H2R ligands in comparison with the 
endogenous ligand histamine fitted with the operational model of agonism as described in 6.4.2.4 
and the corresponding transduction coefficients log (τ/KA) for the GTPγS binding (1) and arrestin 
recruitment assay (2). Thereof, the normalized transduction coefficients ∆log (τ/KA) (3) for each 
assay were derived. Data shown are mean values ± SEM calculated as described in 6.4.2.4 for 
amthamine (A), UR-BIT108 (B) and UR-NK52 (C). 
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other compounds showed a neutral, unbiased characteristic in the operational model, 
which was not expected from the concentration-response curves. Both impromidine (4) 
and the carbamoylguanidine UR-NK52 (cf. Fig 6-12 C) exhibited a decreased efficacy in 
arrestin recruitment but showed ∆∆log (τ/KA) values around zero. In both cases, an 
increased potency in arrestin recruitment compared to the endogenous ligand histamine 
compensated for the loss in efficacy and resulted in comparable normalized transduction 
coefficients in both readouts. Whether those findings really imply a neutral agonistic 
behavior of these compounds under physiological conditions remains elusive. 
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 Tab. 6-2: Transduction coefficients log (τ/KRAR) and normalized transduction coefficients ∆log (τ/KRAR) in the 
GTPγS and arrestin recruitment assay and the bias factors ∆∆log (τ/KRAR) of the tested HR2R  agonists. 
Cpd. 
GTPγS βArr2 ∆∆log (τ/KRAR)  
(G-Arr) log (τ/KRAR) ∆log (τ/KRAR) log (τ/KRAR) ∆log (τ/KRAR) 
(1) HIS 6.32 ± 0.07    5.41 ± 0.03       
(2) AMT 6.61 ± 0.08 0.30 ± 0.08 5.69 ± 0.04 0.28 ± 0.05 0.01 ± 0.09 
(3) DIM 6.52 ± 0.08 0.20 ± 0.11 5.46 ± 0.05 0.05 ± 0.06 0.15 ± 0.12 
(4) IMP 6.83 ± 0.08 0.51 ± 0.10 6.01 ± 0.15 0.61 ± 0.15 -0.10 ± 0.18 
(5) UR-AK156 7.99 ± 0.08 1.67 ± 0.11 6.63 ± 0.06 1.23 ± 0.07 0.44 ± 0.13 
(6) UR-AK224 8.15 ± 0.09 1.83 ± 0.11 6.57 ± 0.07 1.16 ± 0.08 0.66 ± 0.14 
(7) UR-AK437 7.85 ± 0.08 1.54 ± 0.11 6.34 ± 0.10 0.93 ± 0.10 0.61 ± 0.15 
(8) UR-AK284 7.67 ± 0.08 1.35 ± 0.11 5.93 ± 0.12 0.52 ± 0.13 0.83 ± 0.17 
(9) UR-ML17 7.64 ± 0.15 1.32 ± 0.17 5.70 ± 0.21 0.29 ± 0.21 1.03 ± 0.27 
(10) UR-ML22 7.41 ± 0.08 1.10 ± 0.11 5.99 ± 0.07 0.59 ± 0.08 0.51 ± 0.13 
(11) UR-AK472 7.59 ± 0.09 1.28 ± 0.12 5.82 ± 0.26 0.42 ± 0.26 0.86 ± 0.29 
(12) UR-AK477 7.98 ± 0.08 1.66 ± 0.11 5.77 ± 0.16 0.37 ± 0.16 1.30 ± 0.20 
(13) UR-AK479 7.79 ± 0.08 1.48 ± 0.11 5.71 ± 0.22 0.31 ± 0.22 1.17 ± 0.25 
(14) UR-BIT336 8.00 ± 0.08 1.69 ± 0.10 5.77 ± 0.18 0.37 ± 0.18 1.32 ± 0.21 
(15) UR-AK423 7.58 ± 0.10 1.26 ± 0.12 5.40 ± 0.23 -0.01 ± 0.24 1.27 ± 0.27 
(16) UR-BIT24 7.70 ± 0.08 1.38 ± 0.11 6.05 ± 0.20 0.65 ± 0.20 0.74 ± 0.23 
(17) UR-BIT237 7.39 ± 0.09 1.07 ± 0.11 5.81 ± 0.09 0.40 ± 0.09 0.67 ± 0.15 
(18) UR-AK480 7.91 ± 0.07 1.59 ± 0.10 6.17 ± 0.16 0.76 ± 0.17 0.83 ± 0.19 
(19) UR-AK381 7.56 ± 0.07 1.24 ± 0.10 5.35 ± 0.24 -0.06 ± 0.24 1.30 ± 0.26 
(20) UR-BIT108 7.50 ± 0.08 1.18 ± 0.10 5.21 ± 0.12 -0.20 ± 0.12 1.38 ± 0.16 
(21) UR-BIT106 7.42 ± 0.10 1.10 ± 0.12 5.65 ± 0.16 0.24 ± 0.16 0.85 ± 0.20 
(22) UR-BIT82 7.81 ± 0.10 1.50 ± 0.12 5.92 ± 0.17 0.51 ± 0.17 0.98 ± 0.21 
(23) UR-BIT308 7.40 ± 0.11 1.08 ± 0.13 5.64 ± 0.33 0.23 ± 0.33 0.85 ± 0.36 
(24) UR-NK52 7.32 ± 0.07 1.00 ± 0.10 6.36 ± 0.06 0.95 ± 0.07 0.05 ± 0.12 
(25) UR-NK3 7.65 ± 0.09 1.33 ± 0.11 5.79 ± 0.08 0.38 ± 0.09 0.95 ± 0.14 
(26) UR-NK60 8.50 ± 0.07 2.18 ± 0.10 6.58 ± 0.07 1.17 ± 0.08 1.00 ± 0.13 
(27) UR-NK41 7.26 ± 0.07 0.94 ± 0.10 5.60 ± 0.09 0.19 ± 0.10 0.74 ± 0.14 
(28) UR-NK22 7.73 ± 0.12 1.41 ± 0.14 6.21 ± 0.11 0.80 ± 0.11 0.61 ± 0.18 
(29) UR-NK53 7.65 ± 0.07 1.33 ± 0.10 5.92 ± 0.14 0.51 ± 0.14 0.82 ± 0.18 
The transduction coefficients log (τ/KRAR) were derived from pooled functional data of 2 – 6 independent 
experiments fitted to the operational model of agonism as described in 6.4.2.4. Data are given as mean 
values ± SEM calculated as described in 6.4.2.4. 
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6.3. Summary and conclusions 
All of the investigated H2R antagonists exhibited a neutral, unbiased characteristic in 
the arrestin and G-protein readout. Amongst the H2R agonists, the acyl- and 
carbamoylguanidines revealed varying degrees of G-protein bias; most compounds being 
strong or full agonists in the GTPγS assay, while only producing weak partial agonistic 
effects in arrestin recruitment. None of the tested compounds exhibited functional 
selectivity towards arrestin activation. Furthermore, no significant differences were 
detectable regarding the recruitment of the two arrestin isoforms, except for minor 
variations in potency for some of the compounds with low efficacy. The application of the 
operational model of agonism enabled the calculation of a bias factor to quantify the 
functional selectivity between the two pathways. A method for the quantification of ligand 
bias is crucial for the analysis of structure-activity relationships to guide the development 
of new biased ligands. 
In the case of the H2R, selective agonists came into focus as potential new drug 
candidates for the treatment of acute myeloid leukemia. For AML patients, histamine in 
combination with interleukin IL-2 (Ceplene)38 is available as post consolidation therapy 
and has shown to prolong leukemia free survival compared to the standard therapy.39 The 
putative mode of action for histamine hereby is the inhibition of ROS-induced apoptosis of 
T- and NK-cells via H2R-mediated inhibition of NADPH oxidase in myeloid cells.40,41 Hereby, 
the substitution of histamine by selective H2R agonists could prevent several severe side 
effects caused by the activation of HXR subtypes other than H2R, in particular H1R and H4R.41 
A recent study investigating the pharmacological profile of several known H2R agonists on 
native monocytes identified several compounds exhibiting functional selectivity between 
the induction of cAMP production and the inhibition of fMLP stimulated ROS generation,41 
thus emphasizing the necessity to fully characterize the functional profile of potential drug 
candidates regarding non-canonical signaling pathways. Besides the unknown implications 
on receptor signaling, treatment with G-protein biased agonists could be beneficial 
compared to neutral agonists in reducing adverse effect associated with arrestin mediated 
processes such as receptor down-regulation and drug resistance. 
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6.4. Materials and methods 
6.4.1. Materials 
Unless stated otherwise, all chemicals and reagents were purchased from Sigma-
Aldrich Chemie (Munich, Germany) or Merck (Darmstadt, Germany). Insect-Xpress medium 
was from Lonza (Verviers, Belgium), FCS was from Biochrom (Berlin, Germany). The DC 
protein assay kit was purchased from Bio-Rad Laboratories (München, Germany), BSA 
(Albumin bovine Fraction V receptor grade) was from Serva Electrophoresis (Heidelberg, 
Germany). [35S]GTPγS was purchased from Hartmann Analytic (Braunschweig, Germany), 
guanosine diphosphate (GDP) was from Sigma-Aldrich Chemie (Munich, Germany), 
unlabeled GTPγS was from Roche (Mannheim, Germany). GF/C glass fiber filter were from 
Whatman International (Maidstone, UK). Rotiscint eco plus scintillation cocktail was from 
Roth Carl (Karlsruhe, Germany). For media and reagents used for the luciferase 
complementation assay, see 3.4. 
 
6.4.1.1. HR2R  ligands 
Histamine dihydrochloride (1) was from Alfa Aesar (Karlsruhe, Germany). Amthamine 
dihydrobromide (2) and dimaprit dihydrochloride (3) were from Tocris Bioscience (Ellisville, 
MO, USA). The compounds 4-29 and 33-36 were synthesized in our laboratory.27,28,32,33,42 
Famotidine (30) and ranitidine (32) were from Sigma (St. Louis, USA). Cimetidine (31) was 
from Tocris Bioscience (Ellisville, USA). Stock solutions (10 mM) of compounds 1-4 and 30-
32 were prepared with distilled water. In case of compounds 5-29 and 33-36, stock 
solutions (10 mM) were prepared with 10 mM TFA. 
 
6.4.2. Methods 
6.4.2.1. Sf9 insect cell membrane preparation 
Sf9 membranes were prepared as previously described43,44 using a baculovirus 
transfection system. The Sf9 insect cells (Spodoptera frugiperda ovary cells) and the stock 
solution of the baculovirus encoding the human H2R-GsαS fusion construct were kindly 
provided by Prof. Dr. Roland Seifert (Institute of Pharmacology, Medical School of 
Hannover, Germany). Sf9 cells were seeded at a density of 3 million cells/ml in Insect 
express medium supplemented with 5 % FCS and infected with a 1:100 titer of the virus 
stock. After incubation for 48 h at 28 °C under shaking, membranes were prepared as 
described.43 Membranes were resuspended in binding buffer (12.5 mM MgCl2, 1 mM EDTA 
and 75 mM Tris/HCl, pH 7.4) and aliquots were stored at -80 °C until use. The protein 
content of the membranes was determined using the DC protein assay kit (BioRad) 
according to manufacturer`s instructions. A BSA dilution series served as reference. 
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6.4.2.2.  [35S]GTPγS functional binding assay 
[35S]GTPγS functional binding assay was performed as previously described.16,44 The 
Sf9 membranes expressing the hH2R-GsαS fusion protein were thawed, sedimented by 
centrifugation at 16000 g for 10 min at 4 °C and thoroughly resuspended in ice cold binding 
buffer. The assay was performed in a 96 well polypropylene plate. Each well contained Sf9 
membranes (10 µg protein/well), 1 µM GDP, 0.05 % BSA, 0.2 nM [35S]GTPγS and the 
corresponding ligands in varying concentrations, brought to a total volume of 100 µl with 
binding buffer. The plates were incubated for 90 min under shaking at RT. Subsequently, 
the membranes were harvested by filtration through GF/C filters using a Brandel 96 sample 
harvester (Brandel, Gaithersburg, MD). After 3 washing steps with ice cold binding buffer, 
the membrane bound radioactivity was measured by liquid scintillation counting using the 
Micro Beta2 1450 scintillation counter (Perkin Elmer, Rodgau, Germany). 
 
6.4.2.3. Luciferase complementation assay  
The luciferase complementation assay was performed as described above (cf. 3.4.7) 
using the HEK293T-βArr1-H2R and HEK293T-βArr2-H2R cell lines stably expressing the H2R-
ElucC and either the βArr1-ElucN or βArr2-ElucN fusion constructs (cf. 3.2). For cell culture 
conditions and media requirements, see 3.4.2. Dilution series of the tested compounds 
were prepared with the same solvent as the stock solutions (cf. 6.4.1.1). The cells were 
stimulated for 60 min with varying concentrations of the ligands. The results were 
normalized to the maximum effect induced by 1 mM histamine (100 % value) and solvent 
(0 % value). Concentration-response curves determined for histamine, using either distilled 
water or 10 mM TFA as solvent, revealed no significant differences. 
 
6.4.2.4. Data analysis 
Data analysis was performed as described above (cf. 4.3.2.2). Statistical analysis of 
the variances was performed either by unpaired T test for comparing 2 sets of values or by 
one way ANOVA followed by Bonferoni`s multiple comparison test for multiple sets of 
values. The analysis was performed using GraphPad Prism 5 software (GraphPad Software, 
La Jolla, CA, USA). 
To allow for the quantification of functional bias, the concentration-response curves 
of the ligands producing agonistic effects in both readouts were fitted to the operational 
model of agonism34 as previously described35,37 using the following equation: 
𝑌𝑌 = 𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 + (𝐸𝐸𝑚𝑚  − 𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏) � 𝜏𝜏𝐾𝐾𝐴𝐴�𝑛𝑛  [𝐴𝐴]𝑛𝑛[𝐴𝐴]𝑛𝑛  � 𝜏𝜏𝐾𝐾𝐴𝐴�𝑛𝑛 +  �1 +  [𝐴𝐴]𝐾𝐾𝐴𝐴 �𝑛𝑛 (1) 
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where Em is the maximal response of the system, basal is the background level of the 
response, KA is the equilibrium dissociation constant of the ligand A, τ is a measure of the 
signaling efficacy of the agonist and is defined as RT/KE, where RT is the total receptor 
number and KE is the coupling efficacy of the ligand-receptor complex to the downstream 
effector, and n is the slope of the transducer function that links occupancy to response.37 
It is assumed, that the maximal response of the system (Em) and the transduction 
machinery used for a specific pathway are identical for all agonists, such that the Em and 
transducer slope (n) are shared between agonists.37 The pooled data for all ligands for a 
given readout was fitted globally to determine the log (τ/KA) ratio using an implementation 
for GraphPad Prism kindly provided by Dr. J. Robert Lane from the Monash University, 
Australia. The transduction coefficient log (τ/KA) is an excellent parameter to describe bias 
between two given pathways, as bias can either originate from a different affinity (KA) of a 
ligand for different receptor conformations and/or different coupling efficacies of the 
ligand-receptor complex to the respective downstream effectors.37 
In order to mitigate the influence of a possible systematic bias between the two 
different readout systems, the log (τ/KA) values for each ligand were normalized to that of 
the endogenous ligand histamine for the given pathway as follows 
∆𝑏𝑏𝑙𝑙𝑙𝑙 �
𝜏𝜏
𝐾𝐾𝐴𝐴
� = 𝑏𝑏𝑙𝑙𝑙𝑙 � 𝜏𝜏
𝐾𝐾𝐴𝐴
�
𝑐𝑐𝑐𝑐𝑐𝑐
−  𝑏𝑏𝑙𝑙𝑙𝑙 � 𝜏𝜏
𝐾𝐾𝐴𝐴
�
𝐻𝐻𝐻𝐻𝐻𝐻
 
Using the normalized ∆log (τ/KA) values, a bias factor can be calculated for each ligand 
for the G-protein over the β-arrestin mediated pathway as follows 
∆∆𝑏𝑏𝑙𝑙𝑙𝑙 �
𝜏𝜏
𝐾𝐾𝐴𝐴
�
𝐺𝐺−𝐴𝐴𝐴𝐴𝐴𝐴
= ∆𝑏𝑏𝑙𝑙𝑙𝑙 � 𝜏𝜏
𝐾𝐾𝐴𝐴
�
𝐺𝐺
  − ∆𝑏𝑏𝑙𝑙𝑙𝑙 � 𝜏𝜏
𝐾𝐾𝐴𝐴
�
𝐴𝐴𝐴𝐴𝐴𝐴
 
An unbiased response of given ligand for the two investigated pathways would result 
in a bias factor ∆∆log (τ/KA) around 0, while positive or negative values indicate a bias for 
the G-protein or arrestin pathway, respectively. 
The propagation of the error when employing equation (2) and (3) was addressed 
using the following equation 
𝑆𝑆𝐸𝐸𝑆𝑆 =  �(𝑆𝑆𝐸𝐸𝑆𝑆𝑖𝑖)2 + (𝑆𝑆𝐸𝐸𝑆𝑆𝑗𝑗)2 
  
(2) 
(3) 
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7. Analysis of functional selectivity at the 
histamine H4 receptor 
7.1. Introduction 
The histamine H4 receptor represents the newest addition to the histamine receptor 
family. Its existence was first postulated by Raible et al. in 1994, triggered by the finding 
that human eosinophils express a histamine receptor with a pharmacological profile 
distinct from that of the three other histamine receptor subtypes.1 However, it was not 
until after the successful cloning of the histamine H3 receptor in 19992 that the H4R was 
identified with the aid of genomic databases due its high homology with the H3R. In the 
years 2000 and 2001, independent of each other, several research groups reported the 
cloning of the H4R.3-9 
The analysis of the expression pattern of the H4R in humans and mice has been 
performed mostly by using reverse transcriptase PCR (RT-PCR) techniques detecting 
transcription levels of the corresponding mRNA transcripts in the different tissues.10,11 
Hereby, H4R expression was detected in spleen, lung, liver, thymus, bone marrow, small 
intestines and colon as well as in several cells of the hematopoietic lineage.3,8,9,11,12 Reports 
about H4R expression in the brain have so far been inconclusive, as RT-PCR techniques are 
prone to contamination and detailed expression analysis on the protein level has so far 
been hampered by the lack of suitable, specific H4R antibodies or radioligands for 
autoradiography studies.13-15 
The predominant expression of the H4R in hematopoietic cells, including neutrophils, 
mast cells, eosinophils, basophils, dendritic cells and T cells,11 suggest a broad involvement 
of the H4R in immune modulation and inflamation.16 It has been demonstrated that the H4R 
is involved in the chemotaxis of eosinophils through induction of actin rearrangement and 
upregulation of certain adhesion proteins.1,16,17 In mast cells, H4R activation induces 
chemotaxis without triggering degranulation and thereby might be crucial for the 
development of chronic allergic inflammation.12,16 Furthermore, the H4R plays a role in the 
activation of dendritic cells and the release of interleukins from T lymphocytes.16,18 
Therefore, the H4R is considered as a promising new target for the treatment of allergic and 
inflammatory disorders, like asthma, pruritus and allergic rhinitis, and several H4R 
antagonists are currently under investigation in clinical trials.19-23 
The full length H4R is a 390 aa protein belonging to the class A, rhodopsin-like GPCRs. 
The coding sequence of the H4R gene is separated by two large intron sequences, 
theoretically allowing for multiple alternative splice variants of the gene transcript.3 So far 
only two truncated variants of the H4R have been identified, H4R(67) and H4R(302), neither 
exhibiting GPCR-like functions on their one, but rather playing a role in regulation of the 
full length H4R.11,24 The H4R couples to pertussis toxin (PTX) sensitive Gαi/0 proteins leading 
to inhibition of the ACs and, thus, a decrease in intracellular cAMP levels, thereby inhibiting 
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transcription of genes under control of the CRE promoter.5,8,11 Furthermore H4R stimulation 
induced a PTX sensitive activation of downstream MAPK pathways.5 In addition to Gαi/0 
activation, the H4R couples to PLC dependent pathways via the Gα15/16 proteins,5,8 which 
are exclusively expressed in hematopoietic cells.25 In most recombinant systems, the H4R 
exhibited constitutive activity, susceptible to inhibition by different inverse agonists.11 In 
mast cells endogenously expressing the H4R, histamine stimulation induced a Ca2+ signal, 
which was inhibited by PTX and the PLC inhibitor U73122.12 
In 2011, the functional versatility of the H4R came into focus, when Rosethorne et al. 
identified the indole derivative JNJ7777120, previously regarded as a standard antagonist 
for the H4R, as a biased agonist, inducing H4R-mediated β-arrestin recruitment.26,27 The 
authors reported that JNJ7777120, while being an antagonist in a [35S]GTPγS binding assay, 
exhibited strong partial agonistic activity in a β-arrestin recruitment assay and that the 
observed stimulation by JNJ7777120 was insensitive to the treatment with PTX.26 
Furthermore, JNJ7777120 induced ERK1/2 phosphorylation in a time course significantly 
prolonged in comparison to the corresponding histamine effect,26 as generally expected for 
G-protein versus β-arrestin mediated signaling.28 Following this initial discovery, a variety 
of known H4R ligands were investigated for functional selectivity, and several compounds 
of different chemical classes were identified as either G-protein or β-arrestin biased ligands 
at the H4R.29 
Due to the reported discrimination between G protein and arrestin signaling, the H4R 
is an especially interesting target to study functional selectivity and to evaluate the enzyme 
fragment complementation based β-arrestin recruitment assay established as part of this 
doctoral project. In addition to several reference compounds previously tested for biased 
agonism in other laboratories, new classes of H4R ligands synthesized in our department30-
32 were selected for pharmacological characterization in the β-arrestin recruitment assay. 
 
7.1.1. HR4R  ligands selected for the functional selectivity screening 
The pharmacological investigations were performed with a set of 29 structurally 
diverse H4R ligands (chemical structures, cf. Fig. 7-1). This selection included the 
endogenous ligand histamine (1) as well as several methylhistamine derivatives (2-5) with 
known affinity for the H4R, including 4(5)-methylhistamine (5), the first potent and selective 
agonist for the H4R.33 Furthermore, several imidazole containing compounds, originally 
designed as H3R agonists, but also exhibiting H4R affinity, were included (6-10).33 The same 
holds for the thiourea derivative thioperamide (11), a known inverse agonist at the H3R and 
H4R, and the isothiourea-type H3R antagonists clobenpropit (12) and iodophenpropit (13). 
Similar to 4(5)-methylhistamine, VUF8430 (14)33,34 as well as the acylguanidine UR-AK51 
(15) were initially designed as H2R agonist, but found to be potent H4R agonists. UR-AK51 
triggered the development of UR-PI294 (16), a potent full agonist at the H4R with strong 
selectivity over the H1R and H2R and low efficacy at the H3R.30 The atypical antipsychotic 
dibenzodiazepine derivative clozapine (17) and its structural analog isoloxapine (18) are 
known to possess affinity to the H1R and H4R.33 The aminopyrimidines A943931 (19) and 
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A987306 (20) were described as new potent and selective H4R antagonists with anti-
inflammatory and pain blocking efficacy in mice.35,36 Independently, Sanders et al. 
developed another set of aminopyrimidines and identified ST-1006 (21) and ST-1012 (22) 
as high affinity H4R ligands.37 Interestingly, while 22 acted as inverse agonist at the H4R, 21 
exhibited partial agonistic activity.37 As mentioned above, JNJ7777120 was the first β-
arrestin biased ligand at the H4R described in the literature and, therefore, included as 
reference compound.29 The cyanoguanidine UR-PI376 (24) was developed from the NG-
Fig. 7-1: Structures of the selected H4R ligands 
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acylated guanidines (cf. 15 and 16) to improve subtype selectivity for the H4R.38 Aiming at 
a further improvement of the selectivity over the H3R, the introduction of a cyclopentane-
1,3-diyl linker resulted in a set of four chiral compounds with interesting selectivity profiles 
depending on the stereochemistry (25-29).39 The 2-aryl-benzimidazole 30 (UR-PB195) was 
described as a full agonist with subnanomolar affinity for the H4R and excellent selectivity 
over the other histamine receptor subtypes.40 
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7.2. Results and discussion 
The selected H4R ligands were studied for functional selectivity using two different 
assay systems. H4R-dependent G-protein activation was determined in a reporter gene 
assay, measuring the Gαi mediated inhibition of forskolin stimulated expression of a firefly 
luciferase under control of the cAMP response element.41 β-Arrestin recruitment to the 
H4R was measured in the established luciferase complementation assay. In an initial 
screening, all ligands were tested for functional differences in recruitment of the two β-
arrestin isoforms. As no major differences became obvious, further investigations were 
performed solely with the β-arrestin 2 expressing cells. 
Table 7-1 gives a summary of the potencies and efficacies of the tested ligands in the 
CRE-luciferase and the β-arrestin 2 recruitment assay. The responses in both assays were 
normalized to the maximum effect induced by 1 mM histamine (100 % value) and solvent 
(0 % value). Therefore, the endogenous ligand histamine (1) is defined as a full, unbiased 
agonist in both assays (cf. Fig. 7-3). Generally, the determined potencies were higher in the 
reporter gene assay compared to the arrestin recruitment assay (cf. Fig. 7-2). Except for 
VUF8430 (14) (∆pEC50 = -0.12) and imetit (9) (∆pEC50 =0.27), which were equipotent in both 
readouts, all agonists exhibited a considerably lower potency regarding β-arrestin 2 
recruitment (∆pEC50 = 0.49 – 1.39). These results are consistent with previously published 
data, showing a similar systematic shift between an enzyme fragment complementation 
(EFC)-based arrestin recruitment assay and the CRE luciferase assay.29 In theory, such 
differences can be attributed to the signal amplification occurring in the distal, second 
messenger based CRE-luciferase assay compared to the proximal EFC-based arrestin 
Fig. 7-2: Comparison of the luciferase gene reporter and β-arrestin 2 recruitment assay. A) The 
efficacies of the selected ligands in the luciferase gene reporter against βArr2 recruitment assay. 
Responses were normalized to the maximal effect induced by histamine (100 %) and solvent (0 %). 
B) pEC50 values of the tested ligands in the luciferase gene reporter and βArr2 recruitment assay. A, 
B) Data are mean values of 2-7 independent experiments. 
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recruitment assay. A similar decrease in potency was evident for arrestin recruitment 
compared to G-protein activation in case of the H2R (cf. Chapter 6), even though the GTPγS 
binding assay was performed with membranes expressing H2R-GsαS fusion ensuring a 1:1 
stoichiometry of receptor and effector protein as in the EFC-based arrestin recruitment 
assay, thus annihilating presumed differences in signal amplification. 
Fig. 7-3 gives the concentration response curves of compounds acting as full agonists 
in both assays, thus exhibiting no bias with regard to the intrinsic activities of the 
compounds. The potencies of the compounds, however, show a completely different 
picture. While histamine (1) and Nα-methyl-histamine (4) exhibited only a minor shift 
towards lower potencies in arrestin recruitment (∆pEC50 (1) = 0.53; ∆pEC50 (4) = 0.52), the 
benzimidazole UR-PB195 showed a pronounced decrease (∆pEC50 = 1.03; p = 0.0014). The 
isothiourea VUF8430 on the other hand displays equal potencies in either readout (∆pEC50 
= -0.12; p = 0.35). These differences imply that, despite comparable response to all four 
ligands, 30 induces a G-protein biased response (∆E (1 nM UR-PB195) = 0.57) at submaximal 
concentrations, in contrast to 14, which produces unbiased effects over the whole 
concentration range. Whether such a bias in the detected potencies implies distinct, ligand 
specific receptor conformations and different physiological responses to the corresponding 
compounds, remains to be determined. 
Fig. 7-3: Concentration-response curves of selected full H4R agonists in the luciferase gene reporter 
( circles) and β-arrestin 2 recruitment assay ( triangles). Data presented are mean ± SEM of 2-
4 independent experiments. Data were analyzed by nonlinear regression and best fitted to 
sigmoidal concentration-response curves. 
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Fig. 7-4: Concentration- response curves of selected H4R ligands in the luciferase gene reporter ( 
circles) and β-arrestin 2 recruitment assay ( triangles). Data presented are mean ± SEM of 2-6 
independent experiments. Data were analyzed by nonlinear regression and best fitted to sigmoidal 
concentration-response curves. 
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Of the tested methyl-histamine derivatives (2-5) only 4 acted as full agonist in both 
assays, the other three compounds revealed a moderate decrease in efficacy in arrestin 
recruitment (∆Emax = 0.16 – 0.27). Of the enantiomers 2 and 3, (R)-α-methylhistamine was 
the eutomer in both pathways. Immepip (6) exhibited a higher potency and efficacy than 
its pyridine analog immethridine (8) in both readouts, while both compounds revealed a 
decrease in potency as well as efficacy in β-arrestin compared to G-protein activation. 
Several structurally related compounds exhibited interesting functional profiles (cf. 
Fig. 7-4). Clobenpropit (12) displayed a significant bias towards G-protein activation, acting 
as full agonist in the luciferase gene reporter assay, while exhibiting significantly lower 
potency and efficacy in arrestin recruitment (∆Emax = 0.37, p = 0.0115; ∆pEC50 = 0.97, p = 
0.0002). In contrast to full agonism in the luciferase assay, 12 was reported to be a partial 
agonists in the GTPγS functional binding assay at H4R expressing Sf9 cell membranes.42 The 
homologization of the linker between the phenyl and isothiourea moiety and the 
replacement of the chlorine by iodine (cf. iodophenpropit, 13), had a considerable impact 
on the pharmacological properties of the compound. In the G-protein based readout, 13 
still displayed partial agonism, though at lower levels of potency and efficacy compared to 
12. By contrast, 13 was completely devoid of intrinsic activity in the β-arrestin recruitment 
assay. Although such a profile suggests a strong bias of 13 for G-protein over arrestin 
activation, these results have to be interpreted with caution, as controversial results on the 
pharmacology of 13 at the H4R have been reported. For example, 13 was a neutral H4R 
antagonist in a CRE-β-galactosidase gene reporter assay in SK-N-MC cells33 and in the GTPγS 
functional binding assay at Sf9 membranes (David Wifling, personal communications), but 
a H4R partial agonist in HEK293T cells in the CRE-luciferase assay41 as well as in a Ca2+ 
mobilization assay, when the H4R was co-expressed with the chimeric Giq5 protein.9 
Additionally, 13 showed different pharmacological properties depending on H4R species 
orthologs, exhibiting partial agonism at the human H4R but neutral antagonism at the 
rodent receptor orthologs.41 So far, it cannot be ruled out that the observed effects of 13 
in the CRE based luciferase assay are, at least in part, mediated by mechanisms distinct 
from the Gαi pathway. 
The acylguanidine UR-AK51 (15), originally developed as H2R agonist, revealed 
functional selectivity for G-protein activation at the H4R. Acting as highly potent nearly full 
agonist in the CRE-luciferase assay (pEC50 = 8.09; Emax = 0.93), 15 only exhibited partial 
agonism at a significantly lower potency in β-arrestin recruitment (pEC50 = 7.19; Emax = 
0.45). Interestingly, this functional characteristic closely resembles the bias of structurally 
related acylguanidine-type ligands containing imidazole moieties, when tested for agonism 
at the H2R (cf. Chapter 6.2; compds. 5-10). The structurally closely related UR-PI294 (16), 
devoid of a phenyl substituent as in 15, showed a significantly increased potency compared 
to 15 in both assay system. Additionally, 16 is devoid of functional bias for either pathway. 
This suggests that, in addition to generally reducing the H4R affinity,30 the bulky phenyl 
substituent in 15 impedes the receptor from adapting conformation(s) required for arrestin 
binding. 
Both the benzodiazepine clozapine (17) and its benzoxazepine analog isoloxapine 
(18) gave superagonistic responses in the CRE-luciferase assay, exceeding the maximal 
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histamine induced effect (Emax (17) = 1.45; Emax (18) =1.31). However, while 18 also acted 
as full agonist in arrestin recruitment (Emax = 1.13), though with lower potency compared 
to the G-protein readout, 17 showed an almost 3-fold reduction in efficacy in the arrestin 
pathway (Emax = 0.54). Comparing these two readouts suggests a strong bias of 17 for G-
protein activation. However, it should be stressed that the exceedingly high efficacy of 
these two compounds could not be confirmed in other G-protein based functional assays. 
For example, in the GTPγS functional binding assay on membranes of Sf9 insect cells 
expressing the H4R, 17 and 18 exhibited partial agonism instead of superagonism,42 
questioning the interpretation of data from different assay systems as functional bias. 
Among the four tested aminopyrimidines, as expected from the published data, only 
ST-1006 (21) showed H4R agonism.35-37 Compared to arrestin recruitment, the CRE-
luciferase data revealed a significant bias for G-protein over arrestin activation (∆Emax = 
0.51, p = 0.0001; ∆pEC50 = 0.51, p = 0,038). Again, considerably lower efficacies of 21 in the 
proximal GTPγS binding assay37 compared to the gene reporter assay have to be taken into 
consideration with respect to interpretation of data as functional selectivity. 
The chiral cyanoguanidines containing a cylopentane-1,3-diyl-linker (25-29) reveal an 
interesting relationship between their functional characteristic and their absolute 
Fig. 7-5: Concentration-response curves of the stereoisomers of the conformationally constrained 
cyanoguanidines 25-27 and 29 in the luciferase gene reporter ( circles) and β-arrestin 2 
recruitment assay ( triangles). Data presented are mean ± SEM of 2-4 independent experiments. 
Data were analyzed by nonlinear regression and best fitted to sigmoidal concentration-response 
curves. 
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configuration (cf. Fig. 7-5). From each group of compounds, the methyl- and the 
phenylsulfanylethyl-substituted cyanoguanidines, several stereoisomers were selected, 
namely those possessing highest H4R agonist potency in the GTPγS assay.39 For UR-RG94, 
both, the trans-(1S,3S)- (25) and the cis-(1R,3S)-configured (26) diastereomers, were full 
agonists with comparable potencies in the CRE gene reporter assay (pEC50 (25) = 7.17; pEC50 
(26) = 7.28). In arrestin recruitment both diastereomers showed nearly full maximal 
response, but revealed a remarkable drop in potency (∆pEC50 (25) = 1.39, p = 0.0003; 
∆pEC50 (26) = 0.91, p = 0.043) compared to the data from the luciferase assay. In case of 
UR-RG98 (27-29), bearing the bulkier phenylsulfanylethyl moiety, the configuration of the 
stereoisomers had a more pronounced effect on the pharmacological properties. While the 
three tested diastereomers exhibited comparable efficacies in the G-protein readout (∆Emax 
< 0.21, p = 0.21), the cis-configured compounds, cis-(1S,3R) (28) and cis-(1R,3S) (29), 
induced significantly lower maximal responses in arrestin recruitment than trans-(1S,3S)-
UR-RG98 (27), revealing a significant bias for G-protein activation. These data suggest that 
that in case of the bulky substituents cis-configuration of the ligand disfavors receptor 
conformation(s) enabling arrestin recruitment, whereas a methyl group is still tolerated. In 
contrast to 27-29, the flexible parent compound UR-PI376 (24) was an unbiased full agonist 
in both readouts. Unfortunately, as for other compounds, differing efficacies for these 
cyanoguanidines have been reported in the GTPγS binding assay.39 
The discrepancies between the efficacies of several compounds in assays based on 
distal and proximal G-protein dependent readouts challenge whether the apparent 
functional bias is truly mediated by ligand-specific receptor conformations or rather caused 
by an amplification of the signal by the effector cascade downstream of G-protein 
activation. The agonism/antagonism switch in case of 13, evident in CRE-based reporter 
gene assays depending on the cellular background,33,41 further indicates, that these 
processes are highly susceptible to variations in the expression patterns of signal effector 
proteins. In the functional GTPγS binding assay, the human H4R was reported to exhibit 
very high constitutive activity, thus producing unfavorable signal-to-noise ratios, limiting 
the reliability of the assay for the detection of variation in the intrinsic activity of related 
compounds, further complicating the interpretation of the aforementioned discrepancies. 
The H4R ligands selected for the investigations for functional selectivity included 
several compounds that were previously described as inverse agonists or neutral 
antagonists at the H4R (cf. Fig. 7-6). For the indole derivative JNJ7777120 (23), the first 
biased H4R ligand reported in the literature,26,29 functional selectivity for β-arrestin 
recruitment could be confirmed. Compound 23 acted as inverse agonist in the luciferase 
gene reporter assay (Emax = -0.31) while exhibiting partial agonism in arrestin recruitment 
(Emax = 0.22). VUF5681 (7) was the only compound displaying neutral behavior in both 
assays, all other “antagonists” revealed inverse agonistic activity in at least one assay. 
Thioperamide (11) was an inverse agonist in both readouts (Emax (G-protein) = -0.50, Emax 
(βArr2) = -0.09), the aminopyrimidines A987306 (20) and ST-1012 (22) behaved as neutral 
antagonists in arrestin recruitment, while exhibiting inverse agonistic effects comparable 
to 11 in the CRE luciferase assay. This functional characteristic is most pronounced for 
A943931 (19), which showed the strongest inverse efficacy of all compounds in G-protein 
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activation (Emax = -0.62), while revealing even slight agonistic effect in arrestin recruitment 
(Emax = 0.06). Though this increasing difference for 19 compared to 11, regarding the 
efficacies for either readout, suggest a functional bias for the compounds, the 
interpretation of these findings, as mentioned in previous chapters (cf. 5.2.1.), is 
complicated as the detectability of inverse agonism depends on the level of constitutive 
activity of the receptor of interest in the respective assay.  
 
  
Fig. 7-6: Concentration-response curves of the selected H4R antagonists or inverse agonists in the 
luciferase gene reporter ( circles) and β-arrestin 2 recruitment assay ( triangles). Data 
presented are mean ± SEM of 2-6 independent experiments. Data were analyzed by nonlinear 
regression and best fitted to sigmoidal concentration-response curves. 
- 124 - 
7.2 Results and discussion 
 
Tab. 7-1: Potencies and efficacies of the tested HR4R  ligands in the CRE luciferase gene reporter and β-
arrestin 2 recruitment assay 
Compd. 
CRE luciferase gene reporter β-arrestin 2 recruitment 
pECR50 ERmax N pECR50 ERmax N 
1 Histamine 7.75 ± 0.15 1.00 6 7.21 ± 0.07 1.00 4 
2 (R)-α-Methylhistamine 6.46 ± 0.08 1.02 ± 0.03 5 5.88 ± 0.19 0.76 ± 0.05 4 
3 (S)-α-Methylhistamine 5.24 ± 0.08 0.94 ± 0.06 5 4.69 ± 0.26 0.68 ± 0.01 4 
4 Nα-Methylhistamine 6.74 ± 0.12 0.96 ± 0.03 4 6.22 ± 0.22 0.90 ± 0.08 4 
5 5-Methylhistamine 7.25 ± 0.05 0.95 ± 0.02 3 6.60 ± 0.03 0.78 ± 0.04 3 
6 Immepip 7.64 ± 0.12 0.97 ± 0.00 5 6.98 ± 0.15 0.62 ± 0.03 3 
7 VUF5681 n.d. 0.04 ± 0.01 2 n.d. 0.06 ± 0.01 3 
8 Immethridine 6.14 ± 0.19 0.65 ± 0.06 3 5.46 ± 0.08 0.35 ± 0.04 3 
9 Imetit 7.70 ± 0.16 0.91 ± 0.03 6 7.43 ± 0.08 0.81 ± 0.12 4 
10 Proxyfan 6.95 ± 0.07 0.70 ± 0.06 4 6.03 ± 0.10 0.41 ± 0.05 3 
11 Thioperamide n.d. -0.50 ± 0.11 5 n.d. -0.09 ± 0.02 3 
12 Clobenpropit 7.90 ± 0.07 1.01 ± 0.03 3 6.93 ± 0.04 0.64 ± 0.08 3 
13 Iodophenpropit 7.32 ± 0.11 0.66 ± 0.01 4 n.d. 0.01 ± 0.01 3 
14 VUF8430 7.09 ± 0.09 0.93 ± 0.02 4 7.21 ± 0.07 0.95 ± 0.02 3 
15 UR-AK51 8.09 ± 0.06 0.93 ± 0.06 3 7.19 ± 0.09 0.45 ± 0.10 3 
16 UR-PI294 8.79 ± 0.10 0.95 ± 0.02 6 8.30 ± 0.06 0.83 ± 0.02 2 
17 Clozapine 6.57 ± 0.08 1.45 ± 0.09 4 6.04 ± 0.12 0.54 ± 0.04 4 
18 Isoloxapine 7.58 ± 0.15 1.31 ± 0.12 3 6.49 ± 0.20 1.13 ± 0.14 3 
19 A943931 7.19 ± 0.08 -0.62 ± 0.10 4 n.d. 0.06 ± 0.04 2 
20 A987306 8.15 ± 0.06 -0.53 ± 0.08 4 n.d. -0.02 ± 0.00 2 
21 ST-1006 8.01 ± 0.04 0.89 ± 0.01 3 7.51 ± 0.15 0.38 ± 0.04 4 
22 ST-1012 n.d. -0.42 ± 0.06 3 n.d. 0.02 ± 0.02 3 
23 JNJ7777120 n.d. -0.31 ± 0.06 6 7.40 ± 0.14 0.22 ± 0.03 4 
24 UR-PI376 7.55 ± 0.08 1.11 ± 0.05 7 6.38 ± 0.14 0.92 ± 0.13 3 
25 trans-(1S,3S)-UR-RG94 7.17 ± 0.04 1.04 ± 0.04 4 5.79 ± 0.18 0.90 ± 0.07 3 
26 cis-(1R,3S)-UR-RG94 7.28 ± 0.18 1.09 ± 0.01 2 6.38 ± 0.18 0.91 ± 0.06 3 
27 trans-(1S,3S)-UR-RG98 7.64 ± 0.04 1.07 ± 0.06 4 6.99 ± 0.19 0.78 ± 0.03 3 
28 cis-(1S,3R)-UR-RG98 6.78 ± 0.26 0.86 ± 0.04 2 5.84 ± 0.07 0.45 ± 0.05 3 
29 cis-(1R,3S)-UR-RG98 6.89 ± 0.09 0.92 ± 0.10 3 5.77 ± 0.11 0.37 ± 0.04 4 
30 UR-PB195 9.59 ± 0.17 1.05 ± 0.04 3 8.55 ± 0.06 1.03 ± 0.04 4 
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7.2.1. Quantification of functional bias by use of the operational 
model 
To allow for a quantification of the ligand bias, the operational model, as described 
in 6.2.3, was applied to the functional data from the CRE luciferase and arrestin recruitment 
assay for all ligands producing agonistic effects in both readouts. The absolute and 
normalized transduction coefficients for either readout as well as the bias factors 
∆∆log (τ/KA) of the ligands between the G-protein and arrestin pathway are given in Tab. 
7-2. The negative bias factors determined for some of the compounds indicate a bias 
towards β-arrestin that was not immediately obvious from the concentration response 
Fig. 7-7: Quantification of the functional bias of the tested H4R agonists comparing the CRE 
Luciferase and the arrestin recruitment assay. The normalized ∆log (τ/KA) values for the G-protein 
(A) and arrestin (B) pathway were calculated as described in 6.4.2.4 Eq. 2. Subtraction of the ∆log 
(τ/KA) values determined in the CRE luciferase and the arrestin recruitment assay, respectively, 
yields the bias factors ∆∆log (τ/KA) (C) for the tested compounds. 
- 126 - 
7.2 Results and discussion 
 
data. The isothiourea VUF8430 (14) showed the lowest bias factor (∆∆log (τ(KA) = -0.71), 
despite reaching full agonism in both assays (cf. Fig. 7-8). In this case, the determined 
arrestin bias is caused by a lower potency of 14 in the CRE luciferase compared to 
histamine, while both ligands are equipotent in arrestin recruitment. Therefore, the 
normalized transduction coefficient of 14 is significantly lower in the CRE luciferase than in 
the arrestin recruitment assay. The same effects account for the arrestin bias detected for 
Fig. 7-8: Concentration-response curves of selected H4R ligands in comparison with the 
endogenous ligand histamine fitted according to the operational model of agonism as described in 
6.4.2.4 and the corresponding transduction coefficients log (τ/KA) for the CRE luciferase (1) and 
arrestin recruitment assay (2). Thereof, the normalized transduction coefficients ∆log (τ/KA) (3) for 
each assay were derived. Data shown are mean ± SEM calculated as described in 6.4.2.4 for 
VUF8430 (A), trans-(1S, 3S)-UR-RG94 (B) and ST1006 (C). 
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imetit (9). From the compounds exhibiting G-protein bias, the cyanoguanidine trans-
(1S,3S)-UR-RG94 (25) has the highest bias factor (∆∆log (τ(KA) =1.01). Hereby, as with the 
arrestin biased compounds, the bias factor is driven by large differences in the detected 
potency between the two pathways rather than by (insignificant) changes in intrinsic 
activity, as 25 shows the most pronounced shift towards lower potencies in arrestin 
recruitment of all tested agonists. The same is true for the compounds 26 and 30, which 
showed only minor differences in efficacy. Even so, most of the compounds exhibiting a 
pronounced bias in the detected efficacies, foremost clozapine (17) and cis-(1R,3S)-UR-
RG98 (29), showed biased transduction coefficients, too. An exception was ST-1006 (21), 
which showed a clearly reduced efficacy in arrestin recruitment, while the data analysis 
using the operational model gave comparable ∆log (τ(KA) values for both readouts. This 
effect is caused by an increase in potency relative to histamine in the arrestin recruitment 
assay compensating for the loss in efficacy. Similar effects were registered for some ligands 
at the H2R. 
Collectively, the results obtained according to the operational model indicate that 
the chosen method might overrate the contribution of changes in potency to bias. So far, 
there is no absolute method to quantify functional bias between two distinct signaling 
pathways, and while the above findings advice caution in interpreting results from the 
operational model, it offers the possibility to compensate for systematic bias between the 
different readouts and thus can facilitate the interpretation of bias studies. 
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Tab. 7-2: Transduction coefficients log (τ/KRAR) and normalized transduction coefficients ∆log (τ/KRAR) in the 
CRE luciferase and arrestin recruitment assay and the bias factors ∆∆log (τ/KRAR) of the tested HR2R  agonists. 
Cpd. 
CRE Luc   βArr2 ∆∆log (τ/KRAR) 
(G-Arr) log (τ/KRAR) ∆log (τ/KRAR)   log (τ/KRAR) ∆log (τ/KRAR) 
1 Histamine 7.79 ± 0.06     7.23 ± 0.06       
2 (R)-α-methylhistamine 6.46 ± 0.07 -1.33 ± 0.09  5.96 ± 0.10 -1.27 ± 0.11 -0.06 ± 0.14 
3 (S)-α-methylhistamine 5.25 ± 0.07 -2.54 ± 0.09  4.84 ± 0.11 -2.39 ± 0.13 -0.15 ± 0.16 
4 Nα-methylhistamine 6.72 ± 0.07 -1.07 ± 0.09  6.12 ± 0.06 -1.11 ± 0.08 0.04 ± 0.12 
5 5-methylhistamine 7.18 ± 0.08 -0.61 ± 0.10  6.62 ± 0.11 -0.62 ± 0.13 0.01 ± 0.16 
6 Immepip 7.66 ± 0.07 -0.13 ± 0.09  6.98 ± 0.13 -0.25 ± 0.15 0.12 ± 0.17 
8 Immethridine 5.95 ± 0.14 -1.84 ± 0.15  5.33 ± 0.23 -1.91 ± 0.24 0.07 ± 0.28 
9 Imetit 7.64 ± 0.07 -0.15 ± 0.09  7.40 ± 0.08 0.17 ± 0.10 -0.32 ± 0.13 
10 Proxyfan 6.75 ± 0.11 -1.04 ± 0.13  5.87 ± 0.20 -1.36 ± 0.21 0.33 ± 0.24 
12 Clobenprobit 7.92 ± 0.09 0.13 ± 0.11  6.92 ± 0.13 -0.32 ± 0.15 0.45 ± 0.18 
14 VUF8430 7.00 ± 0.07 -0.79 ± 0.09  7.16 ± 0.07 -0.07 ± 0.09 -0.71 ± 0.13 
15 UR-AK51 8.12 ± 0.08 0.33 ± 0.10  7.12 ± 0.18 -0.12 ± 0.19 0.44 ± 0.22 
16 UR-PI294 8.72 ± 0.06 0.93 ± 0.08  8.30 ± 0.13 1.07 ± 0.14 -0.14 ± 0.17 
17 Clozapine 6.92 ± 0.11 -0.87 ± 0.13  5.97 ± 0.14 -1.26 ± 0.15 0.39 ± 0.20 
18 Isoloxapine 7.91 ± 0.11 0.12 ± 0.12  6.75 ± 0.07 -0.48 ± 0.09 0.60 ± 0.15 
21 ST-1006 7.97 ± 0.09 0.18 ± 0.11  7.53 ± 0.18 0.30 ± 0.19 -0.12 ± 0.21 
24 UR-PI376 7.58 ± 0.07 -0.21 ± 0.09  6.67 ± 0.10 -0.56 ± 0.11 0.36 ± 0.14 
25 trans-(1S, 3S)-UR-RG94 7.22 ± 0.08 -0.57 ± 0.10  5.66 ± 0.08 -1.58 ± 0.10 1.01 ± 0.14 
26 cis-(1R, 3S)-UR-RG94 7.44 ± 0.09 -0.35 ± 0.11  6.25 ± 0.08 -0.98 ± 0.09 0.64 ± 0.15 
27 trans-(1S, 3S)-UR-RG98 7.72 ± 0.09 -0.07 ± 0.10  7.04 ± 0.09 -0.19 ± 0.11 0.12 ± 0.15 
28 cis-(1S, 3R)-UR-RG98 6.73 ± 0.13 -1.06 ± 0.14  5.73 ± 0.17 -1.51 ± 0.18 0.45 ± 0.23 
29 cis-(1R, 3S)-UR-RG98 6.78 ± 0.08 -1.01 ± 0.10  5.63 ± 0.20 -1.61 ± 0.20 0.60 ± 0.23 
30 UR-PB195 9.69 ± 0.08 1.90 ± 0.10  8.58 ± 0.05 1.35 ± 0.08 0.55 ± 0.13 
The transduction coefficients log (τ/KRAR) were derived from pooled functional data of 2 – 6 independent 
experiments fitted to the operational model of agonism as described in 6.4.2.4. Data are given as mean ± 
SEM calculated as described in 6.4.2.4. 
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7.2.2. Comparison of the luciferase complementation and the 
PathHunter assay for measuring arrestin recruitment 
Previous publications addressing functional selectivity at the H4R employed the so-
called PathHunter assay (DiscoverX Corp., Fremont, CA, USA) to measure β-arrestin 2 
recruitment to the receptor.26,29 This assay, like the luciferase complementation assay 
established in our lab, is based on enzyme fragment complementation. Both assays rely on 
fusion constructs between the enzyme fragments and arrestin and the receptor 
respectively, providing a 1:1 receptor:effector stoichiometry and eliminating possible 
effects of variations in signal amplification. The main differences between the two assays 
are the reporter enzyme, β-galactosidase instead of luciferase, and the cell background, an 
osteosarcoma cell line (U2OS) instead of HEK293T cells, respectively. 
Fig. 7-9 gives a comparison of the potencies and efficacies of ligands tested in both 
assay systems (data for the PathHunter assay taken from Nijmeijer et. al.29). Although the 
detected maximal effects were comparable for most compounds, there was a tendency 
towards higher efficacies in the PathHunter assay. This was most pronounced for the biased 
agonist JNJ7777120 (23), which exhibited almost 3-fold higher efficacies in the PathHunter 
assay. The potencies of histamine (1) were nearly identical in the two assays, whereas 
minor differences became obvious for the other compounds. The potencies determined in 
the luciferase complementation assay were lower than in the PathHunter assay for all 
ligands except VUF8430 (14). Nevertheless, the reported results for the PathHunter assay 
were in good agreement with the data determined in the luciferase complementation assay 
in our laboratory. Most importantly, we were able to confirm the previously reported 
functional characteristics of the tested compounds in the arrestin and G-protein readout. 
 
  
Fig. 7-9: Potencies and efficacies of selected H4R ligands determined using the Luciferase 
complementation assay (white) or the PathHunter assay from DiscoverX (grey). Data for the 
PathHunter assay was reported by Nijmeijer et al.29 Data represent mean ± SEM. 
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7.3. Summary and conclusions 
A set of 30 structurally diverse ligands with known affinity for the H4R was 
investigated for functional selectivity regarding G-protein- and β-arrestin-mediated 
signaling pathways. Therefore, a CRE luciferase reporter gene assay and the established 
arrestin recruitment assay were employed. Several structurally different H4R ligands 
exhibited a functional bias towards G-protein activation, including the isothiourea 
iodophenpropit, the acylguanidine UR-AK51, the benzodiazepine clozapine and the 
cyanoguanidine cis-(1R,3S)-UR-RG98. As for β-arrestin bias, previous findings for the indole 
derivative JNJ7777120 could be confirmed. Moreover, variations in inverse agonistic 
efficacy between the two pathways were detected for several H4R antagonists. However, 
conclusion from these findings should be drawn with caution, due to discrepancies 
between intrinsic activities in G-protein based assays, depending on proximal or distal 
readouts, respectively.33,41,42 Apart from the discrepancies in ligand efficacy, several 
compounds revealed pronounced differences in potencies in the two assays, thus, while 
exhibiting unbiased intrinsic activities, mediating a concentration dependent functional 
bias. The use of an operational model to quantify the ligand bias supports functional 
selectivity for those compounds. 
The H4R is a promising target for the development of new drugs for the treatment of 
various allergic and inflammatory disorders. For the profound interpretation of results from 
in vivo studies, a detailed knowledge of the molecular pharmacological properties of the 
administered compounds is mandatory, especially, with regard to alternate signaling 
pathways. In combination with G-protein based readouts, the luciferase complementation 
assay proved to be a valuable method for the pharmacological characterization of H4R 
ligands, therefore aiding in the development of new ligands with distinct functional 
selectivity as valuable pharmacological tools to decipher complex receptor signaling 
profiles in vivo and in vitro. 
  
- 131 - 
7 Analysis of functional selectivity at the histamine H4 receptor 
 
7.4. Materials and methods 
7.4.1. Materials 
Unless stated otherwise, all chemicals and reagents were from Sigma-Aldrich Chemie 
(Munich, Germany) or Merck (Darmstadt, Germany). Hygromycin B was from A.G scientific 
(San Diego, CA, USA). Forskolin was from Sigma-Aldrich Chemie (Munich, Germany). D-
luciferin potassium salt was from Synchem (Felsberg, Germany). For media and reagents 
used for cell culture of the HEK293T cells as well as for the luciferase complementation 
assay, see 3.4.1. 
 
7.4.1.1. HR4R  ligands 
Histamine (1) was from Alfa Aesar (Karlsruhe, Germany). (R)-α-Methylhistamine (2), 
(S)-α-methylhistamine (3), Nα-methylhistamine (4), 4(5)-methylhistamine (5), immepip (6), 
VUF5681 (7), Immethridine (8), imetit (9), proxyfan (10), thioperamide (11), clobenpropit 
(12), iodophenpropit (13), A943931 (19) and A987306 (20) were purchased from Tocris 
Bioscience (Ellisville, MO, USA). Clozapine (17) was a gift from Novartis Pharma 
(Nuremberg, Germany). ST-1006 (21) and ST-1012 (22) were kindly provided by Prof. Dr. 
Holger Stark (Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine 
University, Düsseldorf, Germany). VUF8430 (14), UR-AK51 (15), UR-PI294 (16), Isoloxapine 
(18), JNJ7777120 (23), the cyanoguanidines 24-29 and UR-PB195 (30) were synthesized in 
our lab.30,32,38,39,43 10 mM stock solutions for all compounds were prepared with the 
following solvents: 1-10, 12-14 and 23: distilled water; 11, 17, 19-22 and 24-29: 50 % DMSO; 
15, 16 and 30: 10 mM TFA; 18: 100 % DMSO. 
 
7.4.2. Methods 
7.4.2.1. CRE Luciferase reporter gene assay 
The luciferase reporter gene assay was performed as previously described,41 using 
the HEK293T-SF-hH4R-His6-CRE-Luc cell line, expressing the human H4R as well as the firefly 
luciferase under control of the inducible CRE promoter. The cells were cultivated in DMEM 
with 10 % FCS, 600 µg/ml G418 and 200 µg/ml hygromycin at 37 °C in a water saturated 
atmosphere containing 5 % CO2. Dilution series of 1-10, 12-16, 23 and 30 were prepared in 
DMEM + 10 % (v/v) FCS; of 17-22 and 24-29 in DMEM + 10 % (v/v) FCS + 10 % DMSO, giving 
a final concentration of 1 % DMSO in the assay mixture. 24 h prior to the experiment, cells 
were seeded in DMEM + 10 % FCS in flat bottom 96 well plates at a density of approximately 
2*105 cells/well and cultivated at 37 °C in a water saturated atmosphere containing 5 % 
CO2. The following day, the cells were stimulated by the addition of 0.4 µM forskolin and 
the corresponding ligands at varying concentrations. After incubation for 5 h, the cells were 
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washed once with 100 µl PBS and afterwards lysed by addition of 40 µl lysis buffer (25 mM 
Tricine pH 7.8, 10 % (v/v) glycerol, 2 mM EGTA, 1 % (v/v) Triton X-100, 5 mM MgSO4, 1 mM 
DTT) and shaking for 45 min at 200 rpm. 20 µl of the lysate were transferred to white, flat 
bottom 96 well plates. Luminescence was induced by the injection of 80 µl luciferase assay 
buffer (15 mM KH2PO4 pH 7.8, 25 mM Gly-Gly, 15 mM MgSO4, 4 mM EGTA, 2 mM ATP, 2 
mM DTT, 0.2 mg/ml D-luciferin potassium salt) using the GENios Pro microplate reader 
(Tecan, Salzburg, Austria) immediately before the measurement. RLU (relative light units) 
were measured for 10 s. The raw data was normalized to the maximal effect induced by 1 
mM histamine (100 % value) and solvent (0 % value).The functional data for the compounds 
1-14, 16, 17, 19-25 and 27 were kindly provided by Dr. Uwe Nordemann.41 
 
7.4.2.2. Luciferase complementation assay 
The luciferase complementation assay was performed as described above (cf. 3.4.7) 
using the HEK293T-β-Arr2-H4R cells stably expressing the H4R-ElucC and the ß-Arr2-ElucN 
fusion constructs (cf. 3.2). For cell culture conditions and media requirements, see 3.4.2. 
Dilution series of 1-10, 12-14 and 23 were prepared in distilled water, for 11, 17, 18 and 24-
29 in 10 % DMSO, giving a final concentration of 1 % DMSO in the assay mixture, and for 
15, 16 and 30 in 10 mM TFA. The cells were stimulated for 45 min with varying 
concentrations of the ligands. The results were normalized to the maximum effect induced 
by 1 mM histamine, in the corresponding solvent, (100 % value) and solvent (0 % value). 
 
7.4.2.3. Data analysis 
Data analysis was performed as described above (cf. 4.3.2.2). Statistical analysis of 
the variances was performed either by unpaired T test for comparing two sets of values or 
by one way ANOVA followed by Bonferoni`s multiple comparison test for multiple sets of 
values. The analysis was performed using GraphPad Prism 5 software (GraphPad Software, 
Inc., La Jolla, CA, USA). Quantification of the stimulus bias using the operational model was 
performed as described in 6.4.2.4. 
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8. Summary 
The advances in our understanding of GPCRs and the functional versatility of these 
signal transduction machineries require an extension of the methodology used for ligand 
characterization to account for alternate signaling pathways. This thesis aimed at the 
establishment of an arrestin recruitment assay to allow the comprehensive 
characterization of newly developed ligand classes with respect to alternate, arrestin 
mediated signaling pathways. 
The optimized luciferase complementation assay proofed a fast and reliable method 
to investigate ligand induced arrestin recruitment to GPCRs. Through the chosen modular 
approach, the assay can be easily adapted to a plethora of GPCR targets. This thesis 
demonstrated the feasibility of an EFC based arrestin recruitment assay at five distinct 
receptor species, the HR1R , HR2R  and HR4R  from the histamine receptor family, and 
additionally, the NPY YR1R  and YR2R . For all receptors, HEK293T cell lines were generated, 
stably expressing the receptor-ELucC and either the ELucN-βArr1 or ELucN-βArr2 fusion 
construct, respectively. All five receptors coupled to both arrestin isoforms, although the 
absolute signal intensity differed considerably for the different receptors. All cell lines 
produced an excellent signal-to noise ratio in the luciferase complementation assay, thus 
providing a suitable platform for the characterization of compound libraries to identify 
functional selective ligands. 
Of the NPY receptor family, this thesis covered the YR1R  and YR2R , for which a selection 
of subtypspecific, nonpeptidic ligands, including several structurally divers antagonists 
described in literature as well as a set of argininamide type antagonists were available. At 
the YR1R , neither the commercially available antagonists, nor the argininamide type 
BIBP3226 or BIBO3304 derivatives exhibited significant efficacy regarding arrestin 
recruitment. Concerning arrestin and G-protein mediated pathways, none of these 
compounds exhibited a functional bias. Likewise, none of the selected YR2R  antagonists 
revealed functional selectivity towards arrestin recruitment. Therefore, these results do 
not support the assumption that the insurmountable antagonism previously reported for 
this compound class, is due to ligand specific receptor conformations. 
In case of the histamine HR1R , the ligand selection comprised a set of structurally 
divers HR1R  antagonists, amongst them several approved drugs for the treatment of allergic 
or psychological disorders, and additionally, several phenylhistamine and histaprodifen 
type agonists. While none of the antagonists exhibited functional bias, several chiral 
histaprodifen derivatives were identified as arrestin biased ligands. Interestingly, these 
compounds also discriminated between the two arrestin isoforms, with a preference for β-
arrestin 2. Functional screening for selectivity at the HR2R  identified a set of acyl- or 
carbamoylguanidine type ligands as G-protein biased agonists. Several of these compounds 
behaved as full agonists in the G-protein readout, whereas their efficacy was markedly 
lower in the arrestin recruitment assay. At the HR4R  a set of 30 structurally diverse ligands 
was investigated. Regarding their efficacy, several of these compounds exhibited G-protein 
bias. On the contrary, arrestin bias was only confirmed in case of the known, functionally 
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selective, ligand JNJ7777120. The findings at the HR2R  and HR4R  were verified using a bias 
quantification approach based on the operational model of agonism. This method allows 
the integration of both efficacy and potency information derived from the concentration 
response data into a single bias value, thereby enabling the elucidation of structure activity 
relationship to guide the development of biased ligands. 
With increasing insight into the physiological implications of arrestin mediated 
signaling, biased agonism has gained interest as a new means to fine-tune drug action 
towards a desired outcome. The findings in this thesis emphasize the necessity to fully 
characterize newly designed compounds classes with regard to their functional behavior 
towards alternate pathways. The established arrestin recruitment assay, in combination 
with various G-protein based readouts and holistic, label free assay systems, established in 
our research group, should allow the comprehensive exploration of the impact of putative 
signaling outcome. 
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95% CI 95% confidence interval 
aa amino acid 
AAP atypical antipsychotics 
AB antibody 
AC adenylate cyclase 
AC adenylate cyclase 
ARRDC arrestin domain containing protein 
βArr1 β-arrestin 1 
βArr2 β-arrestin 2 
BIFC bimolecular fluorescence complementation 
CAM calmodulin 
cAMP cyclic adenosine monophosphate 
CCP clathrin coated pit 
CRE cAMP response element 
CREB cAMP response element binding protein 
DAG diacyl glycerol 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO dimethyl sulfoxide 
DTT dithiotreitol 
ECL extracellular loop 
EFC enzyme fragment complementation 
EGTA ethyleneglycoltetraacetic acid 
ERK extracellular signal-regulated kinase 
ERK endoplasmatic reticulum 
ERK extracellular regulated kinase 
GDI guanine nucleotide dissociation inhibitor 
GEF guanine-nucleotide exchange factor 
GPCR G-protein coupled receptor 
GRK G-protein receptor kinase 
GTP guanosine triphosphate 
HR1R  histamine HR1R receptor 
HR2R  histamine HR2R receptor 
HR3R  histamine HR3R receptor 
HR4R  histamine HR4R receptor 
ICL intracellular loop 
IPR3 inositol 1,4,5-trisphosphate 
MAPK mitogen-activated protein kinases 
mRNA messenger ribonucleic acid 
NaSSA noradrenergic and specific serotonergic antidepressant  
NFκB nuclear factor κB  
 
 NO nitric oxide 
NPY neuropeptide Y 
NRI norepinephrine reuptake inhibitor 
PBS Phosphate buffered saline 
PDE phosphodiesterase 
PIPR2 phosphatidylinositol 4,5-bisphosphate  
PKA protein kinase A 
PKC protein kinase C  
PKD protein kinase D 
PLC phospholipase C 
PP pancreatic polypeptide 
PTX pertussis toxin 
PYY peptide YY 
RGS regulator of G-protein signaling 
ROS reactive oxygen species 
RT room temperature 
RT-PCR reverse transcriptase polymerase chain reaction 
TM transmembrane helix 
YR1R  neuropeptide Y receptor 1 
YR2R  neuropeptide Y receptor 2 
 
 
 
